Document:

EX-10.23

 Exhibit 10.23 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. 
 Execution Version 

ASSET PURCHASE AGREEMENT AND PLAN OF REORGANIZATION 

THIS ASSET PURCHASE AGREEMENT AND PLAN
OF REORGANIZATION (the “Agreement”) is made and entered into as of June 30, 2018, by and between: BIODESIX, INC., a Delaware
corporation (“Purchaser”); INTEGRATED DIAGNOSTICS, INC., a Delaware corporation (“Seller”); and the stockholders of Seller set forth on Exhibit A (each a
“Stockholder”). Certain capitalized terms used in this Agreement are defined in Exhibit B. 

RECITALS 

Seller and Purchaser wish to provide for the sale of the Transferred Assets (as defined in Section 1.1) to Purchaser on the terms, and
subject to the conditions, set forth in this Agreement. 
 Seller and Purchaser intend for the Transactions to constitute a
“reorganization” within the meaning of Section 368(a) of the Code, and for this Agreement to constitute a “plan of reorganization” within the meaning of Treasury Regulations Sections
1.368-2(g) and 1.368-3(a). 
 AGREEMENT 

The parties to this Agreement, intending to be legally bound, agree as follows: 

SECTION 1. SALE OF TRANSFERRED ASSETS; RELATED TRANSACTIONS;
CLOSING. 
 1.1    Sale of Transferred Assets. At the Closing (as
defined in Section 1.6), Seller shall cause to be sold, assigned, transferred, conveyed and delivered to Purchaser all of the Transferred Assets (as defined below), free of any Encumbrances (other than Permitted Encumbrances), on the terms and
subject to the conditions set forth in this Agreement. For purposes of this Agreement, “Transferred Assets” shall mean and include all of the properties, rights, interests and other tangible and intangible assets of Seller (other
than the Excluded Assets). Without limiting the generality of the foregoing, the Transferred Assets shall include: 

(a)    all of the Intellectual Property and Intellectual Property Rights that are owned by Seller,
together with the goodwill associated with the Transferred Assets; 
 (b)    all machinery,
equipment, furniture, fixtures, improvements, computer equipment, servers and other tangible or fixed assets that are owned or controlled by Seller; 

 (c)    all books, records, information, files,
data, customer lists, records, mailing lists, correspondence, research and development reports and advertising and promotional materials; 

(d)    all rights of Seller under the Seller Contracts identified on
Schedule 1.1(d) (the Seller Contracts referred to in this Section 1.1(d) being referred to as the “Transferred Contracts”); 

(e)    all claims of Seller against other Persons relating to the Transferred Assets and all rights
of indemnity, warranty rights, rights of contribution, rights to refunds, rights of reimbursement and other rights of recovery possessed by Seller relating to the Transferred Assets; and 

(f)    all accounts receivable, notes receivable and other receivables of Seller; and 

(g)    all deposits, advances, prepaid expenses, accrued rebates and credits. 

1.2    Excluded Assets. Notwithstanding anything to the contrary contained in this Agreement,
the parties agree that Seller is not selling, assigning, transferring, conveying or delivering to Purchaser, and the Transferred Assets shall not include, any of Seller’s rights under this Agreement and the Ancillary Agreements and any of the
assets specifically identified on Schedule 1.2 (the “Excluded Assets”). 

1.3    Purchase Price. As consideration for the sale, assignment, transfer, conveyance and
delivery of the Transferred Assets to Purchaser, at the Closing (a) Purchaser shall issue to Seller at the Closing an aggregate of 10,649,904 shares of Series G Preferred Stock (the “Closing Shares”), of which 2,219,981 shares
of Series G Preferred Stock will be held by Purchaser pursuant to Section 1.4 and Section 7 hereof (the “Holdback Shares”); (b) when and if the Milestone Event is achieved
prior to the seventh anniversary of the date hereof, Purchaser shall issue to Seller (or if Seller has been dissolved at such time, to the Stockholders who have executed a Stockholder Package) an aggregate of 14,959,114 shares of Series G Preferred
Stock (as adjusted for share splits, share dividends, recapitalizations and the like) (as adjusted, the “Milestone Shares”, and together with the Closing Shares, the “Securities”), or if an Acquisition of Purchaser
has occurred prior to the date the Milestone Event is achieved prior to the seventh anniversary of the date hereof, in lieu of the Milestone Shares, Purchaser (or its
successor-in-interest) shall issue to Seller (or if Seller has been dissolved at such time, to the Stockholders who have executed a Stockholder Package) the same
consideration received by the other holders of Series G Preferred Stock in such Acquisition equivalent to the number of Milestone Shares otherwise receivable pursuant to this clause (b), (c) Purchaser shall assume the Assumed Liabilities; and
(d) Purchaser shall assume all other liabilities of Seller (other than the Assumed Liabilities) up to an amount equal to the amount of Accrued Wages (subject to adjustment pursuant to Section 5.11) (the “Additional
Liabilities”), provided, however, that if the Additional Liabilities assumed by Purchaser are less than the amount of Accrued Wages, then Purchaser shall pay to Seller the difference in cash no later than December 31,

  
 2 

 
2018 ((a), (b), (c) and (d) collectively, the “Purchase Price”). The Closing Shares (including, for the avoidance of doubt, the Holdback Shares except to the extent
forfeited pursuant to Section 7.8) shall be reflected on Purchaser’s books and records as issued at Closing to Seller (and Seller shall have the rights to vote and dividends, if any, paid with respect to such Securities), for which stock
certificates will be delivered by Purchaser after Closing (subject to the provisions of this Agreement in the case of the Holdback Shares). 

1.4    Holdback Shares. At Closing, Purchaser shall issue the Holdback Shares to the Seller,
provided, however, that the Holdback Shares shall be subject to forfeiture to Purchaser in accordance with Section 7.8, for no consideration payable to the applicable holder of such Holdback Shares (the “Holdback Forfeiture
Condition”). On the date [***] days after the Survival Date (the “Release Date”), the Holdback Forfeiture Condition shall expire with respect to the number of Holdback Shares equal to the then remaining Holdback Shares as
of the Release Date and shall be, to the extent such number of shares exceeds the aggregate value of all Unresolved Claims as of the Release Date, issued to Seller (or if Seller has been dissolved at such time, to the Stockholders who have executed
a Stockholder Package). Any portion of the Holdback Shares that is retained to satisfy such Unresolved Claims shall be referred to as the “Retained Amount.” Following the Release Date, once an Unresolved Claim is finally resolved,
then, promptly upon the final resolutions of such Unresolved Claim, the Holdback Forfeiture Condition shall expire with respect to the number of Holdback Shares equal to the amount not required to satisfy such claim, if any, to the extent that the
portion of the Retained Amount not permanently withheld by Purchaser as of such time exceeds the aggregate of all amounts then subject to Unresolved Claims, issued to Seller (or if Seller has been dissolved at such time, to the Stockholders who have
executed a Stockholder Package). 
 1.5    Assumption of Certain Liabilities.
Purchaser will not assume any Liabilities of Seller (whether or not related to the Transferred Assets), including any Liabilities (including costs and expenses) incurred as a result of Legal Proceedings relating to any such Liabilities. As the
sole exception to the foregoing, effective as of the close of business on the Closing Date, Purchaser will assume, discharge and perform as and when due all of the obligations of Seller (a) under the Transferred Contracts, but in any case only
to the extent that such obligations: (i) arise after the Closing Date; (ii) do not arise from or relate to any breach by Seller of any provision of any of such Transferred Contracts prior to the Closing; (iii) do not arise from or
relate to any event, circumstance or condition occurring or existing on or prior to the Closing Date that, with notice or lapse of time, would constitute or result in a breach of any of such Transferred Contracts; and (iv) are ascertainable
solely by reference to the express terms of such Transferred Contracts; provided, however, Purchaser shall not be obligated to assume, discharge or perform any Liability under any Transferred Contract, if Seller shall not have obtained any
Consent required to be obtained from any Person with respect to the assignment or delegation to Purchaser of any rights or obligations under such Transferred Contract; and (b) those Liabilities expressly set forth on Schedule 1.5
(collectively, the “Assumed Liabilities”). 
 1.6    Closing. The closing
of the sale of the Transferred Assets to Purchaser and the other Transactions contemplated by this Agreement (the “Closing”) shall take place concurrently with the execution and delivery of this Agreement. The date on which the
Closing is held is herein referred to as the “Closing Date.” 

  
 3 

 1.7    Transaction Taxes. 

(a)    Seller shall be liable for any stamp, documentary, sales, use, value added, registration,
property, excise, transfer or similar Taxes, charges or fees (“Transfer Taxes”) that may become payable in connection with the conveyance and transfer of the Transferred Assets to Purchaser or otherwise in connection with the
Transactions, and Seller will make all filings, returns, reports and forms as may be required to comply with the provisions of all applicable Legal Requirements relating to Transfer Taxes. Purchaser and Seller will cooperate to the extent reasonably
necessary to prepare and file all necessary documents relating to Transfer Taxes as may be required. 

(b)    Each of Purchaser and Seller shall reasonably cooperate, and shall cause their respective
Affiliates to reasonably cooperate, with each other to lawfully minimize any Transfer Taxes. At Purchaser’s discretion, any such Transfer Taxes incurred by Purchaser may be withheld from payments otherwise due pursuant to this Agreement. 

1.8    Withholding. Purchaser shall be entitled to deduct and withhold from all amounts
payable pursuant to this Agreement all amounts that Purchaser is required to deduct and withhold under any provision of applicable Legal Requirements. To the extent such amounts are withheld or deducted and paid over to the applicable Governmental
Body, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. 

1.9    Seller Put Option. 

(a)    General. Subject to the terms and conditions of this Section 1.9, if the
Milestone Event is achieved prior to the seventh anniversary of the date hereof, Seller shall have the option (the “Put Option”) to cause Purchaser to redeem the Milestone Shares from Seller and the Stockholders at a price
equal to [***] per share (as adjusted for share splits, share dividends, recapitalizations, conversions and the like) (as adjusted, the “Redemption Price”) after receipt by Purchaser of Seller’s election to exercise the
Put Option (the “Redemption Request”). The Put Option shall expire six months after the date the Milestone Event is achieved. Upon receipt of a Redemption Request, Purchaser shall redeem the Put Option over up to eight
calendar quarters in equal quarterly installments, plus interest as described below, with redemption payments commencing in the calendar quarter following the calendar quarter when Purchaser receives the Redemption Request. The date of each such
installment shall be referred to as a “Redemption Date.” On each Redemption Date, Purchaser shall redeem, on a pro rata basis in accordance with the number of Milestone Shares owned by Seller or a Stockholder, that
number of outstanding Milestone Shares determined by dividing (i) the total number of Milestone Shares outstanding immediately prior to such Redemption Date by (ii) the number of remaining Redemption Dates (including the Redemption Date to
which such calculation applies). This Section 1.9 shall be interpreted to conform, to the greatest extent possible, with the provisions of Delaware law governing distributions to stockholders. If

  
 4 

 
on any Redemption Date Delaware law governing distributions to stockholders prevents Purchaser from redeeming all Milestone Shares to be redeemed, Purchaser shall ratably redeem the maximum
number of Milestone Shares that it may redeem consistent with such law, and shall redeem the remaining Milestone Shares as soon as it may lawfully do so under such law. Following a Redemption Request, Purchaser may elect to redeem all remaining
Milestone Shares outstanding at any time. 
 (b)    Surrender of Certificates;
Payment. On or before the applicable Redemption Date, each holder of Milestone Shares to be redeemed on such Redemption Date shall, if a holder of shares in certificated form, surrender the certificate or certificates representing such
shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to Purchaser to indemnify Purchaser against any claim that may be made against
Purchaser on account of the alleged loss, theft or destruction of such certificate) to Purchaser, in the manner and at the place designated by Purchaser, and thereupon the Redemption Price for such shares shall be payable to the order of the person
whose name appears on such certificate or certificates as the owner thereof. In the event less than all of the Milestone Shares represented by a certificate are redeemed, a new certificate, instrument, or book entry representing the unredeemed
Milestone Shares shall promptly be issued to such holder. 
 (c)    Interest. If any
Milestone Shares are not redeemed for any reason on any Redemption Date, all such unredeemed shares shall remain outstanding and entitled to all the rights and preferences provided herein, and Purchaser shall pay interest on the Redemption Price
applicable to such unredeemed shares at an aggregate per annum rate equal to [***] (increased to [***] if Purchaser is more than [***] business days late in making a payment on a Redemption Date beginning on the date such payment was due and lasting
until the late redemption payment and any interest thereon has been paid in full), with such interest to accrue daily in arrears beginning on the first day of the calendar quarter following the calendar quarter in which Purchaser receives the
Redemption Request; provided, however, that in no event shall such interest exceed the maximum permitted rate of interest under applicable law (the “Maximum Permitted Rate”), provided, however,
that Purchaser shall take all such actions as may be necessary, including without limitation, making any applicable governmental filings, to cause the Maximum Permitted Rate to be the highest possible rate. In the event any provision hereof would
result in the rate of interest payable hereunder being in excess of the Maximum Permitted Rate, the amount of interest required to be paid hereunder shall automatically be reduced to eliminate such excess; provided, however, that any
subsequent increase in the Maximum Permitted Rate shall be retroactively effective to the applicable Redemption Date to the extent permitted by law. For the avoidance of doubt, there is no prepayment penalty (and no interest shall be due) if any
redemption payments or Redemption Prices are paid prior to a required Redemption Date. 

(d)    Nature of Redemption Payments. The redemption payments set forth in this
Section 1.9 shall be general, unsecured obligations of Purchaser. 

  
 5 

 1.10    Purchaser Call Option. 

(a)    General. Subject to the terms and conditions of this Section 1.10, if the
Milestone Event is achieved prior to the seventh anniversary of the date hereof, Purchaser shall have the option (the “Call Option”) to repurchase the Milestone Shares from Seller and the Stockholders at a price equal to
[***] per share (as adjusted for share splits, share dividends, recapitalizations, conversions and the like) (as adjusted, the “Repurchase Price”). The Call Option shall be exercisable during the twelve month period starting
thirty (30) days following the expiration of the Put Option as described in Section 1.9. 

(b)    Exercise of Call Option. Purchaser, or any assignee or assignees of Purchaser,
may exercise the Call Option with respect to all or a portion of the Milestone Shares by giving notice to the holder of the Milestone Shares during the period of the Call Option in writing. Upon exercise of the Call Option, Purchaser will pay to the
holder of the Milestone Shares the Repurchase Price for the Milestone Shares being repurchased. Purchaser may pay the Repurchase Price in two equal quarterly installments, plus interest at an aggregate per annum rate equal to [***], with such
interest to accrue daily in arrears beginning on the first day of the calendar quarter following the calendar quarter in which Purchaser exercises the Call Option; provided, however, that in no event shall such interest exceed the
Maximum Permitted Rate, provided, however, that Purchaser shall take all such actions as may be necessary, including without limitation, making any applicable governmental filings, to cause the Maximum Permitted Rate to be the highest
possible rate. In the event any provision hereof would result in the rate of interest payable hereunder being in excess of the Maximum Permitted Rate, the amount of interest required to be paid hereunder shall automatically be reduced to eliminate
such excess provided, however, that any subsequent increase in the Maximum Permitted Rate shall be retroactively effective to the applicable Redemption Date to the extent permitted by law. Purchaser is entitled to pay for any Milestone
Shares purchased pursuant to its Repurchase Option at Purchaser’s option in cash or by offset against any indebtedness owing to Purchaser, or by a combination of both. Upon exercise of the Repurchase Option and payment of the purchase price in
any of the ways described above, Purchaser will become the legal and beneficial owner of the Milestone Shares being repurchased and all rights and interest in or related to the Milestone Shares, and Purchaser will have the right to transfer to its
own name the Milestone Shares being repurchased by Purchaser, without further action by Purchaser. The certificate(s) representing the Milestone Shares that have been repurchased by Purchaser will be delivered to Purchaser. It is expressly agreed
between the parties that money damages are inadequate to compensate Purchaser for the Milestone Shares and that Purchaser will, upon proper exercise of the Repurchase Option, be entitled to specific enforcement of its rights to purchase and receive
said Milestone Shares. 
 (c)    Nature of Repurchase Payments. The repurchase
payments set forth in this Section 1.10 shall be general, unsecured obligations of Purchaser. 

1.11    Block of Payments. Notwithstanding anything in Section 1.9 and Section 1.10
to the contrary, no payments to Seller in connection with the Put Option or the Call Option may be made until the [***] day after the payment in full in cash of all obligations (other than inchoate indemnity obligations or other obligations that
specifically survive termination) under that certain Loan and Security Agreement dated as of February 23, 2018 (as amended, restated or modified from time to time) between Purchaser, the other parties

  
 6 

 
thereto from time to time, and Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership, and its permitted successors and assigns (the “Senior Lender”). For the
avoidance of doubt, any amounts owed but not paid under Section 1.9 or 1.10 shall be considered owed and accruing until paid in full, but shall not be permitted to be paid until the conditions specified in the immediately preceding sentence are
satisfied. Sections 1.9, 1.10 and 1.11 cannot be amended or modified without the written consent of the Senior Lender. The Purchaser and Seller hereby agree that (x) the Senior Lender is an express third party beneficiary of this
Section 1.11 and can enforce its rights as such express third-party beneficiary to the fullest extent of the law and (y) this Section 1.11 may not be amended without the Senior Lender’s prior written consent, which may be granted
or withheld in its sole discretion. 
 1.12    No Distributions. Purchaser hereby covenants
to Seller that until all amounts owed and owing to Seller under Section 1.9 and 1.10 (which include, for the avoidance of doubt, all amounts that are owed and accruing but not payable due to the effect of Section 1.11) have been paid in
full in cash, Purchaser, either directly or indirectly, will not pay any dividends or make any distribution or payment on account of, or redeem, retire or purchase any capital stock, except that (i) Purchaser may convert any of its convertible
securities into other securities pursuant to the terms of such convertible securities or otherwise in exchange thereof, and (ii) Purchaser may pay dividends or distributions solely in its common stock, in each case of (i) and (ii) of
this paragraph, as long as no payments in cash are made in connection thereto. 
 SECTION 2. REPRESENTATIONS AND
WARRANTIES OF SELLER 
 Seller represents and warrants to and for the benefit of the
Purchaser Indemnitees, subject to such exceptions as are specifically disclosed in the disclosure schedule (referencing the appropriate section and subsection numbers) supplied by Seller to Purchaser (the “Disclosure Schedule”) (it
being understood that the disclosure set forth in each section and subsection of the Disclosure Schedule shall qualify (a) the representations and warranties set forth in the corresponding section or subsection of this Section 2,
(b) any exception or disclosure explicitly cross-referenced to such part or subpart of the Disclosure Schedule by reference from another part or subpart of the Disclosure Schedule and (c) any other representations and warranties set forth
in this Section 2 if it is readily apparent based on the substance of such disclosure that the disclosure applies to such other representations and warranties), as follows: 

2.1    Corporate Status; Subsidiaries. 

(a)    Seller (a) is a corporation duly organized, validly existing and in good standing under
the laws of the state of Delaware, (b) has all requisite corporate power and authority to carry on its Business and (c) is duly qualified to do business and is in good standing in each of the jurisdictions in which the ownership, operation
or leasing of its properties and assets and the conduct of its business requires it to be so qualified, licensed or authorized, except, in each case, as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. True and complete copies of (a) the certificate of incorporation, bylaws and other charter and organizational documents of Seller, each as amended and in effect as of the date of this Agreement (the

  
 7 

 
“Organizational Documents”), (b) the stock records of Seller and (c) the minutes and other records of the meetings and other proceedings (including any actions taken by
written consent or otherwise without a meeting) of the stockholders of Seller, the board of directors of Seller and all committees thereof have been delivered to Purchaser. Seller is not in violation in any material respect of any of the provisions
of the Organizational Documents and Seller has not taken any action that is inconsistent with any resolution adopted by the stockholders of Seller, the board of directors of Seller or any committees thereof, except, in each case, as would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

(b)    Seller has no Subsidiaries, and other than Common Stock, Series Seed Preferred Stock and
Series A Preferred Stock of Indi Molecular, Inc., and Seller does not own any capital stock of, or any equity interest of any nature in, any other Entity. Seller has not agreed and is not obligated to make, nor is it bound by any Contract under
which it may become obligated to make, any future investment in or capital contribution to any other Entity. 

2.2    Authorization and Enforceability; No Conflict 

(a)    Seller has all necessary corporate power and authority to enter into this Agreement, to
perform its obligations hereunder and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by Seller, the performance by Seller of its obligations hereunder, and the consummation by Seller of
the transactions contemplated by this Agreement, have been duly authorized by the board of directors of Seller, and no other corporate action on the part of Seller is necessary to authorize the execution and delivery of this Agreement by Seller, the
performance by Seller of its obligations hereunder or the consummation by Seller of the Transactions, other than the approval of the stockholders of Seller. This Agreement has been duly executed and delivered by Seller and (assuming due
authorization, execution and delivery by the other parties to this Agreement) constitutes a valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as enforceability may be limited by or subject to
(i) bankruptcy, insolvency, reorganization, moratorium and other similar Laws relating to or affecting creditors’ rights generally or (ii) the effect of rules of Legal Requirements and general principles of equity, including those
governing specific performance, injunctive relief and other equitable remedies (regardless of whether such enforceability is considered in a proceeding in equity or at law) (the “Enforceability Exception”). 

(b)    The board of directors of Seller (at a meeting duly called and held) has (i) unanimously
determined that the Agreement is advisable and fair and in the best interests of Seller and the Stockholders, (ii) unanimously authorized and approved the execution, delivery and performance of this Agreement by Seller and
(iii) unanimously resolved to recommend adoption of this Agreement and approval of the Transactions by the Stockholders. 

(c)    The execution and delivery of this Agreement, the performance by Seller of its obligations
hereunder and the Ancillary Documents to which Seller is a party, 

  
 8 

 
and the consummation by Seller of the Transactions or the Ancillary Documents to which Seller is a party, do not (i) conflict with, or result in any violation of the Organizational
Documents; (ii) conflict with or result in a violation of any material permit or Legal Requirement applicable to Seller or its assets; or (iii) result in a material breach of, or constitute a material default (or event which with the
giving of notice or lapse of time, or both, would become a default) under, or give rise to any rights of termination, cancellation or acceleration of any obligation or to loss of a material benefit under, or result in the creation of any Encumbrance
(excluding Permitted Encumbrances) upon any of the Transferred Assets. 
 (d)    No consent of, or
registration, declaration, notice or filing with, any Governmental Authority is required to be obtained or made by Seller in connection with the execution, delivery and performance of this Agreement and the Ancillary Documents to which Seller is a
party or the consummation of the Transactions, except for such consents, registrations, declarations, notices or filings which, if not obtained, would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse
Effect. 
 2.3    Capitalization. 

(a)    The outstanding capital stock of Seller is held by the stockholders identified on Exhibit
C hereto. Such stockholders collectively own all the outstanding capital stock of Seller (the “Capital Stock”). 

(b)    There are outstanding Seller Options to purchase [***] shares of Company Common Stock, all of
which Seller Options were granted pursuant to the Seller Equity Plan (and the per share exercise price for each outstanding Seller Option is below the fair market value per share of the Seller’s Common Stock). 

(c)    Seller’s capitalization table attached hereto as Exhibit C is true and complete,
in all material respects, as of the Closing Date. 
 (d)    Except as set forth in
Section 2.3(b) or in Part 2.3(c) of the Disclosure Schedule, there is no: (A) outstanding Seller Stock Awards or any subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the
capital stock or other securities of Seller; (B) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Seller; (C) Contract under
which Seller is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities; or (D) condition or circumstance that would reasonably be expected to give rise to or provide a reasonable basis for the
assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Seller or any portion of the consideration payable in connection with the Transactions. Except for
the Seller Equity Plan, Seller has never adopted, sponsored or maintained any stock option plan or any other plan or agreement providing for equity compensation to any Person. 

  
 9 

 (e)    None of the provisions of this Agreement
will violate the terms of the Seller Equity Plan or any agreement pursuant to which stock options or other compensatory equity awards have been issued under the Seller Equity Plan. 

(f)    All outstanding shares of Capital Stock, and all outstanding Seller Options and Seller Stock
Awards, have been issued and granted in compliance with (i) all applicable securities laws and other applicable Legal Requirements and (ii) all requirements set forth in applicable Contracts governing the issuance of such Seller Options
and Seller Stock Awards, as applicable. 
 2.4    Financial Statements; Undisclosed
Liabilities. 
 (a)    Seller has delivered to Purchaser the following financial statements
(collectively, the “Seller Financial Statements”): (a) the audited financial statements of Seller as of and for the years ended December 31, 2014 and December 31, 2015, and (b) the unaudited financial statements
of Seller as of and for the years ended December 31, 2016 and December 31, 2017 and for the five months ended May 31, 2018 (the “Balance Sheet Date”). 

(b)    The Seller Financial Statements are accurate and complete in all material respects and fairly
present in all material respects the financial position of Seller as of the respective dates thereof and the results of operations and cash flows of Seller for the periods covered thereby in accordance with GAAP. Seller Financial Statements have
been prepared in accordance with GAAP applied on a consistent basis throughout the periods covered; provided, however, that the unaudited Seller Financial Statements are subject to normal recurring
year-end audit adjustments (none of which individually or in the aggregate will be material in amount) and do not contain all footnotes required under GAAP. 

(c)    Seller does not have any Liability which is material and required by GAAP to be shown on a
balance sheet, except for (a) Liabilities shown on the most recent balance sheet included in Seller Financial Statements (the “Balance Sheet”) and (b) liabilities which have been incurred by Seller since the Balance Sheet
Date in the ordinary course of business and consistent with Seller’s past practices. 

(d)    Except as may be listed on Part 2.4(d) of the Disclosure Schedules, Seller is not now
insolvent, nor will it be rendered insolvent by any of the Transactions. As used in this section, “insolvent” means the debts and other probable Liabilities of an Entity exceed the sum of the present fair saleable value of the assets of
such Entity. Except as may be listed on Part 2.4(d) of the Disclosure Schedules, immediately after giving effect to the consummation of the Transactions: (i) Seller will be able to pay its Liabilities as they become due in the usual course of
its business; and (ii) Seller will have assets (calculated at fair market value) that exceed its Liabilities. 

2.5    Absence of Changes. 

(a)    Since the Balance Sheet Date, there has not been, occurred or arisen any event, occurrence,
development or state of circumstances or facts that has had or would reasonably be expected to have, individually or in the aggregate, any Material Adverse Effect. 

  
 10 

 (b)    Since the Balance Sheet Date,
(i) there has not been any material loss, damage or destruction to, or any material interruption in the use of, any of the assets of Seller; (ii) Seller has not declared, accrued, set aside or paid any dividend or made any other
distribution in respect of any shares of capital stock or other securities or repurchased, redeemed or otherwise reacquired any shares of capital stock or other securities; (iii) Seller has not made any capital expenditure in excess of [***]
individually or [***] in the aggregate; (iv) Seller has not leased or licensed any asset (excluding any renewals of previously leased or licensed asset) to or from any other Person with a value in excess of [***]; (v) Seller has not made
any loan or advance to any other Person (other than travel advances made to employees in the ordinary course of business); (vi) no Seller Contract has been entered into or amended or terminated; (vii) Seller has not forgiven any debt or
otherwise released or waived any right or claim; and (viii) Seller has not agreed, committed or offered (in writing or otherwise) to take any of the actions referred to in clauses “(i)” through “(vii)” above. 

2.6    Title to Assets; Equipment; Leasehold. 

(a)    Seller owns, and has good and valid title to, or has a valid leasehold in, all of the
Transferred Assets. None of such Transferred Assets is subject to any Encumbrances (other than Permitted Encumbrances). The Transferred Assets collectively constitute all of the assets (other than Intellectual Property assets) necessary to enable
Seller to conduct its business as currently conducted. 
 (b)    The equipment owned by or leased
to Seller that is included in the Transferred Assets is in good operating condition and repair and has been reasonably maintained consistent with standards generally followed in the industry (giving due account to the age and length of use of same,
ordinary wear and tear excepted) and is adequate and suitable for its present uses. 

(c)    Seller does not own any real property or any interest in real property. All leases of
personal property that are included in the Transferred Contracts are valid, binding and enforceable against Seller in accordance with their respective terms and, to the Knowledge of Seller, there does not exist under any such lease any default or
any event which with notice or lapse of time or both would constitute a default. 

2.7    Intellectual Property. 

(a)    Products and Services. Part 2.7(a) of the Disclosure Schedule accurately
identifies and describes each Seller Product being designed, developed, manufactured, marketed, distributed, provided, licensed or sold by Seller. 

(b)    Registered IP; Other Seller IP. Part 2.7(b)(i) of the Disclosure Schedule
accurately identifies: (i) each item of Registered IP in which Seller has or purports to have an ownership interest of any nature (whether exclusively, jointly with another Person, or otherwise); (ii) the jurisdiction in which such item of
Registered IP has 

  
 11 

 
been registered or filed and the applicable registration or serial number; (iii) any other Person that has an ownership interest in such item of Registered IP and the nature of such
ownership interest and (iv) to the extent applicable, all inventors of such item of Registered IP. Seller has provided to Purchaser complete and accurate copies of all applications and approvals to or from any Governmental Body. Each item of
Registered IP described in Part 2.7(b)(i) of the Disclosure Schedule is and at all times has been in compliance with all Legal Requirements and all filings, payments, and other actions required to be made or taken to
maintain such item of Registered IP in full force and effect have been made by the applicable deadline. No application for a patent or a copyright, mask work, or trademark registration or any other type of Registered IP filed by or on behalf of
Seller that is material to the Seller’s business, including the Registered IP listed in Part 2.7(b)(i) of the Disclosure Schedule, has been abandoned, allowed to lapse, withdrawn, disclaimed, cancelled, forfeited, relinquished or
rejected, except in the ordinary course of prosecution. Part 2.7(b)(i) of the Disclosure Schedule accurately identifies and describes each formal action, filing, and payment that must be taken or made on or before the date
that is [***] days after the date of this Agreement to maintain such item of Registered IP in full force and effect. No interference, opposition, reissue, reexamination, or other Legal Proceeding is or has been pending or, to Seller’s
Knowledge, threatened, in which the scope, validity, or enforceability of any Seller IP is being or has been contested or challenged. To Seller’s Knowledge, there is no basis for a claim that any Registered IP described in
Part 2.7(b)(i) of the Disclosure Schedule is invalid or unenforceable and no Intellectual Property or Intellectual Property Rights of any third party are dominating, interfering or potentially dominating or interfering with
the Registered IP described in Part 2.7(b)(i) of the Disclosure Schedule. Seller has taken reasonable measures to record and maintain any and all inventions and discoveries that are, in the reasonable discretion and judgment of the Seller, both
material to the Business and reasonably likely to be patentable. To Seller’s Knowledge, Seller has not engaged in any inequitable or unlawful conduct, patent or copyright misuse, or fraud, or failed to disclose material prior art, in connection
with the prosecution of any Registered IP described in Part 2.7(b)(i) of the Disclosure Schedule or the enforcement or licensing of any such Registered IP, in a manner that would result in the lapse, abandonment, disclaimer, cancellation,
forfeiture, relinquishment, invalidity or unenforceability of such Registered IP, and to Seller’s Knowledge, no third party has engaged in such activity with respect to such Registered IP. Part 2.7(b)(i) of the Disclosure Schedule
accurately identifies all Seller IP specifically including patents and pending patent applications that is material to Seller’s business as currently conducted and proposed to be conducted. 

(c)    Inbound Licenses. Schedule 1.1(d) accurately identifies: each Contract entered into by
Seller pursuant to which any Intellectual Property Right or Intellectual Property, or any contingent right thereto, is or has been licensed, sold, assigned, optioned or otherwise conveyed, granted or provided to Seller (other than
(i) agreements between Seller and its employees in Seller’s standard form thereof, which form has been provided to Purchaser, and (ii) non¬exclusive licenses to commercially available, off-the-shelf third-party software, on general commercial terms which continue to be widely available on such commercial terms, that are not incorporated into, or distributed with any Seller Product and that
are not otherwise material to Seller’s business or constitute a Material Contract) (this clause (ii), the “OTS Agreements”). Complete and correct copies 

  
 12 

 
of each such Contract listed in Schedule 1.1(d) (including all amendments, supplements, liens and waivers thereto) have been made available to Purchaser and each such Contract represents the
complete agreement and understanding in all material respects between the parties thereto relating to the Seller IP that is the subject of such Contract. 

(d)    Outbound Licenses. Schedule 1.1(d) accurately identifies each Contract pursuant to
which any Person has been granted any license under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Seller IP, other than non-disclosure agreements
entered into in the ordinary course of business and user agreements for the use of Seller Products substantially on the form provided to Purchaser. Seller is not bound by, and no Seller IP is subject to, any Contract entered into by Seller
containing any covenant or other provision that in any way limits or restricts the ability of Seller to use, exploit, assert, register, prosecute, maintain or enforce any Seller IP anywhere in the world, other than those Contracts to be listed in
Schedule 1.1(d). Complete and correct copies of each such Contract listed in Schedule 1.1(d) (including all amendments, supplements, liens and waivers thereto) have been made available to Purchaser and each such Contract represents the
complete agreement and understanding in all material respects between the parties thereto relating to the Seller IP that is the subject of such Contract. 

(e)    Royalty Obligations. Schedule 1.1(d) accurately identifies each Contract pursuant to
which any royalties, fees, commissions, and other amounts are payable by Seller to any other Person (other than sales commissions payable to employees of Seller and OTS Agreements) upon or for the development, manufacture, sale, or distribution of
any Seller Product or the use of any Seller IP. 
 (f)    Ownership Free and Clear;
Governmental Rights. Seller exclusively owns all right, title, and interest to and in Seller IP (other than Intellectual Property Rights exclusively licensed to Seller, as identified in Schedule 1.1(d)) free and clear of any Encumbrances (other
than licenses and rights granted pursuant to the Contracts identified in Schedule 1.1(d)). To Seller’s Knowledge, all Seller IP is valid, subsisting, and enforceable and is currently in compliance with all Legal Requirements (other than any
requirement that, if not satisfied, would not result in a revocation, cancellation or lapse, or otherwise adversely affect the enforceability, use or priority of such Seller IP). Seller is not and has never been a member or promoter of, or a
contributor to, any industry standards body or similar organization that requires or obligates Seller to grant or offer to any other Person any license or right to any Seller IP. No Governmental Body has any right to (including any “step-in” or “march-in” rights with respect to), ownership of, or right to royalties for, or to impose any requirement on the manufacture or
commercialization of any Seller Product or any other product incorporating any Seller IP. Without limiting the generality of the foregoing, except to the extent listed in Part 2.7(f) of the Disclosure Schedule, no invention claimed or covered by any
patent application, patent or other patent right within the Seller IP (i) was conceived or reduced to practice in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency
thereof, (ii) is a “subject invention” as that term is described in 35 U.S.C. § 201(e) or (iii) is otherwise subject to the provisions of the Bayh-Dole Act or any similar Legal Requirement of any other jurisdiction. No
funding, facilities, or personnel of 

  
 13 

 
any educational or research institution were used to develop or create in whole or in part, any of the Seller IP, and, to Seller’s Knowledge, no educational or research institution has any
right to, or right to royalties for, or to impose any requirement on the manufacture or commercialization of any Seller Product or any other product incorporating any Seller IP. 

(g)    Confidentiality and Data Protection. Seller has taken commercially reasonable steps to
maintain the confidentiality of and otherwise protect and enforce their rights in all proprietary information pertaining to Seller, all Seller IP or any Seller Product. To Seller’s Knowledge, Seller has not suffered a security breach with
respect to such proprietary information since its inception. To Seller’s Knowledge, no material trade secret, proprietary know-how, or other proprietary, non-public
information of Seller has been disclosed or authorized to be disclosed to any third party not subject to confidentiality obligations to Seller, and no third party to such a nondisclosure agreement with Seller is in breach or default thereof. 

(h)    Sufficiency. Except as listed in Part 2.7(h) of the Disclosure Schedule, to the
actual knowledge (without any obligation to conduct additional inquiry) of Seller, Seller owns or otherwise has all Intellectual Property Rights needed to conduct Seller’s business as currently conducted. 

(i)    Third-Party Infringement of Seller IP. To Seller’s Knowledge, no Person has
interfered upon, infringed, misappropriated, or otherwise violated, and no Person is currently interfering upon, infringing, misappropriating, or otherwise violating, any Seller IP. Part 2.7(i) of the Disclosure Schedule accurately identifies
(and Seller has provided to Purchaser a complete and accurate copy of) each letter or other written or electronic communication or correspondence that has been sent or otherwise delivered by or to Seller or any representative of Seller regarding any
actual, alleged, or suspected infringement or misappropriation of any Seller IP. 

(j)    Effects of This Transaction. Neither the execution, delivery, or performance of this
Agreement (or any of the ancillary agreements) nor the consummation of any of the transactions contemplated by this Agreement (or any of the ancillary agreements) will, with or without notice or lapse of time, result in, or give any other Person the
right or option to cause or declare, (i) a loss, alternation or impairment of, or Encumbrance on, any Seller IP; (ii) a breach of or default under any Seller IP Contract; (iii) the release, disclosure, or delivery of any Seller IP by
or to any escrow agent or other Person; or (iv) the grant, assignment, or transfer to any other Person of any license or other right or interest under, to, or in any of Seller IP. Each Seller IP Contract will continue to be in full force and
effect in accordance with its terms immediately following the execution and performance of this Agreement. 

(k)    No Infringement of Third Party IP Rights. To Seller’s Knowledge, Seller has never
infringed, misappropriated, or otherwise violated or made unlawful use of any Intellectual Property Right of any other Person or engaged in unfair competition. To Seller’s Knowledge, the operation of Seller’s business does not infringe,
misappropriate, violate, or make unlawful use of any Intellectual Property any other Person. No intellectual property infringement, misappropriation, or similar claim or Legal Proceeding is pending 

  
 14 

 
or, to Seller’s Knowledge, threatened against Seller or against any other Person who is or may be entitled to be indemnified, defended, held harmless, or reimbursed by Seller with respect to
such claim or Legal Proceeding. Seller has never received any written notice or other communication relating to any actual, alleged, or suspected infringement, misappropriation, or violation by Seller, any of their employees or agents, or any Seller
Product of any Intellectual Property Rights of another Person. 
 (l)    Seller Privacy
Policies; Personal Data. 
 (i)    Part 2.7(k)(i) of the Disclosure Schedule contains
each Seller Privacy Policy and identifies, with respect to each Seller Privacy Policy, (i) the period of time during which such privacy policy was or has been in effect, (ii) whether the terms of a later Seller Privacy Policy apply to the
data or information collected under such privacy policy, and (iii) if applicable, the mechanism (such as opt-in, opt-out, or notice only) used to apply a later
Seller Privacy Policy to data or information previously collected under such privacy policy. 

(ii)    No breach or violation of any Seller security policy has occurred and, to Seller’s
Knowledge, there has been no unauthorized or illegal use of or access to any Personal Data maintained by or for Seller, except as would not reasonably be expected to have a Material Adverse Effect. 

(iii)    Seller has complied in all material respects with all of Seller Privacy Policies and with
applicable Legal Requirements pertaining to the privacy of User Data or Personal Data. 

(iv)    Neither the execution, delivery, or performance of this Agreement (or any of the ancillary
agreements) nor the consummation of any of the transactions contemplated by this Agreement (or any of the ancillary agreements), nor Purchaser’s possession or use of the User Data or any data or information in Seller Databases, will result in
any violation of any Seller Privacy Policy or any Legal Requirement pertaining to privacy of User Data or Personal Data. 

(m)    No Defects. Each Seller Product: (i) conformed and complied with the terms and
requirements of any applicable warranty or other Contract and with all Legal Requirements; and (ii) was free of any design defects or other defects or deficiencies at the time it was used to provide a Seller Product, sold, distributed or made
available. Seller has not received any written notice or other communication, and is not otherwise aware of any other information, indicating that any customer of Seller is dissatisfied in any material respect with any Seller Product. 

(n)    Seller is currently evaluating its technology, systems and collection, storage, processing,
distribution and use of data for compliance with the General Data Protection Regulation (“GDPR”) and is taking reasonable steps designed to bring such systems into compliance with the requirements of the GDPR when effective,
including protection of data and security requirements, systems that manage the rights of data subjects, and other compliance tools as required under the GDPR, when effective. 

  
 15 

 2.8    Contracts. 

(a)    Part 2.8(a) of the Disclosure Schedule sets forth a complete and accurate list of all
Seller Contracts, as follows (each such Seller Contract required to be disclosed in Part 2.8(a) of the Disclosure Schedule, a “Material Contract”): 

(i)    any employment or consulting Contract with any employee or consultant, any Contract to grant
any severance or termination pay to any Person, other than (A) offer letters in Seller’s standard form that do not contain severance, change in control or similar payments and (B) agreements in Seller’s standard form relating to
acquisition of equity securities of Seller that do not involve any ongoing obligations of Seller thereunder; 

(ii)    any agreement or plan, including any stock option plan, stock appreciation rights plan or
stock purchase plan, any of the benefits of which will be increased, or the vesting of benefits of which will be accelerated, by the occurrence of any of the Transactions or the value of any of the benefits of which will be calculated on the basis
of any of the Transactions; 
 (iii)    any fidelity or surety bond or completion bond; 

(iv)    any lease of personal property; 

(v)    any agreement of indemnification or guaranty; 

(vi)    any Contract relating to capital expenditures; 

(vii)    any Contract relating to the disposition or acquisition of assets or any interest in any
business enterprise; 
 (viii)    any Contract evidencing Indebtedness; 

(ix)    any Seller Contract granting to any third party any most favored nation pricing, exclusive
sales, distribution, marketing, or other exclusive rights, rights of refusal, rights of first negotiation, or similar rights or otherwise restricting the freedom of Seller: (i) to compete with any other Person; (ii) to acquire any product
or other asset or any services from any other Person, to sell any product or other asset to or perform any services for any other Person, or to transact business or deal in any other manner with any other Person; or (iii) to develop or
distribute any technology; 
 (x)    any Contract for the purchase of materials; 

(xi)    any dealer, distribution, joint marketing, strategic alliance, affiliate or development
agreement, any sales representative, original equipment manufacturer, manufacturing, value added reseller or independent software vendor or other agreement for use or distribution of the products, technology or services of Seller; 

(xii)    those Contracts listed in Schedule 1.1(d); 

  
 16 

 (xiii)    any Contract with a Major Supplier;

 (xiv)    any Contract requiring payments by Seller in excess of [***] in the current fiscal
year; 
 (xv)    any Contract providing for receipts by Seller in excess of [***] in the current
fiscal year; or 
 (xvi)    any other Contract that is material to Seller. 

(b)    Each Material Contract that is a Transferred Contract is a valid and binding agreement of
Seller, enforceable against Seller, and, to the Knowledge of Seller, each of the other parties thereto in accordance with its terms. Seller is in compliance with and has not breached, violated or defaulted under, or received notice that it has
breached, violated or defaulted under, any of the terms or conditions of any such Material Contract that is a Transferred Contract, except for any breach, violation or default as would not have a Material Adverse Effect. To the Knowledge of Seller,
no event has occurred that (with or without notice or lapse of time) will, or would reasonably be expected to (i) result in a material violation, breach or penalty under any of the provisions of any Material Contract that is a Transferred
Contract, (ii) give any Person the right to declare a material default or exercise any remedy under any Material Contract that is a Transferred Contract, (iii) give any Person the right to accelerate the maturity or performance of any such
Material Contract that is a Transferred Contract, or (iv) give any Person the right to cancel, terminate or modify any Material Contract that is a Transferred Contract. True and complete copies of each Material Contract have been delivered to
Purchaser. 
 2.9    Compliance with Legal Requirements; Governmental Authorizations. 

(a)    Seller is, and has been since its inception, in compliance, and since December 31, 2015
and prior to such date, to Seller’s Knowledge, no event has occurred and no condition or circumstance exists that would reasonably be expected to (with or without notice or lapse of time) cause Seller to fail to be in compliance, with each
Legal Requirement or Healthcare Law that is applicable to it or to the conduct of its business as currently conducted or the ownership or use of any of its assets. Seller has not received any written notice or other communication from any
Governmental Body regarding any actual, alleged, possible or potential material violation of, or material failure to comply with, any Legal Requirement or Healthcare Law, except in each case where the failure to be in compliance would not have a
Material Adverse Effect. 
 (b)    Seller holds all of the material Governmental Authorizations it
believes necessary to enable Seller to conduct its business in the manner in which such business is currently being conducted, and all such Governmental Authorizations are valid and in full force and effect. Seller is and has been in compliance in
all material respects with such Governmental Authorizations and, since December 31, 2015 and prior to such date, to Seller’s Knowledge, no event has occurred that would reasonably be expected to (with or without notice or lapse of time)
result in the termination or material adverse modification of any such Governmental Authorization. 

  
 17 

 (c)    Neither Seller, and (to the Knowledge of
Seller) no director, officer, agent or employee of Seller, has (a) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b) made any unlawful payment to foreign or
domestic government officials or employees or to foreign or domestic political parties or campaigns or violated any provision of any anti-corruption law, including the Foreign Corrupt Practices Act of 1977, as amended, or (c) made any other
unlawful payment. 
 (d)    Seller has not made an untrue statement of a material fact or
fraudulent statement to the FDA or any other Governmental Body, failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Body, or committed an act, made a statement, or failed to make a statement that, at the
time such disclosure was made, could reasonably be expected to provide a basis for the FDA or any other Governmental Body to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”, set
forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy. 
 (e)    None of Seller,
or to the Knowledge of Seller, any officer, employee or agent of Seller, has been convicted of any crime or engaged in any conduct for which debarment is mandated by 21 U.S.C. § 335a(a) or any similar Legal Requirement or authorized by 21
U.S.C. § 335a(b) or any similar Legal Requirement by a Governmental Body. To Seller’s Knowledge, none of Seller, or any officer, employee or agent of Seller, has been convicted of any crime or engaged in any conduct for which such
Person could be excluded from participating in the federal health care programs under Section 1128 or Section 1877 of the Social Security Act of 1935, in each case, as amended, or any similar Legal Requirement. To Seller’s Knowledge,
none of Seller, or any officer, employee or agent of Seller, has engaged in any conduct that could subject such Person to a civil money penalty or criminal penalty under Sections 1128A or 1128B of the Social Security Act or any similar Legal
Requirement. None of Seller, or any officer, employee or agent of Seller, has been disqualified or restricted by the FDA pursuant to 21 C.F.R. 312.70, 21 C.F.R. 812.119, or any similar Legal Requirement. Seller has provided all information to
Purchaser necessary to comply with any disclosure requirements mandated by the FDA or other Governmental Body with respect to the Seller Products, including any information required to be disclosed in connection with any financial relationship
between the Parties and any other agents or employees. 
 (f)    Seller has obtained valid
informed consents permitting Seller to transfer any patient samples provided to Purchaser within the Transferred Assets and such patient samples may be used by Seller in the same manner and for the same purposes as were used by Seller as of Closing.

 (g)    To Seller’s Knowledge, there are no facts, circumstances or conditions that would
reasonably be expected to form the basis for any Legal Proceeding or imposition of any penalties against or affecting Seller in any material respect relating to or arising under a Healthcare Law. 

  
 18 

 (h)    Seller has not received any written notice
that the FDA or any other Governmental Body has (A) commenced, or threatened to initiate, any action to request the recall of any product, (B) commenced, or threatened to initiate, any action to enjoin reprocessing or distribution of any
product, or (C) commenced, or threatened to initiate, any action to enjoin the reprocessing or distribution of any medical device produced at any facility where any product is reprocessed, tested, or held. 

(i)    All Regulatory Approvals owned or controlled by Seller are listed in Part 2.9(l) of
the Disclosure Schedule. The Seller’s laboratory has valid federal and state licenses, permits, registrations and certificates of compliance as a CLIA-approved laboratory in all jurisdictions listed on Part 2.9(l) of the Disclosure
Schedule (“CLIA Certificates”), which are all the licenses, permits, registrations and certificates required for the operation of the Business as a CLIA-approved laboratory. Seller has not received any notification of any dispute or
challenge or potential dispute or challenge to the validity of any such CLIA Certificates and the Seller is not aware of any circumstances which may lead to the validity being challenged or disputed or the early termination of any such CLIA
Certificates, from any Governmental Body. Except as listed on Part 2.9(l) of the Disclosure Schedule, Seller does not possess any CLIA licenses, permits, registrations or certificates of compliance or any registrations, clearances or
approvals issued under the FD&C Act (collectively, “Laboratory Permits”). No Laboratory Permits are required for Seller to conduct the Business. As of the date hereof, neither Seller’s facilities nor any of its records have
been inspected by the FDA. Seller has neither conducted any clinical studies in the United States nor sponsored the conduct of any clinical research in the United States that is subject to FDA regulation since its incorporation. 

2.10    Tax Matters. 

(a)    Seller has timely filed (taking into account any extensions) with the appropriate
Governmental Body all Tax Returns that are required to have been filed with respect to the Transferred Assets or the Business and all such Tax Returns are correct and complete in all material respects. Seller has timely paid all material Taxes
required to have been paid by it with respect to the Transferred Assets or the Business, other than Taxes that are not yet due and payable or that are being contested in good faith by any appropriate Legal Proceedings (and for which adequate
reserves have been established on the most recent Seller Financial Statements). No deficiency for any material Tax has been asserted or assessed by a Governmental Body against Seller with respect to the Transferred Assets or the Business which
deficiency has not been paid or is not being contested in good faith by any appropriate Legal Proceedings (and for which adequate reserves have been established on most recent Seller Financial Statements). 

(b)    Seller has established, in the ordinary course of business and consistent with its past
practices, reserves adequate for the payment of all material Taxes for the period through the Balance Sheet Date. No material Taxes, other than as a result of the Transactions, have been incurred since the Balance Sheet Date other than in the
ordinary course of business of Seller. The representation in this Section 2.10(b) is made solely with respect to Taxes, or Tax Returns reporting Taxes, in each case: (i) for which Purchaser could bear successor liability,
(ii) that could result in a lien for such Taxes being imposed on any Transferred Asset, or (iii) that might otherwise become a liability of Purchaser after the Closing. 

  
 19 

 (c)    No written claim has ever been made by a
Governmental Body in a jurisdiction where Seller does not file Tax Returns with respect to the Transferred Assets or the Business that Seller is or may be subject to taxation in that jurisdiction with respect to the Transferred Assets or the
Business. There are no security interests or other liens on any of the Transferred Assets that arose in connection with any failure (or alleged failure) to pay any material Tax, other than liens for Taxes not yet due and payable. 

(d)    Seller has timely collected, withheld and paid to the appropriate Governmental Body all Taxes
required to have been collected, withheld and paid under applicable Legal Requirements, including collections and withholdings with respect to amounts paid or owing to any employee, independent contractor, customer, creditor, stockholder or other
third party. The representation in this Section 2.10(d) is made solely with respect to Taxes, or Tax Returns reporting Taxes, in each case: (i) for which Purchaser could bear successor liability, (ii) that could result in a lien for
such Taxes being imposed on any Transferred Asset, or (iii) that might otherwise become a liability of Purchaser after the Closing. 

(e)    No Tax Return with respect to the Transferred Assets or the Business is under audit or
examination by any Governmental Body, and no written (or, to the Knowledge of Seller, oral) notice of such an audit or examination has been received by Seller. No deficiencies for any material Taxes have been proposed, asserted or assessed against
Seller, and no requests for waivers of the time to assess any such Taxes are pending, in each case, with respect to the Transferred Assets or the Business. There are no outstanding waivers of any limitation periods or agreements providing for an
extension of time for (i) the filing of any material Tax Return with respect to the Transferred Assets or the Business, (ii) the assessment or collection of any material Tax by any relevant Governmental Body with respect to the Transferred
Assets or the Business or (iii) the payment of any material Tax by Seller with respect to the Transferred Assets or the Business. No other procedure, proceeding or contest of any refund or deficiency in respect of material Taxes is pending in
or on appeal from any Governmental Body with respect to the Transferred Assets or the Business. No closing agreement, private letter ruling, technical advice memoranda, advance pricing agreement, consent to an extension of time to make an election
or consent to a change a method of accounting, has been requested from, entered into with or issued by any Governmental Body with respect to the Transferred Assets or the Business. 

(f)    Seller (1) is not bound by any Tax sharing, allocation or indemnification agreements
with respect to the Transferred Assets or the Business (other than ancillary provisions in commercial agreements made in the ordinary course of business, the primary subject matter of which is not Tax), (2) has not been a member of an affiliated
group filing a consolidated combined, or unitary income Tax Return (other than a group the common parent of which was Seller) and (3) has no liability for Taxes of another Person (other than members of a group the common parent of which was
Seller) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local or 

  
 20 

 
foreign Legal Requirement), by operation of Legal Requirement, as a transferee or successor, by Contract or otherwise. The representations in this Section 2.10(f) are made solely with
respect to Taxes, or Tax Returns reporting Taxes, in each case: (i) for which Purchaser could bear successor liability, (ii) that could result in a lien for such Taxes being imposed on any Transferred Asset, or (iii) that might
otherwise become a liability of Purchaser after the Closing. 
 (g)    Seller is not a
“foreign person” as that term is used in Treasury Regulations Section 1.1445-2. Since its formation, Seller has been treated as corporation for U.S. federal and applicable state income Tax
purposes. 
 (h)    Seller has not been a party to a transaction that, as of the date of this
Agreement, constitutes a “listed transaction” for purposes of Section 6011 of the Code and applicable Treasury Regulations thereunder (or a similar provision of state Legal Requirement). The representation in this Section 2.10(h)
is made solely with respect to Taxes, or Tax Returns reporting Taxes, in each case: (i) for which Purchaser could bear successor liability, (ii) that could result in a lien for such Taxes being imposed on any Transferred Asset, or
(iii) that might otherwise become a liability of Purchaser after the Closing. 
 (i)    None
of the Transferred Assets represent a direct or indirect interest in any trust, partnership, corporation, limited liability company, or other “business entity” for U.S. federal income Tax purposes. To the Knowledge of Seller, Seller is not
subject to any Tax payment obligation or Tax Return filing obligation in any jurisdiction outside the United States with respect to the Transferred Assets or the Business. 

(j)    There is no property or obligation of Seller, including uncashed checks to vendors, customers
or employees, non-refunded overpayments, credits or unclaimed amounts or intangibles, that is, or may become, escheatable or reportable as unclaimed property to any Governmental Body under any applicable
escheatment, unclaimed property or similar Laws. 
 (k)    None of the Transferred Assets are
(i) property required to be treated as being owned by another Person pursuant to the provisions of Section 168(f)(8) of the Internal Revenue Code of 1954, as amended and in effect immediately prior to the enactment of the Tax Reform Act of
1986, (ii) “tax-exempt use property” within the meaning of Section 168(h)(1) of the Code, (iii) “tax-exempt bond financed property”
within the meaning of Section 168(g) of the Code, (iv) subject to Section 168(g)(1)(A) of the Code, or (v) subject to a “section 467 rental agreement” as defined in Section 467 of the Code. 

(l)    Seller has not taken any action, or has any knowledge of any fact or circumstance, that could
reasonably be expected to prevent the Transactions from qualifying as a reorganization within the meaning of Section 368(a) of the Code. 

2.11    Customers and Suppliers. Part 2.11 of the Disclosure Schedule lists the five
largest suppliers (measured by invoiced dollars) of Seller for the fiscal year ended 

  
 21 

 
December 31, 2017 and for the year to date (“Major Suppliers”) and the dollar amount of business conducted with each Major Supplier in such year and the year to date. Seller
is not engaged in any dispute with any Major Supplier, Seller is not in material breach of or in material default of any agreement with any of the Major Suppliers, and to Seller’s Knowledge, no Major Supplier intends to cancel or otherwise
adversely modify its relationship with Seller or to decrease materially or limit its services, supplies or materials to Seller or its usage or purchase of the services or products of the business. 

2.12    Employee and Labor Matters; Benefit Plans. 

(a)    Part 2.12(a) of Seller Disclosure Schedule contains a true, correct and complete list
of the names and current annual salary rates or current hourly wages, as applicable, bonus opportunity, hire date, accrued vacation and paid time-off, principal work location and leave status of all present
employees of Seller and each such employee’s status as being exempt or nonexempt from the application of state and federal wage and hour Legal Requirements applicable to employees who do not occupy a managerial, administrative, or professional
position. 
 (b)    Part 2.12(b) of the Disclosure Schedule contains a list of all
independent contractors, consultants, agents or agency employees who are entitled to compensation in excess of [***] per year currently engaged by Seller and its Subsidiaries, along with the position, date of retention and rate of remuneration for
each such Person, and any other Persons who have had access to Seller’s confidential or proprietary information, or who have contributed in any material respect to the development of the Seller Products. Each such independent Contractor,
consultant, agent or agency employee has entered into customary covenants regarding confidentiality and valid and enforceable written assignments of Intellectual Property in such Person’s agreement with Seller, a copy of which has been
delivered to Purchaser. All of the assignments referred to in the immediately preceding sentence have been timely and properly filed with the United States Patent and Trademark Office (“USPTO”), and to the extent applicable and
required by applicable Legal Requirements, its foreign equivalents. To the Seller’s Knowledge, none of such independent Contractors, consultants, agents or agency employees, are subject to any Order, Contract or other binding obligation from or
to any Governmental Body or other third party, that would conflict with such confidentiality or assignment obligations to Seller. 

(c)    Seller has not implemented any employee layoffs in the past three years that would be
reasonably likely to implicate the Worker Adjustment Retraining and Notification Act of 1988, as amended, or any similar Legal Requirement. Except as would not reasonably be expected to result in material Liability to Purchaser, Seller is, and has
been since inception, in compliance in all material respects with all applicable Legal Requirements relating to employment and employment practices, workers’ compensation, terms and conditions of employment, worker classification, wages and
hours, discrimination, immigration and collective bargaining. Except as would not reasonably be expected to result in material Liability to Purchaser, Seller has properly classified its Seller Employees as “employees” or “independent
contractors” and as “exempt” or “non-exempt” for all purposes and has properly reported all compensation paid to such Persons for all purposes. 

  
 22 

 (d)    Part 2.12(d) of the Disclosure
Schedule identifies each Seller Employee Plan. Except as would not reasonably be expected to result in material Liability to Purchaser, each Seller Employee Plan is being and has at all times been operated and administered in compliance with the
provisions thereof. There are no claims or Legal Proceedings pending, or, to the Knowledge of Seller, threatened or reasonably anticipated, against any Seller Employee Plan or against the assets of any Seller Employee Plan. 

(e)    Except as expressly required or provided by this Agreement, neither the execution or delivery
of this Agreement nor the consummation of any of the Transactions will (either alone or upon the occurrence of any additional or subsequent events) constitute an event under any Seller Employee Plan, Seller Employee Agreement, trust or loan, in each
case, that will or could reasonably be expected to result (either alone or in connection with any other circumstance or event) in any material payment (whether of severance pay or otherwise), acceleration of any material right, material obligation
or benefit, material forgiveness of indebtedness, vesting, distribution, material increase in benefits or obligation to fund benefits with respect to any Seller Employee. 

(f)    Except as set forth in Part 2.12(f) of the Disclosure Schedule, Seller has no legally
binding plan or program requiring the payment of severance compensation in connection with the termination of employment of its employees. Except as would not reasonably be expected to have a Material Adverse Effect, with respect to employees, there
are no grievances, complaints or charges pending against Seller or Seller Subsidiaries under any dispute resolution procedure. Any individual or entity that has been treated as an independent contractor by Seller within the past three (3) years
has been classified properly as an independent contractor under all applicable laws and no material tax or other payment is due to or with regard to such individual or entity. 

2.13    Environmental Matters. Seller possesses all permits and other Governmental
Authorizations required under applicable Environmental Laws, and is in material compliance with the terms and conditions thereof. Seller has not received any notice or other communication (in writing or otherwise), whether from a Governmental Body,
citizens group, employee or otherwise, that alleges that Seller is not in compliance with any Environmental Law. To the Knowledge of Seller, (a) all property that is leased to, controlled by or used by Seller, and all surface water, groundwater
and soil associated with or adjacent to such property, is free of any material environmental contamination of any nature, (b) none of the property leased to, controlled by or used by Seller contains any underground storage tanks, asbestos,
equipment using PCBs, underground injection wells, and (c) none of the property leased to, controlled by or used by Seller contains any septic tanks in which process wastewater or any Materials of Environmental Concern have been disposed of.

 2.14    Insurance. Part 2.14 of the Disclosure Schedule identifies each insurance
policy maintained by, at the expense of or for the benefit of Seller and identifies any claims (including any workers’ compensation claims) made thereunder. Each insurance policy 

  
 23 

 
identified in Part 2.14 of the Disclosure Schedule is in full force and effect and is of the type and in the amount customarily carried by Persons conducting businesses similar to those of
Seller. Seller has not received any notice or other communication (in writing or otherwise) regarding any actual or possible (a) cancellation or invalidation of any insurance policy, (b) refusal of any coverage or rejection of any claim
under any insurance policy, or (c) material adjustment in the amount of the premiums payable with respect to any insurance policy. 

2.15    Related Party Transactions. No present or former director or officer, record or
beneficial owner of one percent (1%) or more of Seller Capital Stock, Affiliate or “associate”, members of any of their “immediate family” (as such terms are respectively defined in Rule
12b-2 and Rule 16a-1 of the Securities and Exchange Act of 1934), of Seller (each of the foregoing, a “Related Party”), other than in its capacity as a
director or officer of Seller (a) is or was involved, directly or indirectly, in any business arrangement, transaction, Contract or other relationship (whether written or oral) with Seller or any assets or property thereof, (b) directly or
indirectly owned or owns, or otherwise had or has any right, title, claim, interest in, to or under, any asset, property or right, tangible or intangible, that is used by Seller, (c) to the Knowledge of Seller, has any claim or cause of action
against Seller or (d) owes any money to, or is owed any money by, Seller, other than for advances made to directors or officers of Seller in the ordinary course of business to meet reimbursable business expenses reasonably anticipated to be
incurred by such individuals. 
 2.16    Legal Proceedings; Orders. There are no, and since
inception there have not been, any Legal Proceedings pending by or against or, to the Knowledge of Seller, threatened against, Seller or any officer or director of Seller in his or her capacity as such. To the Knowledge of Seller, no event has
occurred that would reasonably be expected to give rise to or serve as a basis for the commencement of any such Legal Proceeding. Seller is not, and since inception, has not been, subject to any Order that restricts the activities of the business.
There is no Legal Proceeding pending by Seller or that Seller intends to initiate against any other Person. 

2.17    Financial Advisor. No broker, finder or investment banker is entitled to any
brokerage, finder’s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of Seller. 

2.18    No Other Representations and Warranties. Except for the representations and
warranties contained in this Section 2 (including the related portions of the Disclosure Schedules), neither Seller nor any other Person has made or makes any other express or implied representation or warranty, either written or oral, on
behalf of Seller, including any representation or warranty as to the accuracy or completeness of any information regarding Seller and the Transferred Assets furnished or made available to Purchaser and its Representatives (including any information,
documents or material delivered to Purchaser, in management presentations or in any other form in expectation of the transactions contemplated hereby) or as to the future revenue, profitability or success of the Business, or any representation or
warranty arising from statute or otherwise in law. 

  
 24 

 SECTION 3. REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS 

Each Stockholder represents and warrants to and for the benefit of the Purchaser Indemnitees as follows: 

3.1    Authority; Binding Nature of Agreement. Such Stockholder has the absolute and
unrestricted right, power and authority to perform his obligations under this Agreement. This Agreement constitutes the legal, valid and binding obligation of such Stockholder, enforceable against him in accordance with its terms, subject to
(a) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (b) rules of law governing specific performance, injunctive relief and other equitable remedies. 

3.2    Title. Such Stockholder (a) is the record and beneficial owner of the Capital
Stock set forth opposite such Stockholder’s name on Exhibit A hereto; (b) is not a party to any voting trust, proxy or other agreement or understanding with respect to the voting of any Capital Stock; 

(a)    is not a party to any option, warrant, purchase right or other Contract that could require
the Stockholder to sell, transfer or otherwise dispose of any of his Capital Stock (other than this Agreement); (d) has full power, right and authority, and any approval required by applicable Legal Requirement, to make and enter into this
Agreement; and (e) has good and valid title to the Capital Stock set forth opposite such Stockholder’s name on Exhibit A hereto, free and clear of all Encumbrances (except Permitted Encumbrances). 

3.3    Non-Contravention. To the Knowledge of
Stockholder, neither (x) the execution, delivery or performance of this Agreement, nor (y) the consummation of the Transactions, will directly or indirectly (with or without notice or lapse of time): 

(a)    contravene, conflict with or result in a violation of, or give any Governmental Body or other
Person the right to challenge the Transactions or to exercise any remedy or obtain any relief under, any Legal Requirement or any order, writ, injunction, judgment or decree to which the Stockholder, or the Capital Stock owned by such Stockholder,
is subject; 
 (b)    contravene, conflict with or result in a violation of any of the terms or
requirements of, any Governmental Authorization that relates to the Stockholder or the Capital Stock owned by such Stockholder; or 

(c)    result in the imposition or creation of any Encumbrance (except any Permitted Encumbrance)
upon or with respect to any Capital Stock owned by such Stockholder. 
 3.4    Finders’
Fees. There is no investment banker, broker, finder or other intermediary that has been retained by or is authorized to act on behalf of the Stockholder who might be entitled to any fee or commission from Purchaser upon consummation of the
Transactions. 

  
 25 

 3.5    Investment Representations.
Stockholder understands that the Securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Stockholder also understands that the Securities are being offered and sold pursuant to an
exemption from registration contained in the Securities Act based in part upon Stockholder’s representations contained in the Agreement. Stockholder hereby represents and warrants as follows: 

(a)    Stockholder Bears Economic Risk. Stockholder has substantial experience in
evaluating and investing in private placement transactions of securities in companies similar to Purchaser so that it is capable of evaluating the merits and risks of its investment in Purchaser and has the capacity to protect its own interests.
Stockholder must bear the economic risk of this investment indefinitely unless the Securities are registered pursuant to the Securities Act, or an exemption from registration is available. Stockholder understands that Purchaser has no present
intention of registering the Securities or any shares of its common stock. Stockholder also understands that there is no assurance that any exemption from registration under the Securities Act will be available and that, even if available, such
exemption may not allow Stockholder to transfer all or any portion of the Shares or the Conversion Shares under the circumstances, in the amounts or at the times Stockholder might propose. 

(b)    Acquisition for Own Account. Stockholder is acquiring the Securities for
Stockholder’s own account for investment only, and not with a view towards their distribution. 

(c)    Stockholder Can Protect Its Interest. Stockholder represents that by reason of its, or
of its management’s, business or financial experience, Stockholder has the capacity to protect its own interests in connection with the transactions contemplated in this Agreement and the Ancillary Documents. Further, Stockholder is aware of no
publication of any advertisement in connection with the transactions contemplated in the Agreement. 

(d)    Accredited Investor. Stockholder represents that it is an accredited investor
within the meaning of Regulation D under the Securities Act. 
 (e)    No “Bad
Actor” Disqualification. Stockholder represents that none of (i) Stockholder, (ii) any other entity that Stockholder controls, directly or indirectly, nor (iii) any person or entity that would be deemed to
beneficially own voting securities of Purchaser as a result of Stockholder’s ownership of voting securities of Purchaser is subject to or has taken any of the actions described in Rule 506(d)(1)(i)-(viii) promulgated under the Securities Act.

 (f)    Purchaser Information. Stockholder has received and read the Financial Statements
and has had an opportunity to discuss Purchaser’s business, management and financial affairs with directors, officers and management of Purchaser and has had the opportunity to review Purchaser’s operations and facilities. Stockholder has
also had the opportunity to ask questions of and receive answers from, Purchaser and its management regarding the terms and conditions of this investment. 

  
 26 

 (g)    Rule 144. Stockholder acknowledges
and agrees that the Securities are (or will, once issued, be) “restricted securities” as defined in Rule 144 promulgated under the Securities Act as in effect from time to time and must be held indefinitely unless they are subsequently
registered under the Securities Act or an exemption from such registration is available. Stockholder has been advised or is aware of the provisions of Rule 144, which permits limited resale of shares purchased in a private placement subject to the
satisfaction of certain conditions, including, among other things: the availability of certain current public information about Purchaser, the resale occurring following the required holding period under Rule 144 and the number of shares being sold
during any three-month period not exceeding specified limitations. 
 (h)    Residence.
If Stockholder is an individual, then Stockholder resides in the state or province identified in the address of Stockholder set forth on Exhibit A; if Stockholder is a partnership, corporation, limited liability company
or other entity, then the office or offices of Stockholder in which its investment decision was made is located at the address or addresses of Stockholder set forth on Exhibit A. 

(i)    Foreign Investors. If Stockholder is not a United States person (as defined by
Section 7701(a)(30) of the Code), Stockholder hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Securities or any use of this
Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Securities, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any government or other consents that may need to be
obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Securities. Purchaser’s offer and sale and Stockholder’s subscription and payment
for and continued beneficial ownership of the Securities will not violate any applicable securities or other laws of Stockholder’s jurisdiction. 

3.6    Transfer Restrictions. Each Stockholder acknowledges and agrees that the Securities
are subject to restrictions on transfer as set forth in the Stockholder Agreements. 

3.7    No Other Representations and Warranties. Except for the representations and warranties
contained in this Section 3 (including the related portions of the Disclosure Schedules), neither Stockholder nor any other Person has made or makes any other express or implied representation or warranty, either written or oral, on behalf of
Stockholder, including any representation or warranty as to the accuracy or completeness of any information regarding Seller, Stockholder and the Transferred Assets furnished or made available to Purchaser and its Representatives (including any
information, documents or material delivered to Purchaser, in management presentations or in any other form in expectation of the transactions contemplated hereby) or as to the future revenue, profitability or success of the Business, or any
representation or warranty arising from statute or otherwise in law. 

  
 27 

 SECTION 4. REPRESENTATIONS AND WARRANTIES OF PURCHASER 

Purchaser represents and warrants to and for the benefit of the Seller Indemnitees, as of the Closing Date, as follows: 

4.1    Due Organization. Purchaser is a corporation duly incorporated, validly existing and
in good standing under the laws of Delaware. 
 4.2    Authority; Binding Nature of Agreement.
Purchaser has the corporate power and authority to enter into and to perform its obligations under this Agreement and under each Ancillary Document to which it is or will be a party; and the execution, delivery and performance by Purchaser of this
Agreement and of each such Ancillary Document have been duly authorized by all necessary action on the part of Purchaser. Assuming the due authorization and execution by the other parties hereto and thereto, this Agreement and each Ancillary
Document to which Purchaser is or will be a party constitutes the legal, valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, subject to the Enforceability Exception. 

4.3    Non-Contravention; Consents. Neither the
execution, delivery or performance of this Agreement by Purchaser or any of the Ancillary Documents to which Purchaser is or will be a party nor the consummation by Purchaser of the Transactions will (with or without notice or lapse of time):
contravene, conflict with or result in a violation of (a) any of the provisions of the certificate of incorporation or bylaws of Purchaser or (b) any resolution adopted by the stockholders, the board of directors or any committee of the
board of directors of Purchaser. 
 4.4    Capitalization. 

(a)    The authorized capital stock of Purchaser, immediately prior to the Closing, consists of
(i) 152,687,844 shares of Common Stock, par value $0.001 per share, 1,125,733 shares of which are issued and outstanding, and (ii) 132,400,836 shares of Preferred Stock, par value $0.001 per share, (A) 700,000 shares of which are
designated Series A-1 Preferred Stock, all of which are issued and outstanding, (B) 266,688 shares of which are designated Series A-2 Preferred Stock, all of which are
issued and outstanding, (C) 750,000 shares of which are designated Series A-3 Preferred Stock, all of which are issued and outstanding, (D) 3,641,817 shares of which are designated Series B Preferred
Stock, all of which are issued and outstanding, (E) 2,998,852 shares of which are designated Series B-1 Preferred Stock, all of which are issued and outstanding, (F) 2,356,597 shares of which are designated
Series C Preferred Stock, all of which are issued and outstanding, (G) 11,781,710 shares of which are designated Series D Preferred Stock, 10,874,876 of which are issued and outstanding, (H) 13,972,954 shares of which are designated Series E
Preferred Stock, 7,639,556 of which are issued and outstanding, (I) 19,468,203 shares of which are designated Series F Preferred Stock, all of which are issued and outstanding and (J) 76,464,035 shares of which are designated Series G Preferred
Stock, 35,496,613 of which are issued and outstanding. 
 (b)    Under Purchaser’s Amended
and Restated 2006 Employee, Director and Consultant Stock Plan and its 2016 Equity Incentive Plan (together, the “Plans”), 

  
 28 

 
(i) 1,089,401 shares of Common Stock have been issued pursuant to restricted stock purchase agreements and/or the exercise of outstanding options and are included in 4.4(a)(i) above and
(ii) options to purchase 8,835,542 shares of Common Stock have been granted and are currently outstanding. 

(c)    Other than (i) the shares reserved for issuance under the Plans (including without
limitation shares reserved for issuance upon exercise of outstanding options granted under the Plans), (ii) additional options to purchase 590,645 shares of Common Stock, (iii) warrants to purchase 1,827,384 shares of Purchaser’s
Series E Preferred Stock, (iv) warrants to purchase 613,333 shares of Purchaser’s Series G Preferred Stock and (v) outstanding convertible promissory notes and except as may be granted pursuant to this Agreement and the
Ancillary Documents, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal), proxy or stockholder agreements, or agreements of any kind for the purchase or acquisition from
Purchaser of any of its securities. 
 (d)    Except with respect to the outstanding shares of
Purchaser’s Series B-1 Preferred Stock, each of which is convertible into 1.16363 shares of Purchaser’s Common Stock as of the date hereof, each outstanding series of Purchaser’s Preferred
Stock is convertible into Purchaser’s Common Stock on a one-for-one basis as of the date hereof. 

(e)    The Securities, when issued, sold and delivered in accordance with the terms of this
Agreement, will be duly and validly issued, fully paid and nonassessable. 

4.5    Representations and Warranties Given to Investors of Series G Preferred Stock.
The representations and warranties set forth in the Series G Preferred Stock Purchase Agreement dated February 23, 2018 were true and correct as of February 23, 2018, as qualified by the schedule of exceptions delivered in connection
therewith. 
 4.6    Legal Proceedings. There are no Legal Proceedings pending by or
against, or to the Knowledge of Purchaser, threatened against Purchaser, except as such as would not have a material adverse effect on Purchaser. 

4.7    Financial Advisor. No broker, finder or investment banker is entitled to any
brokerage, finder’s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of Seller. 

4.8    Reorganization. Purchaser has not taken any action, or has any knowledge of any fact
or circumstance, that could reasonably be expected to prevent the Transactions from qualifying as a reorganization within the meaning of Section 368(a) of the Code. 

SECTION 5. COVENANTS OF THE PARTIES 

5.1    Further Actions. 

(a)    From and after the Closing, Seller shall reasonably cooperate with Purchaser and its
Representatives and shall execute and deliver such documents and take such other actions as Purchaser may reasonably request for the purpose of evidencing the 

  
 29 

 
Transactions and putting Purchaser in possession and control of all of the Transferred Assets. To the extent that the parties hereto have been unable to obtain any Consent necessary be obtained
for the transfer to Purchaser of any of the Transferred Assets by the Closing: (a) such Transferred Asset (a “Specified Asset”) shall not be assigned or transferred to Purchaser until such time as such Consent is obtained; and
(b) Seller shall use its reasonable efforts to assist Purchaser in its efforts to obtain such Consent as promptly as practicable thereafter; provided, however, that in no event will Seller by required to incur any unreasonable additional
expenses in connection therewith. Until such Consent is obtained, Seller shall cooperate, and shall use its reasonable efforts to cause its Representatives to cooperate, with Purchaser in any lawful arrangement designed to provide Purchaser with the
benefits of such Specified Assets at no cost to the Purchaser in excess of the cost Purchaser would have incurred (without modification to the terms of any Contract) if the Consent had been obtained. If a required Consent with respect to a Specified
Asset is obtained after the Closing Date, the Specified Asset subject to such Consent shall be deemed to have been assigned and transferred to Purchaser as of the date such Consent is effective (and all references in Section 1.6 to the Closing
Date shall be deemed to be the effective date of such Consent with respect to such Specified Asset). Seller hereby grants Purchaser a limited power of attorney (with full power of substitution) effective as of the Closing, for the limited purpose
of: (i) collecting, asserting, enforcing or perfecting any claim, right or interest of any kind that is included in or constituted in any of the Transferred Assets; (ii) defending or compromising any Legal Proceeding relating to any of the
Transferred Assets; or (iii) with the written consent of Seller, otherwise carrying out or facilitating the transfer or assignment of any of the Transferred Assets; provided, that for each of the subclauses above, Purchaser may not, without the
written consent of Seller, incur any unreasonable expense, liability, obligations, debt or detriment of any kind with respect to Seller. The power of attorney referred to in the preceding sentence is and shall be coupled with an interest and shall
be irrevocable, and shall survive the dissolution or insolvency of Seller. 
 (b)    Following the
Closing, utilizing commercially reasonable efforts, Seller shall work with Purchaser to develop a regulatory transition plan relating to the Transferred Assets and to facilitate the approval of each applicable Governmental Bodies necessary for the
assignment of the CLIA Certificate, and all other certificates and registrations related to the Transferred Assets from Seller to Purchaser. 

5.2    Taxes. 

(a)    Purchaser and Seller shall cooperate fully, as and to the extent reasonably requested by the
other party, in connection with the preparation and filing of any Tax Return, statement, report or form, in any audit, litigation or other proceeding with respect to Taxes relating to the Business or the Transferred Assets or arising from the
transactions contemplated by this Agreement. Such cooperation shall include the retention and (upon the other party’s request) the provision of records and information in such party’s possession that are reasonably relevant to any such
audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. Each of Purchaser and Seller agrees (i) to, subject to
clause (ii), retain all books and records with 

  
 30 

 
respect to Tax matters pertinent to the Business or the Transferred Assets relating to any Pre-Closing Tax Period, and to abide by all record retention
agreements entered into with any taxing authority and (ii) to give the other party reasonable written notice prior to destroying or discarding any such books and records and, if the party so requests, shall allow the other party to take
possession of such books and records. 
 (b)    All real property taxes, personal property taxes
and similar ad valorem obligations levied with respect to the Transferred Assets for a taxable period that includes (but does not end on) the date of the Closing shall be apportioned between Seller and Purchaser as of the Closing based on the number
of days of such taxable period ending on the date of the Closing (the “Pre-Closing Tax Period”) and the number of days of such taxable period after the Closing (with respect to any such
taxable period, the “Post-Closing Tax Period”). Seller shall be liable for the proportionate amount of such Taxes that is attributable to the Pre-Closing Tax Period, and Purchaser shall be
liable for the proportionate amount of such Taxes that is attributable to the Post-Closing Tax Period. Upon receipt of any bill for real or personal property Taxes relating to the Transferred Assets, Seller and Purchaser, as applicable, shall
present a statement to the other setting forth the amount of reimbursement to which each is entitled under this Section 5.2(b) together with such supporting evidence as is reasonably necessary to calculate the proration amount. The
proration amount shall be paid by the party owing it to the other within 20 days after delivery of such statement. In the event that either Seller or Purchaser shall make any other payment for which it is entitled to reimbursement under this
Section 5.2(b), the other party shall make such reimbursement promptly but in no event later than 20 days after the presentation of a statement setting forth the amount of reimbursement to which the presenting party is entitled along with such
supporting evidence as is reasonably necessary to calculate the amount of reimbursement. 

(c)    Purchaser and Seller intend the Transactions to constitute a reorganization within the
meaning of Section 368(a) of the Code, and hereby adopt this Agreement as a plan of reorganization within the meaning of Treasury Regulations Section 1.368-2(g). Purchaser and Seller agree to
file all Tax Returns consistent with, and shall not take any Tax reporting position inconsistent with, such treatment, unless required by the IRS or any other applicable taxing authority. 

(d)    Seller shall be entitled to the amount of any refund of Taxes or other governmental charges
with respect to any Transferred Asset for a Pre-Closing Tax Period. Purchaser shall pay, or cause to be paid, to Seller any amount to which Seller is entitled pursuant to the prior sentence within [***]
business days of the receipt of the applicable refund by Purchaser or its Subsidiaries. To the extent requested by Seller, Purchaser will reasonably cooperate with Seller in obtaining such refund. 

5.3    Continuing Access to Information. Following the Closing, Seller shall give
Purchaser and its Representatives reasonable access during normal business hours to (and shall allow Purchaser and its Representatives to make copies of) any books and records relating to the Transferred Assets that are not acquired by Purchaser
hereunder for any reasonable purpose. 

  
 31 

 5.4    Publicity. Seller agrees that, on
and at all times after the date hereof: (a) no press release or other publicity concerning any of the Transactions shall be issued or otherwise disseminated by it or on its behalf without Purchaser’s prior written consent; and (b) it
shall continue to keep the terms of this Agreement and the Ancillary Documents strictly confidential; provided, however, that the existence and terms of this Agreement and the Ancillary Documents may be disclosed to the extent required
by Legal Requirements; provided, that, before making such a disclosure, Seller first notifies Purchaser and gives Purchaser an opportunity to limit such disclosure or seek a protective order and cooperates with Purchaser as reasonably
requested. 
 5.5    No Post-Closing Operations; Discharge of Liabilities. After the
Closing, Seller shall not conduct any business or otherwise engage in any operations. As promptly as practicable after the Closing, Sellers shall discharge all its Liabilities (other than the Assumed Liabilities and the Additional Liabilities).
Seller will take all actions necessary, appropriate or advisable to ensure that Seller converts into a limited liability company (treated as a partnership for income Tax purposes) within one (1) month after Closing and keeps and maintains a separate
existence in Delaware as a limited liability company and remains validly existing, in good standing, and solvent through the third anniversary of the Closing Date and neither Seller nor any of its Affiliates, or Related Parties (including the
Stockholders) shall authorize, approve, take, participate in, facilitate, assist, acquiesce to, or encourage any action to liquidate, dissolve or otherwise wind-down the Seller (beyond its conversion into a limited liability company) during such
period. 
 5.6    Release. 

(a)    Seller and the Stockholders irrevocably, unconditionally and completely releases, acquits and
forever discharges each of the Purchaser Releasees (as defined below) from any claim, controversy, demand, right, Liability, action and cause of action of every kind and nature (each, a “Claim”), and hereby irrevocably,
unconditionally and completely waives and relinquishes each and every Claim that Seller and the Stockholders may have had in the past, may now have or may have in the future against any of the Purchaser Releasees, directly or indirectly relating to
or directly or indirectly arising out of any events, matters, causes, things, acts, omissions or conduct relating directly or indirectly to the Transactions and occurring or existing at any time up to and including the Closing, but, excluding all
rights of Seller and the Stockholders under this Agreement and the Ancillary Documents. For purposes of this Section 5.6(a), “Purchaser Releasees” means: (i) Purchaser; (ii) each Affiliate and other direct or indirect
parent Entity of Purchaser (together with Purchaser, each, a “Purchaser Entity”); and (iii) the successors and past, present and future successors, assigns and Representatives of the respective Entities identified or otherwise
referred to in clauses “(i)”, “(ii)” and “(iii)” of this Section 5.6(a). 

(b)    Purchaser irrevocably, unconditionally and completely releases, acquits and forever
discharges each of the Seller Releasees (as defined below) from any Claim, and hereby irrevocably, unconditionally and completely waives and relinquishes each and every Claim that Purchaser may have had in the past, may now have or may have in the
future against any of the Seller Releasees, directly or indirectly relating to or directly 

  
 32 

 
or indirectly arising out of any events, matters, causes, things, acts, omissions or conduct relating directly or indirectly to the Transactions and occurring or existing at any time up to and
including the Closing, but, excluding all rights of Purchaser under this Agreement and the Ancillary Documents. For purposes of this Section 5.6(b), “Seller Releasees” means: (i) Seller; (ii) the Stockholders,
(iii) each Affiliate and other direct or indirect parent Entity of Seller or the Stockholders (together with Seller and the Stockholders, each, a “Seller Entity”); and (iv) the successors and past, present and future
successors, assigns and Representatives of the respective Entities identified or otherwise referred to in clauses “(i)”, “(ii)”, “(iii)” and “(iv)” of this Section 5.6(b). 

5.7    Non-Competition;
Non-Solicitation. Seller agrees as follows: 

(a)    From the Closing Date until the third anniversary of the Closing (the “Non-Compete Period”), Seller shall not, in any way, directly, indirectly, individually or through any other Person, or for the benefit of any other Person, without the prior written consent of Purchaser, in
each instance, which Purchaser may withhold or condition in its sole and absolute discretion, own, manage, operate, control or participate in the ownership, management, operation, control of, or consult with or perform services for, or be connected
in any manner with (whether as principal, agent, employee, employer, investor, consultant, shareholder, partner, member, financier or in any other individual or representative capacity of any kind whatsoever), any business that is competitive with
the business of Seller as currently conducted and as currently proposed to be conducted (the “Business”) anywhere in the world where any Purchaser Entity conducts or has plans to conduct the Business during the Non-Compete Period. 
 (b)    During the Non-Compete Period, Seller shall not, in any way, directly, indirectly, individually or through any other Person, or for the benefit of any other Person, without the prior written consent of Purchaser, in each
instance, which Purchaser may withhold or condition in its sole and absolute discretion: 

(i)    solicit, induce, encourage or recruit any employee or contractor of Seller who assumes
employment or other service with any Purchaser Entity to terminate or reduce the scope of his or her employment or other service relationship with any Purchaser Entity or otherwise interfere with such relationship; 

(ii)    employ or engage any Person described in clause (i); or 

(iii)    induce or encourage any licensor, vendor, supplier, client, customer or licensee of the
Business to terminate or reduce the scope of his, her or its relationship with any Purchaser Entity or otherwise interfere with such relationship. 

(c)    For the avoidance of doubt, the restrictions set forth in this section 5.7 shall not
apply to any stockholder of Seller. 
 5.8    Distribution of Securities. Following the
Closing, Seller shall use commercially reasonable efforts to obtain from each Stockholder and to deliver to Purchaser a completed Stockholder Package. Following Purchaser’s confirmation that such Stockholder Package is complete, Seller shall
thereafter distribute to such Stockholder the 

  
 33 

 
portion of the Securities allocable to such Stockholder in accordance with the percentages listed on Exhibit A hereto. For the avoidance of doubt, it shall be a condition precedent to a
Stockholder receiving any Securities that the recipient shall have executed and delivered a Stockholder Package in a manner reasonably satisfactory to Purchaser. 

5.9    “Market Stand-Off” Agreement.
Seller hereby agrees that Seller shall not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of, any Securities (or other securities
of Purchaser) held by Seller for a period specified by the representative of the underwriters of Purchaser’s Common Stock (or other securities of Purchaser) not to exceed 180 days following the effective date of a registration statement of
Seller filed under the Securities Act (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as the underwriters or Purchaser shall request in order to facilitate compliance
with NASD Rule 2711 or NYSE Member Rule 472). Each transferee or assignee of Securities shall be bound by and subject to the terms and conditions of this Section 5.9 and shall, as a condition precedent to receipt of such Closing Shares, agree
in writing to be bound by, and subject to, all the terms and conditions of this Section 5.9. 

5.10    Bulk Sales Laws. The parties hereby waive compliance with the provisions of any bulk
sales, bulk transfer or similar Legal Requirements of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Transferred Assets to Purchaser. 

5.11    Employees and Employee Benefits. 

(a)    Commencing on the Closing Date, Seller shall terminate all Transferred Employees and shall
pay to each such Transferred Employee all accrued but unpaid salary or wages, bonus amounts and other amounts, in each case, as set out on Schedule 5.11 attached hereto, and, unless such Transferred Employee elects to rollover accrued vacation and
paid time-off to Purchaser, the accrued vacation and paid time off listed on Schedule 1.5 hereto (collectively, “Accrued Wages”). 

(b)    Purchaser shall hire each Transferred Employee effective as of the date Seller terminates the
employment of such Transferred Employee on the terms and conditions set forth in the offer letter provided by Purchaser to such Transferred Employee, provided that such offer letter shall include a provision allowing the Transferred Employee to
elect to rollover any accrued vacation and paid time-off as set out on Schedule 1.5 hereto, and Purchaser shall permit such Transferred Employee to use any accrued vacation and paid time-off rolled over to Purchaser in accordance with Purchaser’s policies, which shall be no less favorable to the Transferred Employee than the policies in effect at Seller on the Closing Date. 

(c)    The parties acknowledge and agree that all provisions contained in this Section 5.11 are
included for the sole benefit of the respective parties and shall not create any right or remedy (including any third-party beneficiary rights) in any other Person, including any employees or former employees or other service providers of Seller,
any participant in any employee plan or any beneficiary thereof or any Transferred 

  
 34 

 
Employee. Nothing in this Section 5.11 shall be construed as any right to continued employment, or any particular term or condition of employment, of any Person with Seller or Purchaser (or
any of their respective Affiliates), nor shall any provision of this Section 5.11 require Purchaser or any of its Affiliates to continue, terminate or amend or modify any employee benefit plan on or after the Closing Date for Transferred
Employees. Nothing in this Section 5.11 shall (i) restrict the right of Purchaser or any of its Affiliates to terminate the employment of any Person (including any Transferred Employee) at any time and for any or no reason,
(ii) constitute or be construed as an amendment, termination or other modification of any benefit or compensation plan, program, policy, agreement or arrangement, or (iii) prevent Purchaser or any of its Affiliates from amending, modifying
or terminating any benefit or compensation plan, program, policy, agreement or arrangement at any time assumed, established, sponsored or maintained by any of them in accordance with its terms and applicable law. 

5.12    Financial Statements. Promptly following the date hereof, Purchaser shall use
commercially reasonable efforts to obtain from the Securities and Exchange Commission (the “SEC”) relief pursuant to Regulation S-X Rule 3-13 from the
requirement to provide certain audited financial statements required per Regulation S-X Rule 3-05 related to the transactions contemplated by this Agreement. If the SEC
does not grant such relief, or grants such relief only with respect to a portion of the periods requested, Seller shall deliver to Purchaser by December 31, 2018, and shall use commercially reasonable efforts to deliver such statements to
Purchaser by November 1, 2018, audited financial statements of Seller as of and for the years ended December 31, 2016 and December 31, 2017, audited by a firm registered with the Public Company Accounting Oversight Board
(“PCAOB”), as well as reviewed financial statements as of and for the quarters ended March 31, 2018 and June 30, 2018, reviewed by a firm registered with PCAOB. Such financial statements shall be accurate and complete in
all material respects and shall fairly present in all material respects the financial position of Seller as of the respective dates thereof and the results of operations and cash flows of Seller for the periods covered thereby in accordance with
GAAP. Such financial statements shall be prepared in accordance with GAAP applied on a consistent basis throughout the periods covered. Seller shall provide Purchaser with such other information in a timely manner relating to the financial
condition, business, books and records and financial statements of Seller as Purchaser may reasonably request. 

5.13    Information/Audit Rights. 

(a)    Quarterly Financial Statements. Prior to the seventh anniversary of this
Agreement (the “Milestone Period”), Seller shall be entitled to the following quarterly information/audit rights: 

(i)    Within [***] days after the end of each fiscal quarter, Purchaser shall prepare and deliver
to Seller an unaudited consolidated balance sheet and related statement of income and cash flows of Purchaser (the “Performance Milestone Financial Statements”), setting forth Purchaser’s calculation of Xpresys Lung Gross
Profit for each calendar month during such quarter, together with reasonable data supporting such calculation, and Purchaser’s determination of whether the Milestone Event 

  
 35 

 
was achieved by the end of such period (the “Purchaser Determination”). The Performance Milestone Financial Statements and the calculation of gross profit shall be prepared in
accordance with GAAP consistently applied as reflected on Purchaser’s regularly prepared financial statements. 

(ii)    Seller shall have [***] days following the delivery of the Performance Milestone Financial
Statements (the “Review Period”), to review and object to the Performance Milestone Financial Statements and Purchaser’s calculations of Xpresys Lung Gross Profit or the Purchaser Determination. In the event Seller does not
object to the contents of the Performance Milestone Financial Statements, Purchaser’s calculations of Xpresys Lung Gross Profit or the Purchaser Determination prior to the expiration of the Review Period, the Purchaser Determination shall be
deemed to become the final determination of whether the Performance Milestone was satisfied during such fiscal quarter, subject to any contrary finding in the Annual Milestone Audit (as defined below). In the event Seller objects to the contents of
the Performance Milestone Financial Statements or Purchaser’s calculation of Xpresys Lung Gross Profit or the Purchaser Determination, Seller shall send written notice to Purchaser specifying its objections and the basis therefor, prior to the
expiration of the Review Period (an “Objection Notice”). During the [***] day period following Purchaser’s receipt of an Objection Notice (the “Resolution Period”), Purchaser and Seller shall attempt to resolve
the differences specified in the Objection Notice. 
 (iii)    In the event after the conclusion
of a Resolution Period, the determination of whether the Performance Milestone has been satisfied remains in dispute, the dispute shall be submitted to an independent accounting firm mutually agreed upon, in good faith, in writing by Seller and
Purchaser (the “Settlement Accountant”), within [***] Business Days after expiration of the Resolution Period, as well as any information and documentation reasonably requested by the Settlement Accountant; provided, however, that
if the parties cannot mutually agree on the selection of a Settlement Accountant, each of Purchaser and Seller shall select an independent accounting firm who, in turn, shall select a third independent accounting firm to act in as the Settlement
Accountant. The conclusions of the Settlement Accountant, in the absence of manifest error, be final and binding on the parties hereto, subject to any contrary determination in an Annual Milestone Audit. All fees and expenses of the Settlement
Accountant shall be shared equally between Purchaser and Seller. 
 (b)    Annual Milestone
Audit Rights. Purchaser shall deliver to Seller written notice of the issuance of Purchaser’s annual audit for each fiscal year during the Milestone Period (the “Annual Audit Notice”) within [***] days of the completion
of each such annual audit. During the [***] day period following Seller’s receipt of each Annual Audit Notice, upon the written request of Seller, Seller shall have the right to have an independent certified public accounting firm reasonably
acceptable to Purchaser be provided access during normal business hours, upon reasonable prior written notice, to such books and records of Purchaser as may be required to verify the accuracy of Purchaser Determinations made during such fiscal year
(an “Annual Milestone Audit”). Any and all records of Purchaser examined by such independent certified public accounting firm shall be deemed to be confidential information of Purchaser. In the event of a dispute with

  
 36 

 
respect to any audit conducted under this Section 5.13, such dispute shall be submitted to a Settlement Accountant and resolved in a manner consistent with the process described in
Section 5.13(a)(iii) above. 
 SECTION 6. CLOSING DELIVERABLES 

6.1    Closing Deliverables of Seller. At the Closing, Seller shall deliver, or cause to be
delivered, the following to Purchaser: 
 (a)    a bill of sale and assignment and assumption
agreement in the form of Exhibit E hereto, duly executed by Seller (the “Bill of Sale”); 

(b)    an intellectual property assignment agreement in the form of
Exhibit F hereto, duly executed by Seller (the “IP Assignment Agreement”); 

(c)    a non-foreign affidavit dated as of the Closing Date,
sworn under penalty of perjury in accordance with the requirements of the Treasury Regulations issued pursuant to Section 1445 of the Code, in a form reasonably satisfactory to Purchaser, stating that Seller is not a “foreign person”
as defined in Section 1445 of the Code; 
 (d)    a completed and properly executed IRS Form W-9 (or the appropriate version of IRS Form W-8 (as and if applicable)) from Seller and from each other Person entitled to receive any payment pursuant to this Agreement; 

(e)    a certificate (the “Secretary’s Certificate”) dated as of the Closing
Date, signed by the Secretary of Seller, certifying as to (i) an attached copy of the organizational documents of Seller and stating that such organizational documents have not been amended, modified, revoked or rescinded, (ii) an attached
copy of the resolutions of the board of directors of Seller authorizing and approving the execution, delivery and performance of, and the consummation of, this Agreement and each Ancillary Document and the consummation of the Transactions and
stating that such resolutions have not been amended, modified, revoked or rescinded and (iii) an attached copy of the resolutions of the stockholders of Seller authorizing and approving the execution, delivery and performance of, and the
consummation of, this Agreement and each Ancillary Document and the consummation of the Transactions and stating that such resolutions have not been amended, modified, revoked or rescinded; 

(f)    good standing certificates from the Secretary of State of any State in which Seller is
qualified to do business, dated within 3 business days prior to the Closing Date; 

(g)    counterpart signature pages to each Stockholder Agreement, duly executed by Seller; 

(h)    employment offer letters, duly executed by each employee of Seller to whom such offer letter
is addressed that has accepted an offer of employment with Purchaser following the Closing; 

  
 37 

 (i)    one or more CD ROMS or flash drive
containing electronic copies of the data room as of the Closing; 
 (j)    payoff letters with
respect to all Indebtedness; and 
 (k)    evidence reasonably satisfactory to Purchaser of the
termination of all outstanding Encumbrances (except for Permitted Encumbrances) on the Transferred Assets. 

6.2    Closing Deliverables of Purchaser. At the Closing, Purchaser shall deliver, or cause
to be delivered, the following to Seller: 
 (a)    the Bill of Sale, duly executed by Purchaser;

 (b)    the IP Assignment Agreement, duly executed by Purchaser; 

(c)    a certificate dated as of the Closing Date, signed by the Secretary of Purchaser, certifying
as to (i) an attached copy of the organizational documents of Purchaser and stating that such organizational documents have not been amended, modified, revoked or rescinded, (ii) an attached copy of the resolutions of the board of
directors of Purchaser authorizing and approving the execution, delivery and performance of, and the consummation of, this Agreement, each Ancillary Document and the issuance of the Securities to Seller and the Stockholders and the consummation of
the Transactions and stating that such resolutions have not been amended, modified, revoked or rescinded and (iii) an attached copy of the resolutions of the stockholders of Purchaser authorizing and approving the execution, delivery and
performance of, and the consummation of, this Agreement, each Ancillary Document and the issuance of the Securities to Seller and the Stockholders and the consummation of the Transactions and stating that such resolutions have not been amended,
modified, revoked or rescinded; and 
 (d)    evidence reasonably satisfactory to Seller of the
issuance of the Securities to Seller, including, to the extent requested by Seller, such stock certificate(s) evidencing the Securities issued by Seller at the Closing. 

SECTION 7. INDEMNIFICATION, ETC. 

7.1    Survival of Representations, Exclusive Remedy, Etc. 

(a)    All representations and warranties of Seller, Stockholders and Purchaser set forth in this
Agreement shall expire on the second anniversary of the Closing (the “Survival Date”); provided, however, that (i) the Intellectual Property Representations shall survive until the third anniversary of the Closing;
(ii) the Specified Representations (other than the Tax Representations) shall survive indefinitely; and (iii) the Tax Representations shall survive until 60 days following the expiration of the applicable statute of limitations, including
any extensions. If, at any time on or prior to the expiration of a representation or warranty, any Indemnitee (acting in good faith) delivers to Seller or Purchaser, as applicable, a Notice of Indemnification Claim (as defined in
Section 7.6(a)) alleging the existence of an inaccuracy in or a breach of any of such 

  
 38 

 
representations or warranties and asserting a claim for recovery under Section 7.2 based on such inaccuracy or breach, then the claim asserted in such Notice of Indemnification Claim shall
survive until such time as such claim is fully and finally resolved. All covenants of the parties shall survive until performed. 

(b)    The representations, warranties, covenants and obligations of Seller and the Stockholders,
and the rights and remedies that may be exercised by the Purchaser Indemnitees, shall not be limited or otherwise affected by or as a result of any information furnished to, or any investigation made by or knowledge of, any of the Purchaser
Indemnitees or any of their Representatives. The representations, warranties, covenants and obligations of Purchaser, and the rights and remedies that may be exercised by the Seller Indemnitees, shall not be limited or otherwise affected by or as a
result of any information furnished to, or any investigation made by or knowledge of, any of the Seller Indemnitees or any of their Representatives. 

(c)    For purposes of this Agreement, each statement or other item of information set forth in the
Disclosure Schedule shall be deemed to be a representation and warranty made by Seller in this Agreement. 

(d)    Except in the case of fraud, intentional misrepresentation or willful misconduct
(collectively, “Fraud”), claims for indemnification, compensation and reimbursement brought in accordance with and subject to this Section 7, in addition to such matters and procedures covered by Section 5.2, shall be the
sole and exclusive remedy of any Indemnitee for monetary Damages from and after the Closing with respect to this Agreement. Without limiting the generality of the foregoing, nothing contained in this Agreement shall limit the rights of any
Indemnitee to seek or obtain injunctive relief or any other equitable remedy to which such Indemnitee is otherwise entitled. 

7.2    Indemnification by Seller and Stockholders. From and after the Closing, Seller and the
Stockholders shall hold harmless and indemnify each of the Purchaser Indemnitees from and against, and shall compensate and reimburse each of the Purchaser Indemnitees for, any Damages that are suffered or incurred by any of the Purchaser
Indemnitees or to which any of the Purchaser Indemnitees may otherwise become subject (regardless of whether or not such Damages relate to any third-party claim) and that arise from or as a result of: 

(a)    any inaccuracy in or breach of any representation or warranty of Seller or any Stockholder
set forth in this Agreement, the Disclosure Schedule or in any Ancillary Document; 
 (b)    any
breach of any covenant or obligation of Seller or any Stockholder set forth in this Agreement or in any Ancillary Document; 

(c)    any Liability other than the Assumed Liabilities or Additional Liabilities; 

(d)    any Liability for Excluded Taxes; 

  
 39 

 (e)    any Liability to which Purchaser or any of
the other Purchaser Indemnitees may become subject and that arises from or relates to any failure to comply with any bulk transfer law or similar Legal Requirement in connection with any of the Transactions; 

(f)    any Fraud on the part of Seller, any Stockholder, any Representative of Seller, any
Representative of any Stockholder or any other equityholder of Seller in connection with or relating directly or indirectly to (i) the negotiation, execution, delivery or performance of this Agreement and (ii) any of the Transactions; 

(g)    any claim or Legal Proceeding alleging the occurrence of facts or circumstances that, if
true, would entitle a Purchaser Indemnitee to indemnification hereunder; or 
 (h)    any
successful Legal Proceeding commenced by any Purchaser Indemnitee for the purpose of enforcing any of its rights under this Section 7.2). 

7.3    Indemnification by Purchaser. From and after the Closing, Purchaser shall hold
harmless and indemnify each of the Seller Indemnitees from and against, and shall compensate and reimburse each of the Seller Indemnitees for, any Damages that are suffered or incurred by any of the Seller Indemnitees or to which any of the
Purchaser Indemnitees may otherwise become subject (regardless of whether or not such Damages relate to any third-party claim) and that arise from or as a result of: 

(a)    any inaccuracy in or breach of any representation or warranty of Purchaser set forth in this
Agreement or in any Ancillary Document; 
 (b)    any breach of any covenant or obligation of
Purchaser set forth in this Agreement or in any Ancillary Document; 
 (c)    any Assumed
Liability or Additional Liability; 
 (d)    any Fraud on the part of Purchaser or any
Representative of Purchaser in connection with or relating directly or indirectly to (i) the negotiation, execution, delivery or performance of this Agreement and (ii) any of the Transactions; 

(e)    any claim or Legal Proceeding alleging the occurrence of facts or circumstances that, if
true, would entitle a Seller Indemnitee to indemnification hereunder; or 
 (f)    any successful
Legal Proceeding commenced by any Seller Indemnitee for the purpose of enforcing any of its rights under this Section 7.3) 

7.4    Certain Limitations. 

(a)    Except in the case of Fraud, recovery from the Holdback Shares and setoff against, or
recovery of [***] of the Milestone Shares and any payments due under Section 1.9 or Section 1.10 (which such remedies shall not be cumulative) shall be the 

  
 40 

 
Purchaser Indemnitees’ sole and exclusive remedy for monetary Damages resulting from the matters referred to in Sections 7.2(a) and 7.2(h) (as such Section 7.2(h) relates to
Section 7.2(a)); provided, that, the foregoing shall not apply with respect to any breach of the Specified Representations.

(b)    Except in the case of Fraud, the maximum amount of Damages that the Indemnitees shall be
entitled to recover in respect of an indemnification claim pursuant to Section 7.2(a) or Section 7.3(a) shall be the aggregate Deemed Value of the Securities. 

(c)    Except in the event of Fraud, the liability of a Stockholder under Section 7.2 shall not
exceed the aggregate Deemed Value of the Securities received by the Stockholder. 
 (d)    For
purposes of calculating the amount of Damages in connection with any indemnifiable matter, all qualifications and limitations as to materiality and words of similar import set forth in this Agreement will be disregarded. 

(e)    Notwithstanding the foregoing, nothing in this Agreement shall limit the rights or remedies
of any Indemnitee against any party, or the liability of any party, for a breach by such party of any provision of any agreement (other than this Agreement) executed and delivered by such party in connection with the Transactions. 

7.5    Defense of Third Party Claims. In the event of the assertion or commencement by any
Person of any claim or Legal Proceeding with respect to which any Indemnitee may be entitled to be held harmless, indemnified, compensated or reimbursed pursuant to this Section 7, (a) the Indemnitee shall notify Purchaser or Seller, as
applicable (as applicable, the “Indemnifying Party”), in writing, promptly after the Indemnitee receives written notice of such claim or Legal Proceeding (it being understood that any failure by the Indemnitee to so notify the
Indemnifying Party shall have no effect on an Indemnitee’s ability to recover Damages pursuant to this Section 7 to the extent such failure is not prejudicial), (b) the Indemnitee shall have the right, at its election, to proceed with
the defense of such claim or Legal Proceeding on its own; and (c) the Indemnifying Party shall be entitled, at its expense, to participate in any defense of such claim or Legal Proceeding. The notice sent to the Indemnifying Party by the
Indemnitee shall describe in reasonable detail, to the extent known by the indemnitee, the facts and circumstances with respect to the alleged claim or Legal Proceeding, and include an estimate of the prospective Damages. If the Indemnitee so
proceeds as described in this Section 7 with the defense of any such claim or Legal Proceeding: (i) all reasonable fees and expenses relating to the defense of such claim or Legal Proceeding shall constitute Damages, subject to the
limitations and other provisions in Section 7; (ii) the Indemnifying Party shall make available to the Indemnitee any documents and materials that the Indemnitee determines in good faith may be necessary to the defense of such claim or
Legal Proceeding; and (iii) the Indemnitee shall have the right to settle, adjust or compromise such claim or Legal Proceeding in good faith; provided, however, that if the Indemnitee settles, adjusts or compromises any such claim or
Legal Proceeding without the consent of the Indemnifying Party, such settlement, adjustment or compromise shall not be conclusive evidence of the amount of Damages incurred by the Indemnitee in connection with such claim or Legal

  
 41 

 
Proceeding (it being understood that if the Indemnitee requests that the Indemnifying Party consent to a settlement, adjustment or compromise, the Indemnifying Party shall not unreasonably
withhold, condition or delay such consent). 
 7.6    Indemnification Claims. 

(a)    If any Indemnitee has incurred or suffered or claims to have incurred or suffered, or
believes that it may incur or suffer, Damages for which it is or may be entitled to be held harmless, indemnified, compensated or reimbursed under this Section 7, such Indemnitee may deliver a notice to the Indemnifying Party (any such notice
being referred to as a “Notice of Indemnification Claim,” and the claim for indemnification, compensation and reimbursement described in such Notice of Indemnification Claim being referred to as an “indemnification
claim”), which shall (i) state that such Indemnitee believes that that there is or has been an inaccuracy in or breach of a representation, warranty, covenant or obligation contained in this Agreement or that such Indemnitee is
otherwise entitled to be held harmless, indemnified, compensated or reimbursed under this Section 7, (ii) contain a description of the circumstances supporting such Indemnitee’s belief that there is or has been such an inaccuracy or
breach or that such Indemnitee may otherwise be entitled to be held harmless, indemnified, compensated or reimbursed and (iii) contain a good faith, non-binding, preliminary estimate of the aggregate
dollar amount of actual and potential Damages that have arisen and may arise as a result of the inaccuracy, breach or other matter referred to in such notice (the aggregate amount of such estimate, as it may be modified by such Indemnitee in good
faith from time to time, being referred to as the “Claimed Amount”). 

(b)    During the 20-day period commencing upon the delivery by an Indemnitee to the Representative
of a Notice of Indemnification Claim (the “Dispute Period”), the Indemnifying Party shall deliver to the Indemnitee a written response (the “Response Notice”) in which the Indemnifying Party: (i) agrees that
the full Claimed Amount is owed to the Indemnitee; (ii) agrees that part (but not all) of the Claimed Amount is owed to the Indemnitee; or (iii) asserts that no part of the Claimed Amount is owed to the Indemnitee. Any part of the Claimed
Amount that is not agreed by the Indemnifying Party to be owed to the Indemnitee pursuant to the Response Notice (or the entire Claimed Amount, if the Indemnifying Party asserts in the Response Notice that no part of the Claimed Amount is owed to
the Indemnitee) shall be referred to as the “Contested Amount” (it being understood that the Contested Amount shall be modified from time to time to reflect any good faith and reasonable modifications by the Indemnitee to the
Claimed Amount). If a Response Notice is not sent to the Indemnitee prior to the expiration of the Dispute Period, then, absent any material prejudice to the Indemnitee, the Indemnifying Party shall be conclusively and irrevocably deemed to have
asserted that no part of the Claimed Amount is owed to the Indemnitee. If there is a Contested Amount, the Indemnifying Party (on behalf of the Stockholders) and the Indemnitee shall attempt in good faith to resolve the dispute related to the
Contested Amount. If the Indemnitee and the Indemnifying Party resolve such dispute in writing, then their resolution of such dispute shall be binding on the Indemnifying Party, Seller, Purchaser, the Stockholders and the other Indemnitees and a
settlement agreement stipulating the amount owed to the Indemnitee (the “Stipulated Amount”) shall be signed by the Indemnitee and the 

  
 42 

 
Indemnifying Party. Purchaser, on the one hand, or Seller and the Stockholders, on the other hand, in each case as applicable, shall, within 10 days following execution of such settlement
agreement, pay the Stipulated Amount to the Indemnitee (which, in the case of Seller or a Stockholder, may be through reduction of the Holdback Shares and/or setoff pursuant to the provisions of Section 7.9). 

(c)    If the Indemnifying Party and the Indemnitee are unable to resolve the dispute relating to
any Contested Amount during the 30-day period commencing upon the delivery of the Response Notice, then either the Indemnitee or the Indemnifying Party may submit the contested portion of the indemnification claim to the court in accordance with
Section 7. The final award setting forth the aggregate amount owed to the Indemnitee shall be referred to as the “Award Amount”. Purchaser, on the one hand, or Seller and the Stockholders, on the other hand, in each case as
applicable, shall, within 10 days following the entry by the court of the Award Amount, pay the Award Amount to the Indemnitee; provided, that any payments required to be made by the Seller or the Stockholders in satisfaction of claims for
indemnification pursuant to Section 7.2(a) (other than any inaccuracy in or breach of any Specified Representation) shall first be satisfied by the Purchaser’s cancellation of Holdback Shares with an aggregate Deemed Value equal to
the Award Amount; provided further, that any payments required to be made by the Seller or the Stockholders in satisfaction of claims for indemnification pursuant to Section 7 may, upon Purchaser’s election, be satisfied by the
Purchaser’s cancellation of Holdback Shares with an aggregate Deemed Value equal to the Award Amount. 

7.7    Tax Treatment of Indemnification Payments. All indemnification payments made under
this Agreement shall be treated by Seller and Purchaser as an adjustment to the Purchase Price for all Tax purposes, unless otherwise required by applicable Legal Requirements. 

7.8    Recovery of Securities. For purposes of this Section 7, including with respect to
any Securities redeemed from the Holdback Shares, the deemed value of each share of Purchaser Shares shall be equal to the Deemed Value. Upon determination in accordance with this Agreement that a Purchaser Indemnitee shall recover Securities issued
hereunder, such Stockholder shall take all reasonable action requested by Purchaser to effect the transfer or such shares to the applicable Purchaser Indemnitee or the forfeiture of such shares to the Purchaser, at Purchaser’s discretion,
including returning the stock certificate evidencing such shares to Purchaser. Notwithstanding the foregoing, upon determination in accordance with this Agreement that a Purchaser Indemnitee is entitled to recover Securities issued hereunder,
Purchaser shall be entitled to cancel on its books any stock certificate evidencing such shares and, upon such cancellation, such shares shall cease to be outstanding. 

7.9    Setoff. In addition to any rights of setoff or other similar rights that Purchaser or
any of the Purchaser Indemnitees may have at common law or otherwise, the Purchaser Indemnitees shall have the right to withhold and deduct any sum that is or may be owed to any Purchaser Indemnitee under this Section 7 from the Holdback
Shares, Securities and any payments due under Section 1.9 or Section 1.10. Purchaser shall have the right, exercisable by delivery of written notice to Seller, to set-off against the Holdback

  
 43 

 
Shares, Milestone Shares and Securities issuable by Parent or Purchaser pursuant to this Agreement, and any payments due under Section 1.9 or Section 1.10, an amount equal to the
aggregate amount of all Damages relating to Unresolved Claims for indemnification made by the Purchaser Indemnitees; provided, however, that if the amount of any Damages relating to claims for indemnification made by the Purchaser Indemnitees
that is setoff against the Holdback Shares, Securities or any payments due under Section 1.9 or Section 1.10 exceeds the amount by which the payments were reduced for such claim, then, subject to the provisions of this Section 7, the
Purchaser Indemnitees shall continue to be entitled to indemnification for the amount of such excess. 
 SECTION 8. MISCELLANEOUS PROVISIONS. 

8.1    Fees and Expenses. Except as otherwise provided in this Agreement, each party to this
Agreement shall bear and pay all fees, costs and expenses (including legal fees, accounting fees and investment banking fees) that have been incurred or that are incurred by or on behalf of such party in connection with the Transactions. 

8.2    Attorneys’ Fees. If any Legal Proceeding relating to this Agreement or the
enforcement of any provision of this Agreement is brought against any party hereto, the prevailing party shall be entitled to recover reasonable attorneys’ fees, costs and disbursements (in addition to any other relief to which the prevailing
party may be entitled). 
 8.3    Notices. Any notice or other communication required or
permitted to be delivered to any party under this Agreement shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service or by electronic mail) to
the address or electronic mail address set forth beneath the name of such party below (or to such other address or electronic mail address as such party shall have specified in a written notice given to the other parties hereto): 

if to Purchaser: 

Biodesix, Inc. 

2970 Wilderness Place 

Boulder, CO 80301 

Attention: Chief Executive Officer 

With a copy (which shall not constitute notice) to: 

Cooley LLP 

380 Interlocken Crescent 

Suite 900 

Broomfield, CO 80021 

Attention: Brent Fassett and Laura Medina 

  
 44 

 if to Seller: 

Integrated Diagnostics, Inc. 

219 Terry Avenue N Suite 100 

Seattle, WA 98109 

Attention: Board of Directors 

With a copy (which shall not constitute notice) to: 

IND Funding, LLC (c/o Life Science Alternative Funding LLC) 

[***] 

Attention: [***] 

With a copy (which shall not constitute notice) to: 

Latham & Watkins LLP 

140 Scott Drive 

Menlo Park, CA 94025 

Attention: Jim Morrone and Miles Jennings 

if to Stockholder: 

IND Funding, LLC (c/o Life Science Alternative Funding LLC) 

[***] 

Attention: [***] 

With a copy (which shall not constitute notice) to: 

Latham & Watkins LLP 

140 Scott Drive 

Menlo Park, CA 94025 

Attention: Jim Morrone and Miles Jennings 

8.4    Headings. The headings contained in this Agreement are for convenience of reference
only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. 

8.5    Counterparts and Exchanges by Electronic Transmission. This Agreement may be executed
in several counterparts, each of which shall constitute an original and all of which, when taken together, shall constitute one agreement. The exchange of a fully executed Agreement (in counterparts or otherwise) delivered electronically (including
without limitation transmission by .pdf or other fixed image form) shall be sufficient to bind the parties to the terms and conditions of this Agreement. 

8.6    Governing Law; Consent to Jurisdiction. This Agreement shall be governed by, and
construed in accordance with, the Legal Requirements of the State of Delaware applicable to Contracts executed in and to be performed entirely within such State. Each of the parties to this Agreement hereby irrevocably and unconditionally submits,
for itself and its assets and properties, to the exclusive jurisdiction of any Delaware State court, or Federal court of the United States of America, sitting within the 

  
 45 

 
State of Delaware, and any appellate court from any thereof, in any Legal Proceeding arising out of or relating to this Agreement, the agreements delivered in connection with this Agreement, or
the transactions contemplated hereby or thereby, or for recognition or enforcement of any judgment relating thereto, and each of the parties to this Agreement hereby irrevocably and unconditionally (a) agrees not to commence any such Legal
Proceeding except in such courts; (b) agrees that any claim in respect of any such Legal Proceeding may be heard and determined in such Delaware State court or, to the extent permitted by Legal Requirement, in such Federal court;
(c) waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any such Legal Proceeding in any such Delaware State or Federal court; and (d) waives, to
the fullest extent permitted by Legal Requirement, the defense of an inconvenient forum to the maintenance of such Legal Proceeding in any such Delaware State or Federal court. Each of the parties to this Agreement hereby agrees that a final
judgment in any such Legal Proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Legal Requirement. Each of the parties to this Agreement hereby irrevocably consents to
service of process in the manner provided for notices in Section 8.3. Nothing in this Agreement shall affect the right of any party to this Agreement to serve process in any other manner permitted by applicable Legal Requirement. 

8.7    Waiver of Jury Trial. Each of the parties hereto hereby irrevocably waives any and all right to
trial by jury in any Legal Proceeding arising out of or related to this Agreement or the transactions contemplated hereby 

8.8    Successors and Assigns. This Agreement shall be binding upon, inure to the benefit of
and be enforceable by the parties to this Agreement and their respective successors and assigns. Purchaser may freely assign any or all of its rights and obligations under this Agreement (including its indemnification rights under Section 7),
in whole or in part, to any other Person without obtaining the consent or approval of any other party hereto; provided, that, such Person agrees in writing to be bound by the provisions of this Agreement. Neither Seller nor any Stockholder
may assign its rights and obligations under this Agreement without obtaining the written consent of Purchaser; provided, that, Seller and Stockholder may make such an assignment to any Affiliate who agrees in writing to be bound by the
provisions of this Agreement. 
 8.9    Remedies Cumulative; Specific Performance. The
rights and remedies of the parties hereto shall be cumulative (and not alternative). The parties to this Agreement agree that, in the event of any breach or threatened breach by any party to this Agreement of any covenant, obligation or other
provision set forth in this Agreement for the benefit of any other party to this Agreement, such other party shall be entitled (in addition to any other remedy that may be available to it) to (a) a decree or order of specific performance or
mandamus to enforce the observance and performance of such covenant, obligation or other provision and (b) an injunction restraining such breach or threatened breach. The parties agree that no party shall be required to provide any bond or
other security in connection with any such decree, order or injunction or in connection with any related Legal Proceeding. 

  
 46 

 8.10    Waiver. 

(a)    No failure on the part of any Person to exercise any power, right, privilege or remedy under
this Agreement, and no delay on the part of any Person in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such
power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. 

(b)    No Person shall be deemed to have waived any claim arising out of this Agreement, or any
power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Person; and any such waiver shall
not be applicable or have any effect except in the specific instance in which it is given. 

8.11    Amendments. This Agreement may not be amended, modified, altered or supplemented
other than by means of a written instrument duly executed and delivered on behalf of all of the parties hereto. 

8.12    Severability. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any
other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit
the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or
unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term
or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. 

8.13    Parties in Interest. Nothing expressed or implied in this Agreement is intended or
shall be construed to confer upon or give any Person, other than the parties hereto, any rights or remedies under or by reason of this Agreement; provided, however, that, notwithstanding the foregoing, the Indemnitees shall be and are
intended third-party beneficiaries of, and may enforce, Section 7. 
 8.14    Entire
Agreement. This Agreement and the other agreements referred to herein set forth the entire understanding of the parties hereto relating to the subject matter hereof and thereof and supersede all prior agreements and understandings among or
between any of the parties relating to the subject matter hereof and thereof. 

  
 47 

 8.15    Construction. 

(a)    For purposes of this Agreement, whenever the context requires: the singular number shall
include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. 

(b)    The parties hereto agree that any rule of construction to the effect that ambiguities are to
be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. 

(c)    As used in this Agreement and the Exhibits to this Agreement, the words “include”
and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” 

(d)    The phrase “delivered to Purchaser” or similar phrases used in this Agreement shall
mean that true and correct copies of the subject document were posted to the electronic data room for this transaction or were delivered in accordance with the notice provisions of Section 8.3 at least three (3) business days prior to the
Closing. 
 (e)    Except as otherwise indicated, all references in this Agreement to
“Sections,” “Exhibits” and “Schedules” are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement. 

[Remainder of page intentionally left blank] 

  
 48 

 IN WITNESS
WHEREOF, the parties hereto have caused this Agreement to be executed and delivered as of the date first set forth above. 

 

			
	PURCHASER:
	
	BIODESIX, INC.
		
	By:	 	 /s/ David Brunel

		 	Name: David Brunel
		 	Title: CEO
	
	SELLER:
	
	INTEGRATED DIAGNOSTICS, INC.
		
	By:	 	 /s Albert Luderer

		 	Name: Albert Luderer
		 	Title: Chief Executive Officer
	
	STOCKHOLDER:
	
	IND FUNDING LLC
		
	By:	 	 /s/ Steve DeNelsky

		 	Name: Steve DeNelsky
		 	Title: President

 EXHIBIT B 

CERTAIN DEFINITIONS 

For purposes of the Agreement (including this Exhibit B and the Disclosure Schedule): 

“Acquisition” means: 

(a)    the acquisition, directly or indirectly, in one transaction or a series of related transactions, by any Person or
group (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934) of the beneficial ownership of securities of Purchaser possessing more than 50% of the total combined voting power of all outstanding securities of Purchaser
(provided, however, that a Change of Control will not result upon such acquisition of beneficial ownership if such acquisition occurs as a result of: (i) a public offering of Purchaser’s securities or any financing transaction or series of
financing transactions, in each case for bona fide financing purposes or (ii) a merger or consolidation involving Purchaser where the holders of the outstanding voting securities of Purchaser immediately prior to such merger or consolidation
(taken in the aggregate) possess beneficial ownership of 50% or more of the total combined voting power of all outstanding voting securities of Purchaser, the surviving entity, the acquiring entity or a parent or holding company of the acquiring
entity, immediately after such merger or consolidation); or 
 (b)    the sale, transfer or other disposition (in one
transaction or a series of related transactions) of all or substantially all of the assets of Purchaser, except for a transaction in which the holders of the outstanding voting securities of Purchaser immediately prior to such transaction(s) (taken
in the aggregate) receive as a distribution with respect to securities of Purchaser more than 50% of the total combined voting power of all outstanding voting securities of the acquiring entity or a parent or holding company of the acquiring entity
immediately after such transaction(s). 
 For purposes of this definition of Change of Control, all references to Purchaser will be deemed
to include any successor-in-interest to Purchaser or any direct or indirect parent entity or holding company of Purchaser or such successor-in-interest. 
 “Affiliate” when used with respect to any specified
Person, shall mean any other Person who or that, directly or indirectly through one or more intermediaries, Controls, is Controlled by or is under common Control with such specified Person. 

“Agreement” shall mean the Asset Purchase Agreement and Plan of Reorganization to which this Exhibit B is attached. 

“Ancillary Document” means the Bill of Sale, the IP Assignment Agreement and the Secretary’s Certificate. 

“CLIA” shall mean the Clinical Laboratory Improvement Amendments of 1988, as amended. “COBRA”
shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended. “Code” shall mean the Internal Revenue Code of 1986, as amended. 

 “Consent” shall mean any approval, consent, ratification, permission,
waiver or authorization (including any Governmental Authorization). 
 “Contract” shall mean any written, oral or other
agreement, contract, subcontract, lease, understanding, instrument, note, certificate, warranty, proxy, insurance policy, benefit plan or commitment, arrangement or undertaking of any nature. 

“Control” shall mean, as to any Person, the power to direct or cause the direction of the management and policies of such
Person, whether through the ownership of voting securities, by contract or otherwise. The term “Controlled” shall have a correlative meaning. 

“Damages” shall include claims, liabilities, damages, Taxes, diminution of value, lost profits, payments, obligations,
losses, costs and expenses (including reasonable attorneys’ fees, court costs, expert witness fees, transcript costs and other expenses of litigation), and judgments (at law or in equity) of any nature, but shall not include indirect or
consequential damages (unless such damages are reasonably foreseeable) nor punitive or special damages. 
 “Deemed Value”
of the Securities, with respect to Section 7 only, shall mean, [***] per share of Series G Preferred Stock. 
 “DOL”
shall mean the United States Department of Labor. 
 “Encumbrance” shall mean any lien, pledge, hypothecation, charge,
mortgage, security interest, encumbrance, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction of any nature (including any restriction on the voting of any security, any
restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other
attribute of ownership of any asset). 
 “Entity” shall mean any corporation (including any
non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any limited liability company or joint stock company), firm or
other enterprise, association, organization or entity. 
 “Environmental Law” shall mean any applicable federal, state,
local or foreign Legal Requirement relating to pollution or protection of worker health or safety (with respect to exposure to Materials of Environmental Concern) or the environment (including ambient air, surface water, ground water, land surface
or subsurface strata), including any Legal Requirement relating to emissions, discharges, releases or threatened releases of Materials of Environmental Concern, or otherwise relating to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Materials of Environmental Concern. 
 “ERISA” shall mean the Employee
Retirement Income Security Act of 1974, as amended. 
 “Excluded Taxes” shall mean any (i) Taxes of Seller (or any
member, stockholder or Affiliate of Seller), or for which Seller (or any member, stockholder or Affiliate of Seller) is or are liable, for any taxable period; (ii) to the extent not included in the preceding subpart (i), all Taxes

 
related to the Excluded Assets or Liabilities that are not Assumed Liabilities or Additional Liabilities, in each case, for any taxable period; (iii) Taxes relating to the Business, the
Transferred Assets, the Assumed Liabilities or the Additional Liabilities for any Pre-Closing Tax Period; (iv) other Taxes of Seller (or any member, stockholders or Affiliate of Seller) of any kind or
description (including any Liability for Taxes of Seller (or any member, stockholder or Affiliate of Seller) that becomes a Liability of Purchaser under any common law doctrine of de facto merger or transferee or successor liability or otherwise by
operation of contract or Legal Requirement); and (v) any Transfer Taxes borne by Seller pursuant to Section 1.7. 

“FDA” shall mean the U.S. Food and Drug Administration and any successor organization. 

“FD&C Act” shall mean the Federal Food, Drug, and Cosmetic Act, as set forth in 21 U.S.C. §301 et. seq., and
all applicable regulations promulgated by the FDA. 
 “FMLA” shall mean the Family Medical Leave Act of 1993, as amended.

 “GAAP” shall mean generally accepted accounting principles in the United States. 

“Governmental Authorization” shall mean any: (a) permit, license, certificate, franchise, permission, clearance,
registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Legal Requirement; or (b) right under any Contract with any Governmental Body.

 “Governmental Body” shall mean any: (a) nation, state, commonwealth, province, territory, county, municipality,
district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; or (c) governmental authority of any nature (including any governmental division, department, agency, commission,
instrumentality, official, organization, unit, body or Entity and any court or other tribunal). 
 “Healthcare Laws” shall
mean all applicable federal and state Legal Requirements relating to the regulation, provision or administration of, or payment for, healthcare products or services, including, but not limited to (i) the federal Anti-Kickback Statute (42 U.S.C.
§1320a-7b(b)), the Stark Law (42 U.S.C. §1395nn), the civil False Claims Act (31 U.S.C. §3729 et seq.), TRICARE (10 U.S.C. Section 1071 et seq.), Sections
1320a-7 and 1320-a-7a of Title 42 of the United States Code and the regulations and rules promulgated pursuant to such statutes;
(ii) HIPAA; (iii) Medicare (Title XVIII of the Social Security Act) and the regulations and rules promulgated thereunder; (iv) Medicaid (Title XIX of the Social Security Act) and the regulations and rules promulgated thereunder;
(v) quality and safety laws, rules or regulations relating to the regulation, provision or administration of, or payment for, healthcare products or services; (vi) laws, regulations or rules governing the provision of services to employees
with workers compensation coverage or licensure or certification as a healthcare organization to provide such services; and (vii) licensure laws, rules or regulations relating to the regulation, provision or administration of, or payment for,
healthcare products or services, each of (i) through (vii) as amended from time to time. 
 “HIPAA” shall
mean the Health Insurance Portability and Accountability Act of 1996, and its implementing regulations, as amended and supplemented by the Health Information Technology for Economic and Clinical Health Act of the American Recovery and Reinvestment
Act of 2009, Pub. Law No. 111-5 and its implementing regulations, as effective and as amended through the date of this Agreement. 

 “Indebtedness” shall mean both the current and long-term portions of any
amount owed by Seller, without duplication, in respect of (a) borrowed money, extensions of credit, purchase money financing, and capitalized lease obligations or for the deferred purchase price of property or services, (b) all obligations
for the reimbursement of any obligor for amounts drawn on any outstanding letters of credit, (c) all obligations evidenced by a note, bond, debenture or similar instrument, (d) all accrued and unpaid interest, fees, expenses, prepayment
penalties or premiums on, or any guarantees or other contingent liabilities with respect to, any of the obligations referred to in the foregoing clauses (a) through (d); provided, however, that notwithstanding the foregoing, Indebtedness
shall not be deemed to include any accounts payable incurred in the ordinary course of business except to the extent such amounts are included in clauses (a) through (d) above. 

“Indemnitees” shall mean the Purchaser Indemnitees and the Seller Indemnitees, collectively. 

“Intellectual Property” shall mean and include all algorithms (including classifiers, data analysis, prediction, and
probabilities), application programming interfaces, apparatus, circuit designs and assemblies, data, databases and data collections, diagrams, designs, devices, analytics, materials (including chemical and biological materials and sequences and
structural information thereof), compositions (including transition ion pairs for any diagnostic and normalization proteins), synthetic peptides and fragments, biomarkers, cell lines, viral lines, proteolytic reagents, assays, kits, panels,
formulations, formulae, integrated quantification methods, multiple reaction monitoring mass spectroscopy methods, gate arrays, IP cores, inventions (whether or not patentable), know-how, trade secrets, logos,
marks (including brand names, product names, logos, and slogans), processes, methods, image monitoring methods, network configurations and architectures, net lists, masks, photomasks, processes, proprietary information, protocols, schematics,
models, layouts, diagrams, modules, dies, prototypes, specifications, software, software code (in any form including source code and executable or object code), statistical programs, subroutines, test results, test vectors, user interfaces,
techniques, URLs, web sites, works of authorship, and other forms of technology (whether or not embodied in any tangible form and including all tangible or electronic embodiments of the foregoing). 

“Intellectual Property Opinions” shall mean written opinions regarding the ownership, validity, patentability,
inventorship, or enforceability of any Intellectual Property Rights of Seller or regarding freedom to operate or infringement (or lack of either of the foregoing) of or by the research, development, manufacture, use, sale, importation or other
exploitation of the Seller Products. 
 “Intellectual Property Representations” shall mean the representations and
warranties set forth in Section 2.7. 
 “Intellectual Property Rights” shall mean and include all rights of the
following types, which may exist or be created under the laws of any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, design rights and mask works;
(b) trademark and trade name rights and similar rights; (c) trade secret 

 
rights; (d) patents and industrial property rights; (e) other proprietary rights in Intellectual Property of every kind and nature; and (f) all registrations, renewals, extensions,
continuations, divisions, or reissues of, and applications for, any of the rights referred to in clauses (a) through (e) above, and all goodwill in or to any of the foregoing. 

“IRS” shall mean the United States Internal Revenue Service. 

Knowledge. An individual shall be deemed to have “Knowledge” of a particular fact or other matter if such individual is
actually aware of such fact or other matter or could be expected to have discovered or otherwise became aware of such fact or other matter after reasonable inquiry. Seller shall be deemed to have “Knowledge” of a particular fact or other
matter only if a director or officer of Seller has Knowledge of such fact or other matter. 
 “Legal Proceeding” shall mean
any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before,
or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel. 
 “Legal Requirement”
shall mean any federal, state, local, municipal, foreign or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, order, award, ruling or requirement issued, enacted, adopted,
promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body. 
 “Liability”
means any and all liabilities and obligations of any kind or nature, whether accrued or fixed, absolute or contingent, matured or unmatured, or determined or determinable. 

“Material Adverse Effect” shall mean any change, event, effect, claim, circumstance or matter that is, or would reasonably be
expected to be or to become, materially adverse to the business, , assets, capitalization, Liabilities, results of operations or financial condition of Seller, taken as a whole; provided, however, that “Material Adverse Effect”
shall not include any change, event, effect, claim, circumstance or matter, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the industries in
which Seller operates; (iii) any changes in financial, banking or securities markets in general; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (v) any action
required or permitted by this Agreement or any action taken (or omitted to be taken) with the written consent of or at the written request of Purchaser; the announcement, pendency or completion of the transactions contemplated by this Agreement; or
any natural or man-made disaster or acts of God. 
 “Materials of Environmental
Concern” include chemicals, pollutants, contaminants, wastes, toxic substances, petroleum and petroleum products and any other substance that is now regulated by any Environmental Law. 

“Milestone Event” shall mean [***]. 

“Order” shall mean any order, writ, injunction, judgment or decree. 

 “Permitted Encumbrances” shall mean: (a) liens for Taxes that are not
yet due and payable or that are being contested in good faith and for which appropriate reserves have been established on the most recent Seller Financial Statements; (b) mechanics’, carriers’, workmen’s, repairmen’s or
other like liens arising or incurred in the ordinary course of business; (c) easements, rights of way, zoning ordinances and other similar encumbrances affecting real property; (d) liens imposed by law and incurred in the ordinary course
of business for obligations not yet due and payable; and (e) liens in respect of pledges or deposits under workers’ compensation laws or similar legislation. 

“Person” shall mean any individual, Entity or Governmental Body. 

“Personal Data” shall mean information that alone or in combination can be used to specifically identify a natural person.

 “Pre-Closing Tax Period” shall mean any taxable year or period that ends on or
before the day prior to the Closing Date and, with respect to any Straddle Period, the portion of such taxable year or period ending on the Closing Date. 

“Purchaser Indemnitees” shall mean (a) Purchaser; (b) Purchaser’s current and future Affiliates; (c) the
respective Representatives of the Persons referred to in clauses “(a)” and “(b)” above; and (d) the respective successors and assigns of the Persons referred to in clauses “(a)”, “(b)” and “(c)”
above. 
 “Registered IP” shall mean all Intellectual Property Rights that are registered, filed or issued under the
authority of any Governmental Body, including all patents, registered copyrights, registered mask works, registered designs and registered trademarks and all applications or similar submissions for any of the foregoing. 

“Regulatory Approval” shall mean all necessary approvals, licenses or authorizations of the FDA or other applicable
Governmental Body necessary for the development, manufacture, marketing and sale of a Product in all countries in the world, including any pre-market approval applications, CE marks, de novo classification
petitions, premarket notifications or analogous approvals (including all information submitted or incorporated by reference therewith), pricing or reimbursement approvals, in each case, whether or not legally required in order to sell the product in
such country, and any approvals by the applicable Governmental Body of any expansion or modification of the label for the Product. 

“Representatives” shall mean officers, directors, employees, partners, agents, attorneys, accountants, advisors and
representatives. 
 “Seller Affiliate” shall mean any Person under common control with Seller within the meaning of
Sections 414(b), (c), (m) and (o) of the Code, and the regulations issued thereunder. 
 “Seller Contract” shall mean
any Contract: (a) to which Seller is a party; (b) by which Seller is bound or under which Seller has any obligation; or (c) under which Seller has any right or interest. 

 “Seller Employee” shall mean any current or former employee, consultant,
independent contractor or director of Seller or a Seller Affiliate. 
 “Seller Employee Agreement” shall mean any
management, employment, severance, change in control, transaction bonus, consulting, relocation, repatriation or expatriation agreement or other Contract between Seller or a Seller Affiliate and any Seller Employee, other than any such Contract that
is terminable “at will” and without any obligation on the part of Seller or any Seller Affiliate to make any payments or provide any benefits in connection with termination of such Contract other than the requirement to make continued
healthcare coverage available to the Seller Employee in accordance with applicable Legal Requirements. 
 “Seller Employee
Plan” shall mean any plan, program, policy, practice, Contract or other arrangement providing for compensation, severance, termination pay, deferred compensation, performance awards, stock or stock-related awards, fringe benefits or other
employee benefits or remuneration of any kind, whether written, unwritten or otherwise, and whether funded or unfunded, including each “employee benefit plan,” within the meaning of Section 3(3) of ERISA (whether or not ERISA is
applicable to such plan), that is or has been maintained, contributed to or required to be contributed to by Seller or any Seller Affiliate for the benefit of any Seller Employee and with respect to which Seller or any Seller Affiliate has or may
have any liability or obligation; provided, however, than a Seller Employee Agreement shall not be considered a Seller Employee Plan. 

“Seller Equity Plan” shall mean Seller’s 2009 Equity Incentive Plan. 

“Seller Indemnitees” shall mean (a) Seller; (b) Seller’s current and future Affiliates; (c) the
respective Representatives of the Persons referred to in clauses “(a)” and “(b)” above; and (d) the respective successors and assigns of the Persons referred to in clauses “(a)”, “(b)” and
“(c)” above. 
 “Seller IP” shall mean (a) all Intellectual Property Rights owned by or exclusively
licensed to Seller and (b) all other Intellectual Property Rights used in Seller’s business. 
 “Seller IP
Contract” shall mean any Contract to which Seller is a party or by which Seller is bound, that contains any assignment, option, grant or license of, or covenant not to assert, defend or enforce, any Intellectual Property Right or
that otherwise relates to any Seller IP or any Intellectual Property developed or acquired by, with, or for Seller. 
 “Seller
Option” shall mean a subscription, option, call, warrant or right of any kind to purchase any shares of capital stock of Seller, whether vested or unvested and whether or not granted under the Seller Equity Plan. 

“Seller Pension Plan” shall mean any (a) Seller Employee Plan that is an “employee pension benefit plan,”
within the meaning of Section 3(2) of ERISA, or (b) other occupational pension plan, including any final salary or money purchase plan. 

“Seller Privacy Policy” shall mean each external or internal, past or present privacy policy of Seller, including any policy
relating to (i) the privacy of users of Seller Products or of any website or service operated or maintained by or on behalf of Seller, (ii) the collection, storage, disclosure, and transfer of any User Data or Personal Data, and
(iii) any employee information. 

 “Seller Product” shall mean any product or service designed, developed,
manufactured, marketed, distributed, provided, licensed, or sold at any time by Seller. 
 “Seller Stock Award” shall mean
an award of shares of capital stock of Seller that is subject to a vesting schedule or right of Seller or any Person to repurchase or require such shares or an award of a right to acquire shares of capital stock of Seller (other than a Seller
Option) or cash with a value based on the value of shares of capital stock of Seller, whether vested or unvested and whether or not granted under the Seller Equity Plan. 

“Series G Preferred Stock” shall mean the Series G Preferred Stock of Purchaser, par value $0.001 per share, or the Common
Stock of Purchaser, par value $0.001 if all other shares of Series G Preferred Stock of Purchaser have converted to Common Stock. 

“Specified Representations” shall mean the representations and warranties set forth in Section 2.1 (Corporate Status;
Subsidiaries), Section 2.2 (Authorization and Enforceability; No Conflict), Section 2.3 (Capitalization), Section 2.10 (Tax Matters), Section 2.17 (Financial Advisor), Section 3.1 (Authority; Binding Nature of Agreement),
Section 3.2 (Title), Section 3.4 (Finder’s Fees), Section 4.1 (Due Organization), Section 4.2 (Authority; Binding Nature of Agreement), and Section 4.4 (Capitalization). 

“Stockholder Agreements” shall mean the Tenth Amended and Restated Investor Rights Agreement, the Sixth Amended and Restated
Voting Agreement and the Seventh Amended and Restated Right of First Refusal and Co-Sale Agreement, each between Purchaser and certain of its stockholders dated April 12, 2017. 

“Stockholder Package” shall mean (i) a joinder and release of claims, (ii) a completed Accredited Investor
Questionnaire confirming such Stockholder is accredited within the meaning of Regulation D under the Securities Act and (iii) a counterpart signature page to each of the Stockholder Agreements. 

“Straddle Period” shall mean any taxable that begins on or before but does not end on the Closing Date. 

Subsidiary. An Entity shall be deemed to be a “Subsidiary” of another Person if such Person directly or indirectly owns or
purports to own, beneficially or of record, (a) an amount of voting securities of other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity’s board of directors or
other governing body, or (b) a majority of the outstanding equity or financial interests of such Entity. 
 “Tax”
shall mean any tax of any kind whatsoever including any U.S. federal, state, local, or non-U.S. income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall
profits, environmental, customs duties, capital stock, franchise, escheat, profits, withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, alternative
or add-on minimum, estimated, or other tax, including any interest, penalty, or addition thereto, whether disputed or not and including any obligations to indemnify or otherwise assume or succeed to the Tax
liability of any other Person. 

 “Tax Representations” shall mean the representations and warranties set
forth in Section 2.10. 
 “Tax Return” shall mean any return, declaration, report, claim for refund, or information
return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof. 

“Transactions” shall mean the transactions and other matters contemplated by the Agreement. 

“Transferred Employee” shall mean any Seller Employee set forth on Exhibit G who accepts an offer of employment with
Purchaser in connection with the Transactions contemplated hereunder. 
 “Unresolved Claims” shall mean the aggregate
amount of the Claimed Amounts and Contested Amounts associated with all indemnification claims contained in Notices of Indemnification Claim that have not been finally resolved and paid, if applicable, prior to the Release Date in accordance with
Section 7. 
 “User Data” shall mean any Personal Data or other data or information collected by or on behalf of
Seller from users of Seller Products or of any website or service operated or maintained by or on behalf of Seller. 
 “Xpresys Lung
Diagnostic Test” means the Seller’s blood test, identified as Xpresys Lung version 2 (XL2), with the intended use of identifying lung nodules that are likely benign so those nodules can safely avoid risky and costly invasive procedures
such as biopsy and surgery.EX-10.24

 Exhibit 10.24 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. 
 EXECUTION VERSION 

CONFIDENTIAL 
  

 
  

ASSET PURCHASE AGREEMENT 
 BY AND
BETWEEN 
 ONCIMMUNE LIMITED 

AND 
 BIODESIX, INC. 

Dated as of June 27, 2019 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 ARTICLE I
	 	PURCHASE AND SALE OF ASSETS	  	 	1	 
			
	 Section 1.1
	 	Acquired Assets	  	 	1	 
			
	 Section 1.2
	 	Excluded Assets	  	 	3	 
			
	 Section 1.3
	 	Assumed Liabilities	  	 	4	 
			
	 Section 1.4
	 	Excluded Liabilities	  	 	5	 
			
	 ARTICLE II
	 	PURCHASE PRICE	  	 	6	 
			
	 Section 2.1
	 	Amount and Form of Purchase Price	  	 	6	 
			
	 Section 2.2
	 	Payment of Purchase Price	  	 	6	 
			
	 Section 2.3
	 	Allocation of Purchase Price	  	 	6	 
			
	 ARTICLE III
	 	CLOSING	  	 	6	 
			
	 Section 3.1
	 	Closing Date	  	 	6	 
			
	 Section 3.2
	 	Closing Deliveries	  	 	7	 
			
	 Section 3.3
	 	Conveyance of Acquired Assets and Assumption of Assumed Liabilities	  	 	7	 
			
	 ARTICLE IV
	 	REPRESENTATIONS AND WARRANTIES OF SELLER	  	 	8	 
			
	 Section 4.1
	 	Organization, Existence and Good Standing	  	 	8	 
			
	 Section 4.2
	 	Authorization, Validity and Execution	  	 	8	 
			
	 Section 4.3
	 	Consents and Approvals; No Violations	  	 	9	 
			
	 Section 4.4
	 	Governmental Authorization	  	 	9	 
			
	 Section 4.5
	 	Financial Statements; Absence of Undisclosed Liabilities	  	 	9	 
			
	 Section 4.6
	 	Absence of Certain Changes or Events	  	 	10	 
			
	 Section 4.7
	 	Real Property	  	 	10	 
			
	 Section 4.8
	 	Intellectual Property	  	 	10	 
			
	 Section 4.9
	 	Material Contracts	  	 	11	 
			
	 Section 4.10
	 	Title to Assets; Sufficiency of Assets	  	 	12	 
			
	 Section 4.11
	 	Litigation	  	 	13	 
			
	 Section 4.12
	 	Compliance with Laws; Permits	  	 	13	 
			
	 Section 4.13
	 	Taxes	  	 	14	 
			
	 Section 4.14
	 	Employee Benefit Plans	  	 	14	 
			
	 Section 4.15
	 	Employee and Labor Matters	  	 	14	 
			
	 Section 4.16
	 	Healthcare Matters	  	 	15	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
			
	 Section 4.17
	 	Significant Customers and Suppliers	  	 	16	 
			
	 Section 4.18
	 	Data Privacy	  	 	16	 
			
	 Section 4.19
	 	Accounts Receivable	  	 	16	 
			
	 Section 4.20
	 	Brokers	  	 	16	 
			
	 Section 4.21
	 	Disclaimer of Other Warranties	  	 	17	 
			
	 ARTICLE V
	 	REPRESENTATIONS AND WARRANTIES OF BUYER	  	 	17	 
			
	 Section 5.1
	 	Organization	  	 	17	 
			
	 Section 5.2
	 	Authorization, Validity and Execution	  	 	17	 
			
	 Section 5.3
	 	Consents and Approvals; No Violations	  	 	18	 
			
	 Section 5.4
	 	Governmental Authorization	  	 	18	 
			
	 Section 5.5
	 	Litigation	  	 	18	 
			
	 Section 5.6
	 	Financial Capability	  	 	18	 
			
	 Section 5.7
	 	Brokers	  	 	18	 
			
	 Section 5.8
	 	Acknowledgements	  	 	18	 
			
	 ARTICLE VI
	 	CERTAIN AGREEMENTS	  	 	19	 
			
	 Section 6.1
	 	Conduct of Business	  	 	19	 
			
	 Section 6.2
	 	Access	  	 	21	 
			
	 Section 6.3
	 	Efforts to Close	  	 	21	 
			
	 Section 6.4
	 	Confidentiality	  	 	22	 
			
	 Section 6.5
	 	Further Assurances	  	 	22	 
			
	 Section 6.6
	 	Publicity	  	 	22	 
			
	 Section 6.7
	 	Business Records; Cooperation	  	 	22	 
			
	 Section 6.8
	 	Bulk Transfer Laws	  	 	22	 
			
	 Section 6.9
	 	Excluded Liabilities; Assumed Liabilities	  	 	22	 
			
	 Section 6.10
	 	Expenses	  	 	23	 
			
	 Section 6.11
	 	Certain Consents; Shared Business Contracts	  	 	23	 
			
	 Section 6.12
	 	Seller Name	  	 	24	 
			
	 Section 6.13
	 	Business Balance Sheets	  	 	25	 
			
	 Section 6.14
	 	Non-Test Inventory	  	 	25	 
			
	 Section 6.15
	 	Brookhaven Sub-License	  	 	25	 

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
			
	 ARTICLE VII
	 	EMPLOYMENT MATTERS	  	 	25	 
			
	 Section 7.1
	 	Employment of Transferred Employees; Severance	  	 	25	 
			
	 Section 7.2
	 	Employee Benefit Plans Generally	  	 	26	 
			
	 Section 7.3
	 	401(k) Plan	  	 	26	 
			
	 Section 7.4
	 	Welfare Plans	  	 	26	 
			
	 ARTICLE VIII
	 	CONDITIONS TO CLOSING	  	 	27	 
			
	 Section 8.1
	 	Conditions to Buyer’s Obligations	  	 	27	 
			
	 Section 8.2
	 	Conditions to Seller’s Obligations	  	 	28	 
			
	 Section 8.3
	 	Waiver	  	 	28	 
			
	 ARTICLE IX
	 	INDEMNIFICATION	  	 	29	 
			
	 Section 9.1
	 	Survival	  	 	29	 
			
	 Section 9.2
	 	Indemnification	  	 	29	 
			
	 Section 9.3
	 	Procedures	  	 	30	 
			
	 Section 9.4
	 	Limitations on Liability	  	 	32	 
			
	 Section 9.5
	 	Assignment of Claims	  	 	34	 
			
	 Section 9.6
	 	Exclusivity	  	 	34	 
			
	 Section 9.7
	 	Characterization of Indemnity Payments	  	 	34	 
			
	 Section 9.8
	 	Recovery	  	 	34	 
			
	 ARTICLE X
	 	TAX MATTERS	  	 	34	 
			
	 Section 10.1
	 	Sales and Transfer Taxes	  	 	34	 
			
	 Section 10.2
	 	Property Expense Apportionment	  	 	35	 
			
	 Section 10.3
	 	Amendment of Tax Returns	  	 	36	 
			
	 ARTICLE XI
	 	TERMINATION	  	 	36	 
			
	 Section 11.1
	 	Termination	  	 	36	 
			
	 Section 11.2
	 	Procedure upon Termination	  	 	37	 
			
	 Section 11.3
	 	Effect of Termination	  	 	37	 
			
	 ARTICLE XII
	 	CERTAIN DEFINITIONS	  	 	37	 
			
	 Section 12.1
	 	Certain Definitions	  	 	37	 
			
	 Section 12.2
	 	Cross References	  	 	44	 
			
	 ARTICLE XIII
	 	GENERAL PROVISIONS	  	 	45	 

  
 -iii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
			
	 Section 13.1
	 	Seller Disclosure Letter	  	 	45	 
			
	 Section 13.2
	 	Assignment	  	 	46	 
			
	 Section 13.3
	 	No Third-Party Beneficiaries	  	 	46	 
			
	 Section 13.4
	 	Entire Agreement; Amendments	  	 	47	 
			
	 Section 13.5
	 	Waiver	  	 	47	 
			
	 Section 13.6
	 	Notices	  	 	47	 
			
	 Section 13.7
	 	Interpretation	  	 	48	 
			
	 Section 13.8
	 	Counterparts	  	 	49	 
			
	 Section 13.9
	 	Severability	  	 	49	 
			
	 Section 13.10
	 	Governing Law; Consent to Exclusive Jurisdiction	  	 	49	 
			
	 Section 13.11
	 	WAIVER OF JURY TRIAL	  	 	50	 
			
	 Section 13.12
	 	Recovery of Fees by Prevailing Party	  	 	50	 
			
	 Section 13.13
	 	Specific Performance	  	 	50	 

  
 -iv- 

 EXHIBITS 
  

			
	Exhibit 1.1(e)	 	Assigned Intellectual Property
		
	Exhibit 1.1(i)	 	Acquired IT Assets
		
	Exhibit 1.2(r)	 	Other Excluded Assets
		
	Exhibit 3.2(a)(ii)	 	Form of IP Assignment Agreement
		
	Exhibit 3.2(a)(iii)	 	Form of License Agreement
		
	Exhibit 12.1	 	Transferred Employees

  
 -v- 

 ASSET PURCHASE AGREEMENT 

This Asset Purchase Agreement (this “Agreement”), dated as of June 27, 2019 (the “Execution Date”), is
by and between Oncimmune Limited, a private limited company incorporated under the laws of England and Wales (“Seller”), and Biodesix, Inc., a Delaware corporation (“Buyer”). Each of Seller and Buyer are sometimes
referred to herein as a “Party” or collectively as the “Parties”. 
 RECITALS: 

1.    Seller’s Subsidiary Oncimmune (USA) LLC (“Oncimmune USA”) is engaged in the Business. 

2.    Concurrently with the execution hereof, Seller and Buyer are entering into that certain Purchase and
Commercialization Agreement (the “PCA”), which provides for certain agreements between the Parties with respect to the Business (including Buyer’s operation thereof post-Closing). 

3.    On the terms and subject to the conditions of this Agreement, (a) Buyer desires to purchase the Acquired
Assets, and Seller desires to sell, and cause to be sold, the Acquired Assets to Buyer, and (b) Buyer desires to assume the Assumed Liabilities. 

Accordingly, the Parties agree as follows: 

ARTICLE I 
 PURCHASE AND SALE
OF ASSETS 
 Section 1.1    Acquired Assets. On the terms and subject to the conditions of this
Agreement, at the Closing, Seller will, or will cause Oncimmune USA to, sell, assign, transfer and deliver (“Convey” and variants of this term, such as “Conveyance” will have correlative meanings) to Buyer, and
Buyer will purchase, acquire and accept from Seller or Oncimmune USA, all of Seller’s and Oncimmune USA’s respective right, title and interest in and to the Acquired Assets. For the purposes of this Agreement,
“Acquired Assets” means all Assets owned or held by a member of the Seller Group that are located at the Kansas Lab and either included in any of clauses (a) – (l) below or otherwise primarily used or held for primary use
in the Business and that are not otherwise addressed in such clauses, in each case whether now existing or hereafter acquired prior to the Closing (other than any such Assets that are Conveyed or otherwise disposed of after the date hereof and prior
to the Closing not in violation of Section 6.1, and other than an interest in a business entity as defined in Treasury Regulation Section 301.7701-2(a)): 

(a)    all inventories of raw materials, laboratory supplies, work-in- process, finished goods and packaging materials primarily used or held for primary use in the Business and located at the Kansas Lab as of the Closing (collectively, “Inventory”);

 (b)    all machinery, equipment, furniture, furnishings,
tools and other tangible personal property located at the Kansas Lab as of the Closing (collectively, the “Equipment”); 

(c)    all accounts and notes receivable as of the Closing, in each case to the extent related to the
conduct of the Business; 
 (d)    all pre-paid expenses and
other current assets as of the Closing, in each case to the extent related to the conduct of the Business; 

(e)    all Intellectual Property set forth on Exhibit 1.1(e) (“Assigned Intellectual
Property”); 
 (f)    the Lease; 

(g)    all Contracts exclusively related to the Business; 

(h)    all books and records, including business records, research material, tangible data, documents,
personnel records with respect to Transferred Employees, invoices, customer lists, vendor lists, service provider lists, sales and promotional literature, catalogs and advertising material used for the marketing of products or services, but only to
the extent related primarily to the Business as of the Closing and permitted by applicable Law, and excluding Tax Returns and related notes, worksheets, files and documents relating thereto; 

(i)    (a) the software set forth on Exhibit 1.1(i) (the “Acquired IT Assets”) and
(b) all application systems and software, including all computer software, programs and source disks, and related program documentation, tapes, manuals, forms, guides and other materials, computer hardware and other systems hardware and
networking and communications assets, including servers, databases, backups and peripherals, in each case located at the Kansas Lab as of the Closing and used exclusively in the Business; 

(j)    all Permits, to the extent transferable and related primarily to the Business and held as of the
Closing; 
 (k)    all goodwill generated primarily by, and associated primarily with, the Business; and

 (l)    all guarantees, warranties, indemnities and similar rights in favor of Seller or Oncimmune USA
in respect of any other Acquired Asset or any Assumed Liability. 

  
 -2- 

 Section 1.2    Excluded Assets. Notwithstanding
Section 1.1 or any other provision hereof, the Acquired Assets will not in any event include any of the following Assets of any member of the Seller Group (collectively, the “Excluded Assets”): 

(a)    all books and records not constituting an Acquired Asset described in
Section 1.1(h), including the certificate of incorporation, bylaws and similar organizational documents, minutes, stock records and similar documents of any member of the Seller Group; 

(b)    all cash, cash equivalents (including marketable securities and short-term investments), bank
accounts, lockboxes and deposits of, and any rights or interests in, the cash management system of any member of the Seller Group, including uncleared checks and drafts received or deposited for the account of any member of the Seller Group; 

(c)    all rights to and the use of any member of the Seller Group’s trade names and trademarks, any
derivation or combination thereof and all associated goodwill, and any other Intellectual Property not specifically described in Section 1.1(e); 

(d)    all Contracts between any member of the Seller Group, on the one hand, and any Affiliate of such
Person, on the other hand, and all intercompany receivables owed to any member of the Seller Group by any Affiliate of such Person; 

(e)    all rights under any Contracts (i) other than the Business Contracts and (ii) related to
the purchase of products and services necessary to supply Buyer with the products supplied by Seller under the supply agreement between the Parties contemplated by the PCA (the “Supply Agreement”); 

(f)    all assets used in connection with the centralized management functions provided by the members of
the Seller Group; 
 (g)    all rights to and in Employee Benefit Plans and any trusts, insurance
arrangements or other assets held pursuant to, or set aside to fund the obligations of a member of the Seller Group under, any such Employee Benefit Plans; 

(h)    all insurance policies and all rights of every nature and description under or arising out of such
insurance policies; 
 (i)    all claims for and rights to any Tax asset or to receive Tax refunds, or
any other Tax attribute, in each case relating to the operation or ownership of the Business or the Acquired Assets for any Tax period (or portion thereof) ending on or prior to the Closing, and all Tax Returns of the Seller Group and related work
papers; 
 (j)    except to the extent set forth in Section 1.1(i), all
application systems and software, including all computer software, programs and source disks, and related program documentation, tapes, manuals, forms, guides and 

  
 -3- 

 
other materials, computer hardware and other systems hardware and networking and communications assets, including servers, databases, backups and peripherals; 

(k)    all rights of any member of the Seller Group to owned or leased real estate other than the Lease;

 (l)    all rights under this Agreement, the PCA, the Supply Agreement, the Development Agreement, the
Ancillary Agreements, the other agreements and instruments executed and delivered in connection with this Agreement, and the transactions contemplated hereby or thereby; 

(m)    all inventory that is not Inventory pursuant to Section 1.1(a), including
all inventory not related to the Test; 
 (n)    any claims, course of action, credits, demands or rights
of set-off of the members of the Seller Group related to any Excluded Asset or Excluded Liability, as well as any books, records and privileged information relating thereto, whether choate or inchoate, known
or unknown, contingent or noncontingent; 
 (o)    any rights under any interest rate, currency or other
similar hedging or swap agreement; 
 (p)    any personnel and other files (i) pertaining to any
employee that is not a Transferred Employee and (ii) pertaining to any Transferred Employee or current or former employee of any member of the Seller Group to the extent required by Law not to be transferred; and 

(q)    the assets, properties and rights set forth on Exhibit 1.2(q). 

Notwithstanding anything to the contrary contained in this Agreement, the PCA, the Supply Agreement, the Development Agreement or any of the
Ancillary Agreements, Buyer acknowledges and agrees that all of the following shall remain the property of the Seller Group, and Buyer shall not have any interest therein: (x) all records and other materials prepared or received by Seller or
any of its Affiliates in connection with the transactions contemplated hereby and (y) all privileged materials, documents and records of Seller or any of its Affiliates except to the extent exclusively related to the Assigned Intellectual
Property or the Business. 
 Section 1.3    Assumed Liabilities. Subject to
Section 1.4, on the terms and subject to the conditions of this Agreement, at the Closing, Buyer will assume and be liable for, pay, perform and discharge as and when due, the Assumed Liabilities. As used in this Agreement,
“Assumed Liabilities” means all Liabilities of any member of the Seller Group that are included in any of clauses (a) – (f) below or that otherwise arise out of or relate to the ownership and use of the Acquired Assets or the
operation or conduct of the Business, whether before, at or after the Closing, and that are not otherwise addressed in such clauses: 

  
 -4- 

 (a)    all Liabilities under the Business Contracts;

 (b)    all trade accounts payable, accrued expenses and other current liabilities in each case to the
extent related to the Business; 
 (c)    all Liabilities with respect to any product warranty claim or
recall, in each case made after the Closing, with respect to products that were designed, manufactured, marketed, distributed or sold at any time by the Business or that constitute Inventory; 

(d)    all Liabilities for product liability claims, arising out of occurrences after the Closing, relating
to all products of the Business that were designed, manufactured, marketed, distributed or sold at any time by the Business or that constitute Inventory; 

(e)    any Taxes for any taxable period (or portion thereof), and any liability for Taxes arising from or
attributable to the operation of the Business or use or ownership of the Acquired Assets for all taxable periods (or portions thereof), beginning after the Closing Date; and 

(f)    all other Liabilities to be paid or assumed by Buyer pursuant to the express terms of this
Agreement. 
 Section 1.4 Excluded Liabilities. Notwithstanding Section 1.3, the Assumed Liabilities
will not include the following Liabilities of the members of the Seller Group (collectively, the “Excluded Liabilities”): 

(a)    all Liabilities under debt instruments, loan documents, indentures, debentures or other written
obligations which involve indebtedness for borrowed money; 
 (b)    all Liabilities arising under or
with respect to Contracts between any member of the Seller Group, on the one hand, and any Affiliate of such Person, on the other hand, and all intercompany payables owed by any member of the Seller Group to any Affiliate of such Person; 

(c)    all Liabilities to the extent related to the Excluded Assets; 

(d)    all Liabilities for product liability claims arising out of occurrences prior to the Closing; 

(e)    all Liabilities for legal, accounting, audit and investment banking fees, brokerage commissions and
any other similar expenses incurred by the Seller Group in connection with the negotiation and preparation of this Agreement and the transactions contemplated hereby; 

(f)    any Taxes of any member of the Seller Group for any taxable period, and any liability for Taxes
arising from or attributable to the operation of the Business or use or ownership of the Acquired Assets for all taxable periods (or portions thereof), ending on or prior to the Closing Date; 

  
 -5- 

 (g)    all Liabilities for retention or change of
control payments under Contracts with Transferred Employees; and 
 (h)    all other Liabilities to be
paid or assumed by Seller pursuant to the express terms of this Agreement. 
 ARTICLE II  

PURCHASE PRICE 

Section 2.1    Amount and Form of Purchase Price. The aggregate purchase price to be paid to the Seller in
consideration of the Acquired Assets will consist of: 
 (a)    [***] in cash, to be paid in quarterly
installments of [***] (each installment, a “Quarterly Amount”) pursuant to Section 2.2 (the sum of all such payments, the “Purchase Price”); and 

(b)    the assumption by Buyer as of the Closing of the Assumed Liabilities. 

Section 2.2    Payment of Purchase Price. Within 30 days of the Closing Date, and no later than each of the
three-, six- and nine-month anniversaries of the Closing Date, Buyer will pay to Oncimmune USA by wire of transfer of immediately available funds to an account or accounts designated by Seller or Oncimmune USA
prior to each such payment becoming due, an amount equal to the Quarterly Amount. 
 Section 2.3    Allocation
of Purchase Price. Within 60 days after the Closing Date, Seller will provide Buyer a schedule allocating the Purchase Price among the Acquired Assets in accordance with Code Section 1060 and Treasury Regulations
thereunder (the “Final Allocation”). The Final Allocation will be binding upon Seller and Buyer. Seller, Buyer and their Affiliates will report and file Tax Returns (including, but not limited to, Internal Revenue Service Form 8594)
in all respects and for all purposes consistent with the Final Allocation. Buyer will timely and properly prepare, execute, file and deliver all such documents, forms and other information as Seller may reasonably request in preparing such
allocation. None of Seller, Buyer, or any of their Affiliates will take any position (whether in audits, Tax Returns, or otherwise) that is inconsistent with the Final Allocation unless required to do so by applicable Law. 

ARTICLE III  

CLOSING 

Section 3.1    Closing Date. The closing of the transactions contemplated hereby (the
“Closing”) will take place at the offices of Jones Day, 1420 Peachtree Street, N.E., Suite 800, Atlanta, Georgia 30309, on the Closing Date. In lieu of an in-person Closing, 

  
 -6- 

 
the Closing may instead be accomplished by email (in PDF format) transmission to the respective offices of legal counsel for the Parties of the requisite documents, duly executed where required,
delivered upon actual confirmed receipt, with originals to be delivered promptly following the Closing if requested. All proceedings to be taken and all documents to be executed and delivered by all Parties at the Closing will be deemed to have been
taken and executed simultaneously and no proceedings will be deemed to have been taken nor documents executed or delivered until all have been taken, executed and delivered. Notwithstanding anything to the contrary in this Agreement, the Closing
will be deemed to have occurred as of 11:59 p.m. (U.S. Eastern Time) on the Closing Date. 

Section 3.2    Closing Deliveries. 

(a)    By Seller Group. At the Closing, Seller will deliver or cause to be delivered to Buyer: 

(i)    the Transfer Documents, as applicable; 

(ii)    the Intellectual Property Assignment Agreement, substantially in the form of Exhibit
3.2(a)(ii) (the “IP Assignment Agreement”), duly executed by Seller; 
 (iii)    the
Intellectual Property License Agreement, substantially in the form of Exhibit 3.2(a)(iii) (the “License Agreement”), duly executed by Seller; 

(iv)    the Supply Agreement and the Development Agreement; and 

(v)    each other Ancillary Agreement, duly executed by the applicable member or members of the Seller
Group. 
 (b)    By Buyer. At the Closing, Buyer will deliver, or will cause to be delivered, to
Seller: 
 (i)    the Transfer Documents, as applicable; 

(ii)    the IP Assignment Agreement; 

(iii)    the License Agreement; 

(iv)    the Supply Agreement and the Development Agreement; and 

(v)    each other Ancillary Agreement, duly executed by Buyer. 

Section 3.3    Conveyance of Acquired Assets and Assumption of Assumed Liabilities. In furtherance of the
Conveyance of the Acquired Assets and assumption of the Assumed Liabilities provided in Sections 1.1 and 1.3, on the Closing Date, (a) Seller 

  
 -7- 

 
will execute and deliver, and will cause its Subsidiaries to execute and deliver, such bills of sale, assignments of Contracts and other instruments of Conveyance as necessary and in customary
form to evidence the Conveyance of all of Seller’s and Oncimmune USA’s right, title and interest in and to the Acquired Assets to Buyer (it being understood that no such bills of sale, assignments or other instruments of Conveyance will
require Seller or any of its Affiliates to make any additional representations, warranties or covenants, expressed or implied, not contained in this Agreement) and (b) Buyer will execute and deliver such assumptions of Assumed Liabilities and
other instruments of assumption (in each case in a form that is consistent with the terms and conditions of this Agreement) as and to the extent reasonably necessary to evidence the valid and effective assumption of the Assumed Liabilities by Buyer.
All of the foregoing documents contemplated by this Section 3.3 will be referred to collectively herein as the “Transfer Documents”. 

ARTICLE IV  

REPRESENTATIONS AND WARRANTIES OF SELLER 

Except as set forth in the Seller Disclosure Letter (interpreted as contemplated by Section 13.1), Seller represents
and warrants to Buyer as follows: 
 Section 4.1    Organization, Existence and Good Standing. Each member
of Seller Group is duly organized, validly existing and in good standing under the Laws of its jurisdiction of organization. Each member of the Seller Group has all corporate or equivalent organizational power and authority necessary to own, lease
and operate its properties that will be Conveyed to Buyer and to carry on the Business as currently being conducted. Each member of Seller Group is duly qualified to do business (where such concept is applicable) in each jurisdiction in which the
property owned, leased or operated by the Business that will be Conveyed to Buyer or to where the nature of the Business conducted by it makes such qualification necessary, except where the failure to be so duly qualified would not reasonably be
expected to have a Material Adverse Effect. 
 Section 4.2    Authorization, Validity and Execution. Each of
Seller and Oncimmune USA, as applicable, has all necessary corporate or equivalent organizational power and authority to (a) execute and deliver this Agreement and the Ancillary Agreements, as applicable, (b) perform its respective
obligations hereunder and thereunder and (c) consummate the transactions contemplated hereby and thereby. This Agreement has been, and each Ancillary Agreement to be executed by Seller or Oncimmune USA will be on or prior to the Closing Date,
duly executed and delivered by Seller or Oncimmune USA and, assuming the due execution of this Agreement and the Ancillary Agreements by Buyer, is or will be a legal, valid and binding obligation of Seller or Oncimmune USA, as applicable,
enforceable against each in accordance with its terms, except to the extent that its enforceability may be subject to applicable bankruptcy, insolvency, reorganization, moratorium, receivership and similar Laws affecting the enforcement of
creditors’ rights generally and to general equitable principles (the “Bankruptcy and Equity Exception”). 

  
 -8- 

 Section 4.3    Consents and Approvals; No Violations. The
execution, delivery and performance by Seller and Oncimmune USA, as applicable, of this Agreement and the Ancillary Agreements, and the consummation by Seller Oncimmune USA, as applicable, of the transactions contemplated hereby and thereby will not
(a) violate the provisions of the certificate of incorporation, bylaws or any other similar organizational instruments of any member of the Seller Group; (b) violate any Law of any Governmental Authority by which any member of the Seller
Group is bound or to which any of the Acquired Assets is subject; or (c) result in a violation of, conflict with, constitute a default (or give rise to any right of termination, cancellation, payment or acceleration) under, or result in the
creation of any Encumbrances upon any of the Acquired Assets under, any of the terms, conditions or provisions of any Material Contract to which any member of the Seller Group is a party or by which any of the Acquired Assets may be bound, except,
with respect to clauses (b) and (c), violations, conflicts, defaults or rights of termination, cancellation, payment or acceleration which would not reasonably be expected to be material to the Business taken as a whole. 

Section 4.4    Governmental Authorization. The execution, delivery and performance by Seller and Oncimmune
USA, as applicable, of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated hereby and thereby require no action by or in respect of, or consent from or filing with, any Governmental Authority, other than
any such action or filing the failure of which to be made or obtained would not reasonably be expected to be material to the Business taken as a whole. 

Section 4.5    Financial Statements; Absence of Undisclosed Liabilities. 

(a)    Section 4.5(a) of the Seller Disclosure Letter sets forth the unaudited balance sheet of the
Business as of December 31, 2018 (the “Balance Sheet”), and the unaudited statement of income of the Business for the year ended on December 31, 2018 (together, with the Balance Sheet, the “Financial
Statements”). The Financial Statements are based on the books and records of the Business and are intended to reflect, in all material respects, the combined financial position and combined results of operations of the Business as of the
date or for the time period set forth therein, except (i) for the absence of footnotes and (ii) for normal year-end audit adjustments. This Section 4.5 is qualified by the
fact that the Business has not operated as a separate “stand alone” entity within Seller. As a result, the Business has been allocated certain charges and credits for purposes of the preparation of the Financial Statements. Such
allocations of charges and credits do not necessarily reflect the amounts that would have resulted from arms-length transactions or the actual costs that would be incurred if the Business operated as an independent enterprise. 

(b)    Section 4.5(b) of the Seller Disclosure Letter sets forth a list of all trade accounts
payable related to the Business as of May 31, 2019. 
 (c)    Except (i) as set forth in the
Balance Sheet, (ii) for Liabilities or obligations incurred in the ordinary course of business consistent with past 

  
 -9- 

 
practice since the Statement Date, (iii) for Excluded Liabilities and (iv) for Liabilities or obligations that would not reasonably be expected to be material to the Business taken as a
whole, there are no Liabilities of the Business that would be required to be reflected or reserved against in a balance sheet prepared in accordance with the accounting principles used in preparation of the Financial Statements. 

Section 4.6    Absence of Certain Changes or Events. Except in connection with the transactions contemplated
hereby, during the period beginning on January 1, 2019 and ending on the Execution Date, (a) Oncimmune USA has conducted the Business materially in the ordinary course of business, consistent with past practice, and (b) there has not
been any Effect which has had or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 

Section 4.7    Real Property. 

(a)    Oncimmune USA does not own any real property. 

(b)    The real property that is the subject of the Lease is the only real property leased or subleased to
a member of the Seller Group for use primarily in connection with the Business (the “Leased Real Property”). Seller has made available to Buyer a true and correct copy of the Lease. With respect to the Lease: 

(i)    it is in full force and effect in all material respects and is valid and enforceable by Oncimmune
USA, in accordance with its terms, subject to the Bankruptcy and Equity Exception; 
 (ii)    Oncimmune
USA is not a sublessor or grantor under any sublease or other instrument granting to any other Person any right to the possession, lease or occupancy of any of the Leased Real Property; 

(iii)    Oncimmune USA has not received written notice that it is in breach or default (after the
expiration of any notice or cure period) under such Lease; and 
 (iv)    to the Knowledge of Seller, no
event has occurred that, with the lapse of time or the giving of notice or both, would constitute a material default by Oncimmune USA. 

Section 4.8    Intellectual Property. 

(a)    Section 4.8(a) of the Seller Disclosure Letter sets forth a list of the following Business
IP, in each case to the extent owned by a member of the Seller Group: (i) utility patents and applications therefor; (ii) design patents and applications therefor; (iii) utility models and applications therefor; (iv) registered
trademarks and registered service marks, and applications therefor; (v) registered copyrights and applications therefor; and (vi) material registered domain names. 

  
 -10- 

 (b)    The members of the Seller Group, as applicable,
are the sole and exclusive owners of the Business IP set forth in Section 4.8(a) of the Seller Disclosure Letter. No member of the Seller Group has granted any license or other rights to a third party that would be
inconsistent with the license granted to Buyer pursuant to the License Agreement. 
 (c)    There is no
written claim by any third party against any member of the Seller Group contesting the validity, enforceability or ownership of any of the Business IP, and, to the Knowledge of Seller, no such claims are threatened. During the period from
June 27, 2017 through and including the Execution Date, no member of the Seller Group has received any written notice that any of the Business IP infringes any third party Intellectual Property rights. To the Knowledge of Seller, the operation
of the Business does not, as currently conducted, infringe, misappropriate or otherwise violate or conflict with, in any material respect, the Intellectual Property rights of any third party. 

(d)    The representations in this Section 4.8 and
Section 4.9(a)(viii) (and Sections 4.9(b) and 4.9(c) as applicable thereto) are the sole and exclusive representations made by Seller with respect to any matters relating to Intellectual Property. 

Section 4.9    Material Contracts. 

(a)    Section 4.9 of the Seller Disclosure Letter sets forth a list, as of the Execution Date, of
the following Business Contracts (other than the Lease, such Contracts set forth in Section 4.14(a) of the Seller Disclosure Letter and purchase orders submitted or received in the ordinary course of business): 

(i)    Contracts for the purchase or sale of assets, products or services (other than Contracts for the
purchase or sale of inventory or obsolete equipment in the ordinary course of business), in each case requiring annual payments by any party thereto in excess of [***]; 

(ii)    all Contracts with any HCP; 

(iii)    all Contracts that provide for the indemnification by the Company of any Person (other than
customary commercial indemnification provisions entered into in the ordinary course of business) or the assumption of any Tax, environmental or other Liability of any Person by a member of the Seller Group; 

(iv)    all broker, distributor, dealer, franchise, agency, sales promotion, market research, marketing
consulting and advertising Contracts; 

  
 -11- 

 (v)    all Contracts with independent contractors or
consultants (or similar arrangements) which are not cancellable without penalty or requiring more than [***] days’ notice; 

(vi)    all Contracts with Governmental Authorities; 

(vii)    Contracts containing a covenant that restricts a member of the Seller Group, with respect to the
Business, from engaging in any line of business or competing with any Person; 
 (viii)    a license or
sublicense Contract under which a member of the Seller Group is licensee or licensor, or sub-licensee or sub-licensor of any material Intellectual Property used
exclusively in the Business, other than shrink wrap, click wrap or other software that is generally commercially available and not customized in any material respect; and 

(ix)    joint venture, partnership or other Contracts involving a sharing of profits, losses, costs or
liabilities of the Business with any other Person. 
 (b)    As of the Execution Date, each Contract set
forth in, or required to be set forth in, Section 4.9 of the Seller Disclosure Letter (each, a “Material Contract”) is a legal, valid and binding obligation of a member of the Seller Group and, to the
Knowledge of Seller, each other party thereto, enforceable in accordance with its terms, subject to the Bankruptcy and Equity Exception. The applicable member of the Seller Group is not in default of, nor has it received any written notice of any
default or event that, with notice or lapse of time, or both, would constitute a default by the applicable member of the Seller Group under any Material Contract, except as would not reasonably be expected to result in material Liability to the
Business, taken as a whole, or otherwise materially interfere with the conduct of the Business, taken as a whole, in substantially the manner currently conducted. To the Knowledge of Seller, no other party to a Material Contract is in default of
such Material Contract, except for any such defaults that would not reasonably be expected to result in a material Liability owed to the Business, taken as a whole, or otherwise materially interfere with the conduct of the Business, taken as a
whole, in substantially the manner currently conducted. 
 (c)    Seller has made available to Buyer a
true and correct copy of each Material Contract or, if such Contract is not in written form, a true and correct summary of the material terms thereof. 

Section 4.10    Title to Assets; Sufficiency of Assets. 

(a)    The applicable members of the Seller Group have good and valid title to, or a valid leasehold
interest in, all of the Acquired Assets, free and clear of Encumbrances other than Permitted Encumbrances. 

  
 -12- 

 (b)    The Acquired Assets constitute all of the
tangible assets, properties, rights, titles and interests owned or held by the members of the Seller Group necessary to operate the Business immediately following the Closing in all material respects in substantially the manner conducted immediately
prior to the Closing, except (i) as set forth in Section 4.10(b) of the Seller Disclosure Letter, and (ii) for any assets, properties, rights, titles and interests made available to Buyer following the Closing
pursuant to any Ancillary Agreement or other Contract executed at Closing for the benefit of Buyer; provided, however, the foregoing is subject to the limitation that certain transfers, assignments, licenses, sublicenses, leases and subleases, as
the case may be, of Contracts and Governmental Approvals, and any claim or right or benefit arising thereunder or resulting therefrom, may require consent of a Person or Governmental Authority, which has not been obtained, and that such matters are
addressed elsewhere in this Agreement and the Ancillary Agreements. 
 Section 4.11    Litigation. As of the
Execution Date, there is no Action against any member of the Seller Group with respect to the Business pending, or to the Knowledge of Seller, threatened. No member of the Seller Group has been permanently or temporarily enjoined or barred by order,
judgment or decree of or agreement with any Governmental Authority from engaging in or continuing any conduct or practice in connection with the Business, and there is no outstanding order, judgment, ruling, injunction or decree requiring any such
Person to take, or refrain from taking, action with respect to the Business. 
 Section 4.12    Compliance with
Laws; Permits. 
 (a)    Since June 27, 2017, the Business has been conducted in compliance in
all material respects with all Laws applicable to the conduct of the Business or the ownership or use of the Acquired Assets (each, a “Legal Requirement”). No member of the Seller Group has received, during the period from
June 27, 2017 through and including the Execution Date, any written notice from any Governmental Authority regarding any actual, alleged or potential violation by the Business of, or failure by the Business to comply with, any Legal
Requirement. All material Permits held by a member of the Seller Group and used primarily in connection with the conduct of the Business are in full force and effect in all material respects and no member of the Seller Group has received, during the
period from June 27, 2017 through and including the Execution Date, any written notice of any suspension, modification, revocation, cancellation or non-renewal, in whole or in part, of any such Permit.

 (b)    Since June 27, 2017, Seller has not received notice of any pending or asserted action,
hearing, charge, complaint, claim or demand, and, to the Knowledge of Seller, there is no threatened action, hearing, charge, complaint, claim or demand, by or before any Governmental Authority against or affecting any member of the Seller Group or
the Business, or any assets or properties of any member of the Seller Group or the Business with respect to any anti-money laundering Laws (including the Foreign Corrupt Practices Act of 1977, as amended, and any applicable international conventions
of similar effect). 

  
 -13- 

 Section 4.13    Taxes. 

(a)    All material Tax Returns that were required to be filed prior to the Execution Date by, or with
respect to, the Business, have been filed, and such Tax Returns, as amended, were true, correct and complete in all material respects when filed. 

(b)    All Taxes shown to be due on such Tax Returns have been paid or accrued, other than such Taxes
(i) as are being contested in good faith by or on behalf of a member of the Seller Group, or (ii) that would not reasonably be expected, individually or in the aggregate, to result in a material Liability to the Business, taken as a whole.

 (c)    There are no Encumbrances for Taxes upon any Acquired Asset other than Permitted Encumbrances.

 Section 4.14    Employee Benefit Plans. 

(a)    Section 4.14(a) of the Seller Disclosure Letter lists each material Employee Benefit Plan in
which Transferred Employees participate. With respect to each Employee Benefit Plan, Seller has made available to Buyer current copies of the plan document or summaries thereof. 

(b)    No member of the Seller Group contributes on behalf of a Transferred Employee to a multiemployer
plan within the meaning of ERISA Section 3(37) (a “Multiemployer Plan”). No Employee Benefit Plan is subject to Title IV of ERISA. 

(c)    Each Employee Benefit Plan that is intended to qualify under Code Section 401(a) has either
received a favorable determination letter from the IRS as to its qualified status or the remedial amendment period for such Employee Benefit Plan has not yet expired, and each trust established in connection with any Employee Benefit Plan which is
intended to be exempt from federal income taxation under Code Section 501(a) is so exempt. Each Employee Benefit Plan has been maintained in substantial compliance with the material terms thereof and with the requirements prescribed by
applicable Law. 
 (d)    With respect to the Transferred Employees, there are no employee
post-retirement health plans in effect except as required by ERISA Section 601. 
 Section 4.15    Employee
and Labor Matters. 
 (a)    None of the employment terms of any Transferred Employee are subject to
the terms of a current collective bargaining agreement. 
 (b)    No member of the Seller Group has
received, during the period 

  
 -14- 

 from June 27, 2017 through and including the Execution Date, written notice of any
complaint against or arbitration proceeding involving the Business which is currently pending before the National Labor Relations Board or the Equal Employment Opportunity Commission with respect to any Transferred Employee or, to the Knowledge of
Seller, threatened against any member of the Seller Group with respect to the Business. There are no labor strikes, disputes, grievances pending under any collective bargaining agreements, slowdowns, work stoppages or other labor disturbances or
difficulties pending or, to the Knowledge of Seller, threatened against any member of the Seller Group with respect to the Business. 

(c)    Section 4.15(c) of the Seller Disclosure Letter sets forth a list, as of the Execution Date,
of all employment Contracts between any Transferred Employee, on the one hand, and any member of the Seller Group, on the other hand, other than at-will employment Contracts. 

Section 4.16    Healthcare Matters. 

(a)    During the period from June 27, 2017 through and including the Execution Date, the Business has
been conducted in compliance in all material respects with all Healthcare Laws applicable to the conduct of the Business or the ownership or use of the Acquired Assets. With respect to the Business, (i) no member of the Seller Group is the
subject of any Action relating to Healthcare Laws and (ii) during the period from June 27, 2017 through and including the Execution Date, no member of the Seller Group has received written notice regarding any actual, alleged, or potential
violation of any Healthcare Laws. 
 (b)    With respect to the Business, no owner, director, officer or
employee or, to Seller’s Knowledge, any former owner, director, officer or employee of the Company, has at any time (i) been suspended or excluded from participation in any federal health care program, (ii) been convicted of a
criminal offense related to any Healthcare Laws, or (iii) been convicted of a criminal offense relating to fraud, theft, embezzlement, breach of fiduciary responsibility, or other financial misconduct in connection with the delivery of a
healthcare item or service, or in connection with a program operated by or financed in whole or in part by any Governmental Authority. 

(c)    With respect to the Business, all HCPs performing services through the Company are (i) duly
qualified to perform such services, including having all requisite licenses, (ii) if licensed, performing services that are solely within the scope of their licenses, and (iii) in good standing with all applicable licenses. 

(d)    The representations and warranties set forth in this Section 4.16 are the
sole and exclusive representations and warranties relating to healthcare matters, including Healthcare Laws. 

  
 -15- 

 Section 4.17    Significant Customers and Suppliers.
Section 4.17 of the Seller Disclosure Letter sets forth a list of each of the five largest customers and suppliers of the Business, taken as a whole (such customers and suppliers, the “Material
Relationships”) in terms of payments by each such customer, or in terms of annual volume of sales by each such supplier, during the twelve months ended December 31, 2018. Since December 31, 2018, other than in the ordinary
course of business consistent with past practice, there has not been any written notice or, to the Knowledge of Seller, any oral notice, from any such Material Relationship that such Material Relationship has terminated or canceled or intends to
terminate or cancel within the next [***] months any Material Contract between the Business and any such Material Relationship, other than any such notice that may be received by the Business after the Execution Date primarily as a result of or in
connection with the transactions contemplated by this Agreement. 
 Section 4.18    Data Privacy. 

(a)    With respect to the Business and during the period from June 27, 2017 through and including the
Execution Date, the members of the Seller Group and, to Seller’s Knowledge, any Person acting for or on behalf of the members of the Seller Group have materially complied with (i) all applicable Privacy Laws, (ii) all of the
Business’s policies and notices regarding Personal Information or PHI, and (iii) all of the Business’s contractual obligations with respect to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding,
security (technical, physical and administrative), disposal, destruction, disclosure, or transfer (including cross-border) of Personal Information and PHI. With respect to the Business and during the period from June 27, 2017 through and
including the Execution Date, no member of the Seller Group has received any written notice of any claims of, or been charged with, a violation of any Privacy Laws, applicable privacy policies, or contractual commitments with respect to Personal
Information or PHI. 
 (b)    With respect to the Business and during the period from June 27, 2017
through and including the Execution Date, (i) to Seller’s Knowledge, there have been no breaches, security incidents, misuse of or unauthorized access to or disclosure of any Personal Information or PHI in the possession or control of a
member of the Seller Group or collected, used or processed by or on behalf of a member of the Seller Group, and (ii) no member of the Seller Group has been provided or been required to provide any notices to any Person in connection with an
unauthorized disclosure of Personal Information or PHI. 
 Section 4.19    Accounts Receivable. The accounts
receivable reflected on the Balance Sheet have arisen from bona fide transactions of the Business involving the sale of products or rendering of services in the ordinary course of business consistent with past practice. 

Section 4.20    Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or
other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller. 

  
 -16- 

 Section 4.21    Disclaimer of Other Warranties. NEITHER
SELLER NOR ANY OTHER PERSON MAKES ANY REPRESENTATION OR WARRANTY TO BUYER OR ANY PERSON, EXPRESS OR IMPLIED, WITH RESPECT TO THE BUSINESS, THE MEMBERS OF THE SELLER GROUP, THE ACQUIRED ASSETS, THE EXCLUDED ASSETS, THE EXCLUDED LIABILITIES OR THE
ASSUMED LIABILITIES, INCLUDING ANY REPRESENTATION OR WARRANTY AS TO MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR FUTURE RESULTS, OTHER THAN AS EXPRESSLY PROVIDED IN THIS ARTICLE IV, AND SELLER HEREBY DISCLAIMS ANY OTHER
REPRESENTATIONS AND WARRANTIES, WHETHER MADE BY SELLER, ANY OF ITS AFFILIATES OR ANY OF THEIR RESPECTIVE OFFICERS, DIRECTORS, MANAGERS, EMPLOYEES OR REPRESENTATIVES. WITHOUT LIMITING THE FOREGOING, NEITHER SELLER NOR ANY OTHER PERSON HAS MADE OR
WILL MAKE ANY REPRESENTATION OR WARRANTY TO BUYER, EXPRESS OR IMPLIED, WITH RESPECT TO (A) THE INFORMATION DISTRIBUTED OR MADE AVAILABLE TO BUYER BY OR ON BEHALF OF SELLER IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY
THIS AGREEMENT, (B) ANY MANAGEMENT PRESENTATION OR (C) ANY FINANCIAL PROJECTION OR FORECAST RELATING TO THE BUSINESS. 
 ARTICLE V

 REPRESENTATIONS AND WARRANTIES OF BUYER 

Buyer represents and warrants to Seller as follows: 

Section 5.1    Organization. Buyer is a duly organized corporation, validly existing and in good standing
under the Laws of the State of Delaware, and has the requisite power and authority to carry on its businesses as it is now being conducted. Buyer is duly qualified to do business (where such concept is applicable) in each jurisdiction where the
nature of its business or the ownership of its assets makes such qualification necessary, except where the failure to be so licensed or qualified would not reasonably be expected, individually or in the aggregate, to interfere with, prevent or
materially delay the ability of Buyer to enter into and perform its obligations under this Agreement or consummate the transactions contemplated hereby. 

Section 5.2    Authorization, Validity and Execution. Buyer has all necessary power and authority to execute
and deliver this Agreement and the Ancillary Agreements to which it is a party, to perform its obligations hereunder and thereunder, and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance of this
Agreement and each of the Ancillary Agreements to which Buyer is a party, and the consummation of the transactions contemplated hereby and thereby, have been duly and validly authorized by Buyer. This Agreement and the Ancillary Agreements have been
duly executed and delivered by Buyer and, assuming 

  
 -17- 

 
the due execution of those agreements by a Seller or an Affiliate of a Seller (as applicable), this Agreement and the Ancillary Agreements constitute the valid and binding obligation of Buyer,
enforceable against Buyer in accordance with their terms, subject to the Bankruptcy and Equity Exception. 

Section 5.3    Consents and Approvals; No Violations. The execution by Buyer of this Agreement and the
Ancillary Agreements, and the consummation by Buyer of the transactions contemplated hereby and thereby will not (a) violate the provisions of the certificate of incorporation or bylaws of Buyer; (b) violate any Law of any Governmental
Authority by which Buyer is bound; or (c) assuming compliance with the matters referred to in Section 5.4, require any consent or approval of, or the giving of any notice to, or filing with, any Governmental Authority
on or prior to the Closing Date, excluding from the foregoing clause (c) consents, approvals, notices and filings the absence of which would not adversely impact, or reasonably be expected to adversely impact, the ability of Buyer to consummate
the transactions contemplated by this Agreement. 
 Section 5.4    Governmental Authorization. The
execution, delivery and performance by Buyer of this Agreement and the Ancillary Agreements to which it is a party and the consummation of the transactions contemplated hereby and thereby require no action by or in respect of, or consent from or
filing with, any Governmental Authority, other than any such action or filing the failure of which to be made or obtained would not reasonably be expected, individually or in the aggregate, to interfere with, prevent or materially delay the ability
of Buyer to enter into and perform its obligations under this Agreement or consummate the transactions contemplated hereby. 

Section 5.5    Litigation. There are no (a) outstanding judgments, orders, writs, injunctions or decrees
of any Governmental Authority pending, or the knowledge of Buyer, threatened against Buyer that would or could prevent, or otherwise materially adversely affect the ability of Buyer to consummate, the transactions contemplated by this Agreement; or
(b) Actions pending or, to the knowledge of Buyer, threatened against Buyer that would or could prevent, or otherwise materially adversely affect the ability of Buyer to consummate, the transactions contemplated by this Agreement. 

Section 5.6    Financial Capability. Buyer has, and will have available to it at the Closing, on an
unconditional basis, the financial capability and all sufficient cash on hand (through existing credit agreements and otherwise) necessary and sufficient to complete each of the transactions contemplated hereby and to pay all fees and expenses of or
payable by Buyer, including the Purchase Price, and any other amounts required to be paid by it in connection with the consummation of the transactions contemplated by this Agreement. 

Section 5.7    Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or
other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer or any of its Affiliates. 

Section 5.8    Acknowledgements. Buyer hereby acknowledges that (a) neither

  
 -18- 

 
Seller nor any other Person makes any representation or warranty with respect to the Business, the members of the Seller Group, the Acquired Assets, the Excluded Assets, the Assumed Liabilities,
or the Excluded Liabilities, except as set forth in Article IV, and (b) it has not relied on any representation or warranty that is not set forth in Article IV. Buyer acknowledges that it has conducted, to its satisfaction, an
independent investigation and verification of the financial condition, results of operations, assets, liabilities, properties and projected operations of the members of the Seller Group with respect to the Business and, in making its determination
to proceed with the transactions contemplated by this Agreement, Buyer has relied on the results of its own independent investigation and verification, in addition to the representations and warranties of Seller expressly and specifically set forth
in Article IV. 
 ARTICLE VI 

CERTAIN AGREEMENTS 

Section 6.1    Conduct of Business. 

(a)    Except as expressly provided by this Agreement or any Ancillary Agreement, as required by applicable
Law, as set forth in Section 6.1 of the Seller Disclosure Letter or as expressly consented to in writing by Buyer (which consent will not be unreasonably withheld, conditioned or delayed), between the Execution Date and the
Closing, Seller will, and will cause each member of the Seller Group to, use commercially reasonable efforts to conduct the Business in all material respects in the ordinary course, consistent with past practice (it being understood that a
reasonable good faith action taken solely to address an extraordinary or unusual event occurring after the date of this Agreement that is outside of the control of Seller or its Subsidiaries and is outside of the ordinary course of business will not
be deemed to be a breach of this Section 6.1); provided that, notwithstanding the foregoing, (i) no action by any member of the Seller Group with respect to matters specifically addressed by any other provision of this
Section 6.1 will be deemed a breach of this Section 6.1(a), unless such action would constitute a breach of one or more of such other provisions, and (ii) the Seller Group’s failure to
take any action prohibited by Section 6.1(b) will not be a breach of this Section 6.1(a). 

(b)    Without limiting the generality of Section 6.1(a), and except as otherwise
contemplated or permitted by this Agreement, as required by any Contract set forth on Section 4.9 of the Seller Disclosure Letter, as required by Law or Contract, as set forth in Section 6.1 of the
Seller Disclosure Letter or as expressly consented to in writing by Buyer (which consent will not be unreasonably withheld, conditioned or delayed), Seller will not, and will not permit any member of the Seller Group to: 

(i)    sell, pledge, dispose of, grant, transfer, lease, license, guarantee, encumber or authorize the
sale, pledge, disposition, grant, transfer, lease, guarantee or encumbrance of or on any assets, properties or rights that 

  
 -19- 

 
are (or would otherwise be) material Business Assets (excluding the Business IP, provision for which is made in Section 6.1(b)(iv)), other than any inventory (including
any finished goods or work-in-process) or obsolete equipment in the ordinary course of business; 

(ii)    (A) adopt or amend any Employee Benefit Plan or increase the salaries, wage rates, target bonus
opportunities or equity based compensation of Transferred Employees, in each case except (x) in the ordinary course of business consistent with past practice, (y) in connection with the adoption or amendment of Employee Benefit Plans (or
other practices) that are applicable generally to employees of Seller and its Subsidiaries in the relevant jurisdictions, or (z) as required (1) to comply with applicable Law, (2) by the terms of any Employee Benefit Plan in effect on
the Execution Date, or (3) by the terms of any Contract of Seller or any of its Subsidiaries in effect on the Execution Date, the existence of which Contract does not constitute a breach of any representation, warranty or covenant in this
Agreement, (B) hire, or offer to hire, any Business Employee, (C) terminate the employment, change the title, office or position, or materially reduce the responsibilities or terms and conditions of employment of any Transferred Employee,
(D) enter into, amend or extend the term of any employment or consulting agreement, bonus arrangement, severance agreement, retention bonus, or change of control agreement with any Transferred Employee, or (E) enter into any collective
bargaining agreement or other contract with a labor organization, trade or labor union, workers’ council, employees’ association or similar organization representing any of such employees (unless required by Law). 

(iii)    materially amend or modify or terminate (partially or completely), or enter into any agreement to
materially amend or modify or terminate (partially or completely), any of the Material Contracts, other than in the ordinary course of business, or enter into any agreement that would have been a Material Contract had it been entered into prior to
the Execution Date; 
 (iv)    grant any rights to or transfer any Intellectual Property that is, or
would be, Business IP, other than grants of non-exclusive licenses in the ordinary course of business; 

(v)    enter into any settlement, or offer or propose to enter into any settlement, that would reasonably
be expected to materially and adversely affect the Business or limit the ability of Buyer to conduct the Business following the Closing in any geography or in any other material respect; 

(vi)    take any action for the express purpose of minimizing or reducing the level of working capital to
be delivered to Buyer at the Closing; or 
 (vii)    agree, in writing or otherwise, to take any of the
foregoing actions. 

  
 -20- 

 Section 6.2    Access. Seller will permit Buyer and its
Representatives to have reasonable access, prior to the Closing Date, to the properties, books and records of the Business during normal working hours and upon reasonable advance notice; provided, however, that Buyer will not disrupt the personnel
and operations of the Business or other operations or activities of Seller or any of its Subsidiaries; provided, further, that (a) nothing herein will require any employee of Seller or any of its Subsidiaries to provide any information
regarding the Business in any other format or otherwise to manipulate or reconfigure any data regarding the Business; (b) nothing herein will require Seller or any of its Subsidiaries to provide Buyer with access to or copies of (i) any
information that must be maintained as confidential by applicable Law or in accordance with the terms of a written agreement with a third party, (ii) sensitive customer or employee information, manufacturing processes, pricing lists or other
information that relates to the Business and that, in Seller’s reasonable business judgment, should not be provided to Buyer until the transactions contemplated hereby have been consummated in order to avoid any adverse effect on the Business,
or in order not to violate applicable Laws, unless such information will be acquired by Buyer at the Closing Date, in which case Buyer will enter into any confidentiality agreement(s) that are necessary to review such information (receipt of such
information being subject to execution of any necessary confidentiality agreement(s) by any required third party), or (iii) employee information; and (c) nothing herein will require Seller or any of its Subsidiaries to provide Buyer with
access to or copies of any information that relates to any businesses or operations of Seller or any of its Subsidiaries other than the Business. All requests for access will be made to such Representatives of Seller as Seller will designate, who
will be solely responsible for coordinating all such requests and access thereunder. Notwithstanding the foregoing, prior to the Closing, Buyer and Buyer’s Representatives will not contact or in any other manner communicate with the employees,
customers and suppliers of the Business in connection with the transactions contemplated hereby, except following prior consultation with and written approval from Seller or its Representatives. Notwithstanding the foregoing or any other provision
in this Agreement, none of Buyer, any Affiliate of Buyer or any Representative of Buyer will be entitled to review or have access to any Tax Return of Seller or any Affiliate thereof or any work papers related thereto. 

Section 6.3    Efforts to Close. In addition to the actions specifically provided for elsewhere in this
Agreement or in any Ancillary Agreement, each of the Parties will cooperate with each other and use (and will cause their respective Subsidiaries and Affiliates to use) their reasonable best efforts, prior to, at and after the Closing Date, to take,
or to cause to be taken, all actions, and to do, or to cause to be done, all things reasonably necessary on its part under applicable Law or contractual obligations to consummate and make effective the transactions contemplated by this Agreement and
the Ancillary Agreements as promptly as reasonably practicable; provided, however, that no member of the Seller Group will be required to make any payments, incur any liability, or offer or grant any accommodation (financial or otherwise) to any
third party in connection with obtaining any consent, approval or waiver. Seller and Buyer will comply fully with all applicable notification, reporting and other requirements of applicable Law and Governmental Authorities. 

  
 -21- 

 Section 6.4    Confidentiality. Buyer acknowledges that the
information being provided to it in connection with the transactions contemplated hereby is subject to the terms of a confidentiality agreement by and between Buyer and Seller (the “Confidentiality Agreement”), the terms of which
are incorporated herein by reference. Effective upon the Closing, the Confidentiality Agreement will terminate with respect to information relating solely to the Business; provided, however, that Buyer acknowledges that any and all other information
provided to it by Seller and its Affiliates or their Representatives concerning the Seller and its Affiliates (other than the Business) will remain subject to the terms and conditions of the Confidentiality Agreement after the Closing Date. 

Section 6.5    Further Assurances. From and after the Closing, as and when requested by any Party, each Party
will execute and deliver, or cause to be executed and delivered, all such documents and instruments and will take, or cause to be taken, at the requesting Party’s expense, all such further or other actions, as such other Party may reasonably
deem necessary or desirable to consummate the transactions contemplated by this Agreement. 

Section 6.6    Publicity. The Parties acknowledge and agree to the confidentiality, publicity and related
obligations contained in the PCA. The requirements of this Section 6.6 will be in addition to those included in the Confidentiality Agreement. 

Section 6.7    Business Records; Cooperation. After the Closing, Buyer will cooperate with, and will afford
the members of the Seller Group and their Representatives reasonable access, during normal business hours, to the books and records of the Business (and will permit such Persons to examine and copy such books and records to the extent reasonably
requested by such Person) and will cause the directors, officers and employees of the Business to furnish all information requested by the members of the Seller Group in connection with financial reporting and Tax matters (including financial and
Tax audits and Tax contests), third-party litigation, the Excluded Assets and the Excluded Liabilities, and other reasonable business purposes. Buyer will not destroy or dispose of any such books and records for a period of [***] years after the
Closing without the prior written consent of Seller, and if thereafter Buyer proposes to destroy or dispose of any such books and records, Buyer will offer first in writing to surrender any such books and records to Seller. 

Section 6.8    Bulk Transfer Laws. Buyer hereby waives compliance by the members of the Seller Group with the
provisions of any so-called “bulk transfer law” of any jurisdiction in connection with the Conveyance of the Acquired Assets to Buyer. 

Section 6.9    Excluded Liabilities; Assumed Liabilities. 

(a)    The applicable members of the Seller Group will promptly pay all Excluded Liabilities when due. If
Buyer receives a claim or request for a payment that is an Excluded Liability, it will promptly forward such item to Seller. 

  
 -22- 

 (b)    Buyer will promptly pay all Assumed Liabilities
when due or promptly reimburse the applicable member of the Seller Group if paid by such Person. If a member of the Seller Group receives a claim or request for a payment that is an Assumed Liability, Seller will, or will cause the applicable member
of the Seller Group to, promptly forward such item to Buyer. 
 Section 6.10    Expenses. All costs and
expenses incurred in connection with this Agreement and the transactions contemplated by this Agreement will be paid by the Party incurring such costs and expenses, whether or not the transactions contemplated by this Agreement are consummated,
except as otherwise expressly provided in this Agreement. 
 Section 6.11    Certain Consents; Shared Business
Contracts. 
 (a)    General Pre-Closing Cooperation.
The Parties will use their respective commercially reasonable efforts prior to Closing to obtain all consents and approvals required in connection with the transactions contemplated hereby. To the extent practicable, Seller shall provide Buyer with
a reasonable opportunity to review, comment on and approve any waivers, consents, approvals, notices, orders, registrations and filings to be made, given or used by Seller and shall promptly deliver to Buyer a copy of each such registration or
filing made, each such notice given and each such waiver, consent, approval or order obtained by Seller prior to the Closing Date. Notwithstanding the foregoing, Seller will, in its sole discretion, retain final decision-making authority with
respect to any waivers, consents, approvals, notices, orders, registrations and filings contemplated by this Section 6.11(a). 

(b)    General Post-Closing Cooperation. If and to the extent that the Conveyance to Buyer of any
Acquired Asset would be a violation of applicable Laws or require any consent in connection with the transactions contemplated hereby that has not been obtained as of the Closing, then, notwithstanding any other provision hereof, such Conveyance
will automatically be deferred and will not occur until all legal impediments are removed or such consents have been obtained. Notwithstanding the foregoing, any such Asset will still be considered an Acquired Asset and the Person retaining such
Asset will thereafter hold such Asset in trust for the benefit, insofar as reasonably possible, of the Person entitled thereto (and at such Person’s sole expense) until the consummation of the Conveyance thereof. The Parties will use their
respective commercially reasonable efforts to (i) continue to seek to remove any legal impediments or secure any contractual consents required from third parties necessary to Convey such Asset and (ii) develop and implement arrangements to
place the Person entitled to receive such Asset, insofar as reasonably possible and to the extent not prohibited by applicable Law or the relevant Contract, in the same position as if such Asset had been Conveyed as contemplated hereby such that all
the benefits and burdens relating to such Asset, including possession, use, risk of loss, potential for gain, any Tax liabilities in respect thereof and dominion, control and command over such Asset, are to inure from and after the Closing to such

  
 -23- 

 
Person. If and when the applicable legal or contractual impediments are removed or the applicable Consents are obtained, the Conveyance of the applicable Asset will be effected in accordance with
the terms of this Agreement or such applicable Ancillary Agreement. The obligations set forth in this Section 6.11(b) will terminate on the [***] -year anniversary of the Closing. Nothing in this
Section 6.11(b) will be deemed to apply to any Shared Business Contract, it being understood that Shared Business Contracts are governed by Section 6.11(c). 

 

	 	(c)	 Shared Business Contracts. 

(i)    Seller will use commercially reasonable efforts to either (A) cause any Shared Business
Contract to be assigned in relevant part to Buyer on the Closing Date or to appropriately amend such Shared Business Contract so that Buyer will, at and following the Closing, be entitled to the rights and benefits inuring to the Business under such
Shared Business Contracts or (B) assist Buyer in its efforts to procure an alternative arrangement that provides Buyer with the applicable Business requirements currently procured under such Shared Business Contract. If with respect to any
Shared Business Contract, such partial assignment or amendment provided for in clause (A) cannot be obtained, or if an attempted partial assignment or amendment thereof would adversely affect in a material respect the rights of Seller or Buyer
thereunder, Seller will either provide the assistance called for by clause (B) or Seller and Buyer will use their commercially reasonable efforts to negotiate a mutually acceptable arrangement under which Buyer and Seller will, to the extent
permitted by applicable Law or the relevant Shared Business Contract, obtain the benefits and assume the obligations under such Shared Business Contract to the extent related to the Business (in the case of Buyer) or businesses or operations other
than the Business (in the case of Seller), including entering into sub-contracting, sub- licensing or sub-leasing arrangements
for the benefit of Buyer or Seller, as the case may be (the “Sharing Arrangements”). 

(ii)    Notwithstanding the foregoing, following the expiration or other termination of any Shared Business
Contract, neither Buyer nor Seller will be obligated to continue the Sharing Arrangements, as applicable; provided, that neither Seller nor Buyer may terminate any such Shared Business Contract without the prior written consent of the other Party.

 (iii)    Any
out-of-pocket costs of obtaining the consent of the relevant counterparty to the arrangements contemplated by this Section 6.11(c), including
any payment or fee required to be made to such counterparty in exchange for the grant of such consent, will be paid by Buyer. 

Section 6.12    Seller Name. Within three months of the Closing Date, Seller will cause Oncimmune USA to
prepare and file such documents with the applicable Governmental Authority as are necessary to change its corporate name; provided, however, that the new name shall be able to include “Oncimmune”. 

  
 -24- 

 Section 6.13    Business Balance Sheets. Seller shall
provide to Buyer (a) within three weeks following the Execution Date, the unaudited balance sheet of the Business as of the Execution Date and (b) within three weeks following the Closing Date, the unaudited balance sheet of the Business
as of the Closing Date. 
 Section 6.14    Non-Test Inventory.
Following the Closing, Buyer will permit Seller and its Representatives to have reasonable access to the Kansas Lab during normal working hours and upon reasonable advance notice for purposes of accessing any Excluded Assets located at the Kansas
Lab, including any inventory that constitutes an Excluded Asset; provided, however, that Seller will not disrupt the personnel and operations of the Business or other operations or activities of Buyer in exercising such access right. Buyer will not,
without the prior written consent of Seller, use or access such inventory. The parties will reasonably cooperate regarding the duration of such access right. 

Section 6.15    Brookhaven Sub-License. Prior to the Closing, the
Parties will use commercially reasonable efforts to obtain consent from Brookhaven Science Associates, LLC to sub-license to Buyer certain rights under that certain License Agreement, by and between Brookhaven
Science Associates, LLC and Oncimmune (USA) LLC, dated April 14, 2008. 
 ARTICLE VII 

EMPLOYMENT MATTERS 

Section 7.1    Employment of Transferred Employees; Severance. 

(a)    Effective as of and subject to the Closing, Buyer will offer employment to each Transferred Employee
on substantially similar terms to those that applied to such employees immediately prior to the Closing, and Seller will or will cause the termination of such Transferred Employee’s employment with Seller or its Subsidiaries as of the Closing
Date. 
 (b)    For 12 months following the Closing Date, (i) Buyer will not, and will cause its
Affiliates not to, reduce the salary or base hourly wage rate and bonus opportunity of any Transferred Employee below the rate in effect immediately prior to the Closing Date, except in the case of bona fide performance issues or otherwise for
cause, and (ii) each Transferred Employee that is employed by Buyer or its Affiliates will be eligible for bonuses under Buyer’s bonus plan. 

(c)    To the extent that, following the Closing Date, Buyer or any Affiliate of Buyer terminates the
employment of any Transferred Employee, Buyer will be solely responsible for providing such Transferred Employee any severance benefits in accordance with Buyer’s policies and practices, and will hold harmless the members of the Seller Group
and their Affiliates with respect to any Damages claimed by such Transferred Employee arising therefrom. 

  
 -25- 

 (d)    Nothing in this Article VII will limit
Buyer’s obligations with respect to the Assumed Liabilities or any Liabilities under applicable Law. 

Section 7.2    Employee Benefit Plans Generally. 

(a)    For a period of 12 months following the Closing Date, Buyer will provide employee benefits to
Transferred Employees under Employee Benefit Plans maintained by Buyer that are (x) substantially similar to those provided to Buyer’s similarly situated employees or, at Buyer’s option, (y) substantially comparable in the
aggregate to those provided to Transferred Employees under the Employee Benefit Plans immediately prior to the Closing. 

(b)    Buyer will credit Transferred Employees in accordance with Buyer’s plans for their service with
any member of the Seller Group and their Affiliates (and any predecessors) for purposes of eligibility and vesting under Buyer’s plans in which Transferred Employees participate after the Closing and any applicable vacation or severance
policies or programs. Buyer will permit Transferred Employees (and their eligible spouses and dependents) to participate in Buyer’s plans without being subject to any waiting periods or any restrictions or limitations for pre-existing conditions, except to the extent any such person has not satisfied any corresponding applicable waiting period or limitation under the Employee Benefit Plans. Buyer’s plans will credit each
Transferred Employee (and any spouses and dependents) with the amount, if any, paid during the calendar year in which the Closing Date occurs under the Employee Benefit Plans towards deductibles, co-pays and out-of-pocket maximums. 

Section 7.3    401(k) Plan. Buyer will use commercially reasonable efforts to cause one of its tax-qualified retirement plans intended to comply with Section 401(k) of the Code to accept a rollover by any Transferred Employee of any eligible rollover distribution in the form of cash and any outstanding
loans from any Employee Benefit Plan that is qualified under Section 401(a) of the Code. 

Section 7.4    Welfare Plans. Seller or another member of the Seller Group will retain all Liabilities for
claims incurred by a Transferred Employee (and his or her eligible spouse and dependents) on or prior to the Closing under the Employee Benefit Plans that are welfare benefit plans within the meaning of Section 3(1) of ERISA and all short term
disability, salary continuation, severance plans or arrangements (the “Welfare Plans”). For this purpose, claims under any medical, dental, vision, or prescription drug plan that is a Welfare Plan generally will be deemed to be
incurred on the date that the service giving rise to such claim is performed and not when such claim is made; provided, however, that with respect to claims relating to hospitalization the claim will be deemed to be incurred on the first day of such
hospitalization and not on the date that such services are performed. Claims for disability under any long or short term disability plan that is a Welfare Plan will be incurred on the date the Transferred Employee is first absent from work because
of the condition giving rise to such disability and not when the Transferred Employee is determined to be eligible for benefits under the applicable Welfare Plan. Seller or an Affiliate will provide or cause to be provided

  
 -26- 

 
any continuation coverage required under Part 6 of Title I of ERISA or applicable state law (“COBRA”) to each “qualified beneficiary” as that term is defined in COBRA
who is not a Transferred Employee and whose first “qualifying event” (as defined in COBRA) occurs on or prior to the Closing. 

ARTICLE VIII 
 CONDITIONS TO
CLOSING 
 Section 8.1    Conditions to Buyer’s Obligations. The obligation of Buyer
to consummate the transactions contemplated by this Agreement is conditioned upon the satisfaction or waiver, at or prior to the Closing, of the following conditions; provided, however, that Buyer may not rely on the failure of any of the following
conditions in this Section 8.1 to be satisfied if such failure was caused by Buyer’s failure to act in good faith or to use commercially reasonable efforts to cause the Closing to occur, as required by
Section 6.3: 
 (a)    Representations and Warranties. All
representations and warranties set forth in Article IV (other than the Fundamental Representations), without giving effect to materiality, Material Adverse Effect or similar qualifications, shall be true and correct in all respects at and as
of the Closing Date as though such representations and warranties were made at and as of the Closing Date (other than in the case of any representation or warranty that by its terms addresses matters only as of another specified date, which shall be
so true and correct only as of such specified date), except to the extent the failure of such representations and warranties to be true and correct would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. All Fundamental Representations shall be true and correct in all material respects at and as of the Closing Date as though such Fundamental Representations were made at and as of the Closing Date (other than in the case of any representation
or warranty that by its terms addresses matters only as of another specified date, which shall be so true and correct only as of such specified date); 

(b)    Covenants. Seller shall have performed in all material respects all of the covenants and
agreements required to be performed by it under this Agreement at or prior to the Closing; 

(c)    Officer’s Certificate. Seller shall have delivered to Buyer a certificate
dated as of the Closing Date signed by an officer of Seller to the effect that each of the conditions set forth in Section 8.1(a) and Section 8.1(b) have been satisfied; 

(d)    Closing Deliveries. Seller shall have delivered, or caused to be delivered, to Buyer the
items and documents set forth in Section 3.2(a); 

  
 -27- 

 (e)    No Prohibition. No Law enacted, entered,
promulgated or enforced by any Governmental Authority of competent jurisdiction will be in effect at the Closing preventing the consummation of the transactions contemplated by this Agreement; and 

(f)    PCA. The PCA shall not have been terminated in accordance with its terms. 

Section 8.2    Conditions to Seller’s Obligations. The obligation of Seller to consummate
the transactions contemplated by this Agreement is conditioned upon the satisfaction or waiver, at or prior to the Closing, of the following conditions; provided, however, that Seller may not rely on the failure of any of the following conditions in
this Section 8.2 to be satisfied if such failure was caused by Seller’s failure to act in good faith or to use commercially reasonable efforts to cause the Closing to occur, as required by
Section 6.3. 
 (a)    Representations and Warranties. All
representations and warranties set forth in Article V shall be true and correct in all material respects at and as of the Closing Date as though such representations and warranties were made at and as of the Closing Date (other than in the
case of any representation or warranty that by its terms addresses matters only as of another specified date, which shall be true and correct only as of such specified date); 

(b)    Covenants. Buyer shall have performed in all material respects all of the covenants and
agreements required to be performed by it under this Agreement at or prior to the Closing; 

(c)    Officer’s Certificate. Buyer shall have delivered to Seller a certificate
dated as of the Closing Date signed by an officer of Buyer to the effect that each of the conditions set forth in Section 8.2(a) and Section 8.2(b) have been satisfied; 

(d)    Closing Deliveries. Buyer shall have delivered to Seller the items and documents set forth in
Section 3.2(b); 
 (e)    No Prohibition. No Law enacted, entered,
promulgated or enforced by any Governmental Authority of competent jurisdiction will be in effect at the Closing preventing the consummation of the transactions contemplated by this Agreement; and 

(f)    PCA. The PCA shall not have been terminated in accordance with its terms. 

Section 8.3    Waiver. Upon the occurrence of the Closing, any condition set forth in this Article VIII
that was not satisfied as of the Closing shall be deemed to have been waived as of and from the Closing. 

  
 -28- 

 ARTICLE IX 

INDEMNIFICATION 

Section 9.1    Survival. The representations and warranties of the Parties contained in this Agreement
and all covenants and agreements of the Parties that are to be performed prior to the Closing will survive the Closing for a period of 12 months after the Closing Date; provided, that (i) the representations and warranties of Seller
contained Section 4.10(a) (Title to Assets) will survive for a period of three years after the Closing Date, (ii) the representations and warranties of Seller contained Section 4.13 (Taxes) will survive for
a period of sixty days following the expiration of the applicable statute of limitations, and (iii) the Fundamental Representations (other than the representations and warranties of Seller contained Section 4.10(a)
(Title to Assets)) and the representations and warranties contained in Sections 5.1 (Organization), 5.2 (Authorization, Validity and Execution) and 5.7 (Brokers) will survive indefinitely. All of the covenants contained in this
Agreement that by their nature are required to be performed after the Closing will survive the Closing until fully performed or fulfilled, unless and only to the extent that non-compliance with such covenants
or agreements is waived in writing by the Party entitled to such performance. Notwithstanding the preceding two sentences, any breach of any covenant, agreement, representation or warranty in respect of which indemnification may be sought under this
Agreement will survive the time at which it would otherwise terminate pursuant to the preceding two sentences, if notice of such breach giving rise to such right of indemnification will have been given to the Party against whom such indemnification
may be sought prior to such time. The Parties acknowledge and agree that with respect to any claim that any Party may have against any other Party that is permitted pursuant to the terms of this Agreement, the survival periods set forth and agreed
to in this Section 9.1 will govern when any such claim may be brought and will replace and supersede any statute of limitations that may otherwise be applicable. 

Section 9.2    Indemnification. 

(a)    Subject to the provisions of this Article IX, including the limitations set forth in
Section 9.4, from and after the Closing, Seller agrees to indemnify Buyer and its Affiliates, directors, officers, employees, successors, permitted assigns, agents and representatives (collectively, the “Buyer
Indemnitees”) against and agrees to hold each of them harmless from any and all Damages incurred or suffered by any Buyer Indemnitee to the extent arising out of or relating to: 

(i)    any breach of any representation or warranty of Seller in Article IV; 

(ii)    any breach of any covenant or agreement made or to be performed by Seller pursuant to this
Agreement; or 
 (iii)    any Excluded Liability or any other Liability arising in connection with or
relating to any Excluded Asset. 

  
 -29- 

 (b)    Subject to the provisions of this Article
IX, including the limitations set forth in Section 9.4, from and after the Closing, Buyer agrees to indemnify the members of the Seller Group and their respective Affiliates, directors, officers, employees, successors,
permitted assigns, agents and representatives (collectively, the “Seller Indemnitees”) against and agrees to hold each of them harmless from any and all Damages incurred or suffered by any Seller Indemnitee to the extent arising out
of or relating to: 
 (i)    any breach of any representation or warranty of Buyer in Article V;

 (ii)    any breach of covenant or agreement made or to be performed by Buyer pursuant to this
Agreement; or 
 (iii)    without duplication, any Assumed Liability or any other Liability arising in
connection with or relating to the Business to the extent the Buyer Indemnitees are not entitled to indemnification for Damages arising out of or relating to such other Liability pursuant to this Article IX. 

Section 9.3    Procedures. Claims for indemnification under this Agreement will be asserted and resolved as
follows: 
 (a)    Any Buyer Indemnitee or Seller Indemnitee seeking indemnification under this Agreement
(an “Indemnified Party”) with respect to any claim asserted against the Indemnified Party by a third party (a “Third Party Claim”) in respect of any matter that is subject to indemnification under
Section 9.2 will (i) promptly notify the other Party (the “Indemnifying Party”) of the Third Party Claim (and in any event within 20 days of the date on which the Indemnified Party knows or
reasonably should have known of the Third Party Claim), and (ii) as promptly as practicable transmit to the Indemnifying Party a written notice (a “Claim Notice”) describing in reasonable detail the nature of the Third Party
Claim, a copy of all papers served with respect to such claim (if any), the basis of the Indemnified Party’s request for indemnification under this Agreement and, to the extent estimable, a reasonable estimate of any Damages suffered with
respect thereto. Notwithstanding the foregoing, the delay or failure to give the notice provided in this Section 9.3(a) will not relieve the Indemnifying Party of its obligations under this Article IX, except to the
extent such Indemnifying Party is actually prejudiced by such delay or failure. 
 (b)    The
Indemnifying Party will have the right to defend the Indemnified Party against such Third Party Claim. The Indemnifying Party will promptly notify the Indemnified Party (and in any event within 45 days after having received any Claim Notice) with
respect to whether or not it is exercising its right to defend the Indemnified Party against such Third Party Claim. If the Indemnifying Party notifies the Indemnified Party that the Indemnifying Party elects to assume the defense of the Third Party
Claim (such election to be without prejudice to the right of the Indemnifying Party to dispute whether such claim is an indemnifiable 

  
 -30- 

 
Damage under this Article IX), then the Indemnifying Party will have the right to defend such Third Party Claim with counsel selected by the Indemnifying Party, in all appropriate
proceedings, to a final conclusion or settlement at the discretion of the Indemnifying Party in accordance with this Section 9.3(b). The Indemnifying Party will have full control of such defense and proceedings, including
any compromise or settlement thereof; provided, however, that the Indemnifying Party will not enter into any settlement agreement without the written consent of the Indemnified Party (which consent will not be unreasonably withheld, conditioned or
delayed). Notwithstanding the foregoing, such consent will not be required if (i) the settlement agreement contains a complete and unconditional general release by the third party asserting the Third Party Claim to all Indemnified Parties
affected by the Third Party Claim and (ii) the settlement agreement does not contain any admission of fault or material sanction or restriction upon the conduct or operation of any business conducted by the Indemnified Party or its Affiliates.
The Indemnified Party may participate in, but not control, any defense or settlement of any Third Party Claim controlled by the Indemnifying Party pursuant to this Section 9.3(b), and the Indemnified Party will bear its own
costs and expenses with respect to such participation. 
 (c)    If the Indemnifying Party does not
notify the Indemnified Party that the Indemnifying Party elects to defend the Indemnified Party pursuant to Section 9.3(b) within 45 days after receipt of any Claim Notice, then the Indemnified Party will defend itself
against the applicable Third Party Claim, and be reimbursed for its reasonable cost and expense (but only if the Indemnified Party is actually entitled to indemnification hereunder) in regard to the Third Party Claim with counsel selected by the
Indemnified Party, in all appropriate proceedings and in good faith, which proceedings will be prosecuted diligently by the Indemnified Party. In such circumstances, the Indemnified Party will defend any such Third Party Claim in good faith and have
full control of such defense and proceedings; provided, however, that the Indemnified Party may not enter into any compromise or settlement of such Third Party Claim if indemnification is to be sought hereunder, without the Indemnifying Party’s
consent (which consent will not be unreasonably withheld, conditioned or delayed). The Indemnifying Party may participate in, but not control, any defense or settlement controlled by the Indemnified Party pursuant to this
Section 9.3(c), and the Indemnifying Party will bear its own costs and expenses with respect to such participation; provided, however, if at any time the Indemnifying Party acknowledges in writing that such Third Party
Claim is an indemnifiable Damage under this Article IX, the Indemnifying Party will be entitled to assume the defense of such Third Party Claim in accordance with Section 9.3(b). 

(d)    If requested by the Indemnifying Party, the Indemnified Party agrees, at the sole cost and expense
of the Indemnifying Party (but only if the Indemnified Party is actually entitled to indemnification hereunder), to cooperate with the Indemnifying Party and its counsel in contesting any Third Party Claim that the Indemnifying Party elects to
contest, including providing reasonable access to documents, records and information. In addition, the Indemnified Party 

  
 -31- 

 
will make its personnel reasonably available at no cost to the Indemnifying Party for conferences, discovery, proceedings, hearings, trials or appeals as may be reasonably requested by the
Indemnifying Party. The Indemnified Party also agrees to cooperate with the Indemnifying Party and its counsel in the making of any related counterclaim against the Person asserting the Third Party Claim or any cross complaint against any Person and
executing powers of attorney to the extent necessary. 
 (e)    A claim for indemnification for any
matter not involving a Third Party Claim will be asserted by notice to the Party from whom indemnification is sought as promptly as practicable after the date on which the Indemnified Party knows or reasonably should have known of facts giving rise
to the claim for indemnification, which notice will describe in reasonable detail the nature of the claim and the basis of the Indemnified Party’s request for indemnification under this Agreement and will include, to the extent estimable, a
reasonable estimate of the Damages suffered with respect thereto. Notwithstanding the foregoing, the delay or failure to give the notice provided in this Section 9.3(e) will not relieve the Indemnifying Party of its
obligations under this Article IX, except to the extent such Indemnifying Party is actually prejudiced by such delay or failure. 

Section 9.4    Limitations on Liability. Notwithstanding anything to the contrary herein: 

(a)    Seller will not be liable for (i) any breach of any representation or warranty of Seller set
forth in this Agreement or (ii) any breach of Section 6.1, in either case, unless the aggregate amount of Damages actually incurred by the Buyer Indemnitees for such breach and all other breaches otherwise subject to
indemnification hereunder exceeds [***] (the “Basket”), in which case the Buyer Indemnitees shall be entitled to indemnification for all such Damages, including the initial [***]; provided, however, that the limitations set forth in
this Section 9.4(a) will not apply to indemnification for Damages arising out of or resulting from any breach of any Fundamental Representation (and, for the avoidance of doubt, Damages indemnifiable on account of any
breach of any Fundamental Representation will not be counted towards the calculation of the Basket); 

(b)    in no event will Seller’s aggregate Liability arising out of or relating to
Section 9.2(a)(i) or Section 9.2(a)(ii) (in the case of a breach or breaches of Section 6.1) exceed [***] (the “Cap”); provided, however, that the Cap will not apply to
indemnification for Damages arising out of or resulting from any breach of any Fundamental Representation; 

(c)    notwithstanding anything to the contrary in this Agreement, in no event will Seller’s aggregate
Liability arising out of or relating to Section 9.2(a) exceed the Purchase Price; 

(d)    in no event will Seller be liable under Section 9.2(a) for any Damages
arising from an action taken or not taken by the Seller at the request of Buyer; 

  
 -32- 

 (e)    the Buyer Indemnitees will not have a right to
assert claims for indemnification under any provision of this Agreement for Damages to the extent that such Damages arise out of actions taken (or omitted to be taken) by Buyer, its Affiliates or any Buyer Indemnitee after the Closing; 

(f)    each Indemnified Party will have a duty to use commercially reasonable efforts to mitigate any
Damages arising out of or relating to this Agreement or the transactions contemplated hereby; 

(g)    the amount of any Damages for which an Indemnified Party claims indemnification under this Agreement
will be reduced by the amount of (i) any insurance proceeds actually received from third party insurers with respect to such Damages; (ii) any Tax Benefit that is Actually Realized, which Tax Benefit is attributable to such Damages or to
the facts giving rise to such Damages and (iii) any indemnification, contribution, offset or reimbursement payments actually received from third parties with respect to such Damages; provided, that such Indemnified Party will use
commercially reasonable efforts to obtain recoveries from insurers and other third parties in respect of this Section 9.4(g); and provided, further, that an Indemnified Party will use commercially reasonable
efforts to cause any Tax Benefit to be Actually Realized with respect to such Damages. If an Indemnified Party (A) actually receives insurance proceeds from third party insurers with respect to such Damages, (B) has a Tax Benefit that is
Actually Realized, or (C) actually receives indemnification, contribution, offset or reimbursement payments from third parties with respect to such Damages, in each case, at any time subsequent to any indemnification payment pursuant this
Article IX, then such Indemnified Party will promptly reimburse the applicable Indemnifying Party for any payment made or expense incurred by such Indemnifying Party in connection with providing such indemnification up to such amount actually
received by such Indemnified Party; 
 (h)    in the event an Indemnified Party will recover Damages in
respect of a claim of indemnification under this Article IX, no other Indemnified Party will be entitled to recover the same Damages in respect of a claim for indemnification; and 

(i)    notwithstanding anything provided under applicable Law, no Party will have any Liability (including,
without limitation, under this Article IX) for, and Damages will not include, any punitive, incidental, consequential, special or indirect Damages or Damages based on lost profits, loss in value or Damages that are based on a multiple of
earnings, in each case, except to the extent any such Damages are awarded and paid with respect to a Third Party Claim as to which a Party is entitled to indemnification under this Agreement. 

  
 -33- 

 Section 9.5    Assignment of Claims. If the Indemnified
Party receives any payment from an Indemnifying Party in respect of any Damages pursuant to Section 9.2 and the Indemnified Party could have recovered all or a part of such Damages from a third party (a “Potential
Contributor”) based on the underlying claim asserted against the Indemnifying Party, the Indemnified Party will, to the extent permitted by Law and any pertinent Contract, assign such of its rights to proceed against the Potential
Contributor as are necessary to permit the Indemnifying Party to recover from the Potential Contributor the amount of such payment. 

Section 9.6    Exclusivity. After the Closing, the sole and exclusive remedy for any and all claims, Damages
or other matters arising under, out of, or related to this Agreement or the transactions contemplated hereby, other than in the case of Fraud with respect to a representation and warranty made by a Party in this Agreement, will be the rights of
indemnification set forth in this Article IX only, and no Person will have any other entitlement, remedy or recourse, whether in contract, tort, strict liability, equitable remedy or otherwise, it being agreed that all of such other remedies,
entitlements and recourse are expressly waived and released by the Parties to the fullest extent permitted by Law. This Section 9.6 will not operate to interfere with or impede the operation of the covenants contained in
this Agreement that by their nature are required to be performed after the Closing, with respect to a Party’s right to seek equitable remedies (including specific performance or injunctive relief). The provisions of this
Section 9.6, together with the covenants contained in this Agreement that by their nature are required to be performed after the Closing, were specifically bargained-for between the
Seller Group, on the one hand, and Buyer, on the other hand, and were taken into account by the Parties in arriving at the Purchase Price. Each Party, respectively, specifically relied upon the provisions of this
Section 9.6 in agreeing to the Purchase Price and in agreeing to provide the specific representations and warranties set forth in Article IV (in the case of the Seller Group) and Article V (in the case of
Buyer). 
 Section 9.7    Characterization of Indemnity Payments. The Parties agree that any indemnification
payments made pursuant to this Article IX will be treated for all Tax purposes as an adjustment to the Purchase Price unless otherwise required by applicable Law. 

Section 9.8    Recovery. In the event a Party recovers damages in respect of a claim under an agreement
between the Parties hereto related to the transactions completed hereby, (i) no other party will be entitled to recover with respect to the same claim and (ii) such party which recovers damages shall be barred from recovery with respect to
the same claim under any other agreement between the parties hereto related to the transactions contemplated hereby. 
 ARTICLE X 

TAX MATTERS 

Section 10.1    Sales and Transfer Taxes. Seller and Buyer will each be responsible for 50 percent of all
sales, use, value-added, business, goods and services, 

  
 -34- 

 
transfer, documentary, conveyance or similar taxes or expenses that are imposed as a result of the Conveyance sale of the Acquired Assets (including any stamp duty or other tax chargeable in
respect of any instrument transferring property and any taxes (other than Income Taxes) payable in connection with the sale and transfer of the Intellectual Property), together with any and all penalties, interest and additions to tax with respect
thereto, and Seller and Buyer will cooperate in timely making all filings, returns, reports and forms as may be required to comply with the provisions of such tax Laws. 

Section 10.2    Property Expense Apportionment. The following items relating to the Acquired Assets will be
apportioned at the Closing in an Equitable Manner as of the close of business of the Closing Date so that the income and expense items with respect to the period up to and including the Closing Date will be for the applicable member of the Seller
Group’s account and the income and expense items with respect to the period after the Closing Date will be for Buyer’s account. For purposes of this Section 10.2, the term “Equitable Manner” will
mean that the members of the Seller Group will be allocated such items based on a fraction, the numerator of which is the number of days in the applicable period ending on the Closing Date for which the corresponding item is accrued and the
denominator of which is the total number of days in such period for which the item is accrued, and Buyer will be allocated the remainder. 
  

	 	(a)	 Furthermore, apportionment will be made for: 

(i)    general and special real estate and other ad valorem Taxes and assessments and other state or local
Taxes, fees, charges and assessments in respect of real estate will be based on the fiscal year for which assessed. If the Closing Date will occur before the Tax rate or assessment is fixed for any fiscal year, the apportionment of such Taxes and
payments at the Closing will be based upon the most recently ascertainable Tax bills; provided, however, that Buyer and the members of the Seller Group will recalculate and re-prorate said Taxes and payments
and make the necessary cash adjustments promptly upon the issuance, and based on, the actual Tax bills received for any such fiscal year and the amount of any payments in lieu of Tax made with respect to any such fiscal year; and 

(ii)    personal property Taxes, if any, based on the fiscal year for which assessed. If the Closing Date
will occur before the Tax rate or assessment is fixed for any fiscal year, the apportionment of such Taxes and payments at Closing will be based upon a reasonable estimate mutually agreed upon by Buyer and the members of the Seller Group; provided,
however, that Buyer and the members of the Seller Group will recalculate and re-prorate said Taxes and make the necessary cash adjustments promptly upon the issuance, and based on, the actual Tax bills
received for any such fiscal year. 
 (b)    To the extent any Taxes described in
Section 10.2(a) are adjusted as a result of any Tax audit by a Governmental Authority or administrative or court proceeding initiated by a Governmental Authority with jurisdiction over the properties, Buyer and the members
of the Seller Group will recalculate and re-prorate such Taxes and make the necessary cash adjustments promptly upon the resolution of such audit or proceeding. 

  
 -35- 

 Section 10.3    Amendment of Tax Returns. Except as required
pursuant to applicable Law or contemplated by this Agreement, Buyer shall not, and shall cause its Affiliates not to, amend, refile or otherwise modify any Tax Return or material tax election relating in whole or in part to the Acquired Assets that
was filed on or prior to the Closing Date without the prior written consent of Seller, which consent shall not be unreasonably withheld, conditioned or delayed. 

ARTICLE XI 
 TERMINATION

 Section 11.1    Termination. Anything herein or elsewhere to the contrary notwithstanding, this Agreement
may be terminated and the transactions contemplated herein may be abandoned at any time prior to the Closing: 

(a)    by written consent of Seller and Buyer; 

(b)    by Seller or Buyer if any Governmental Authority having competent jurisdiction has issued a final, non-appealable order, decree, ruling or injunction or taken any other Action permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement; provided, that this right of
termination will not be available to any Party whose failure to comply with its obligations under this Agreement has been the primary cause of, or has primarily resulted in, such order, decree, ruling, injunction or other Action; 

(c)    by Seller or Buyer if any of the conditions set forth in Sections 8.1 and 8.2 of this
Agreement, as applicable, have not been satisfied or waived on or prior to November 1, 2019 (the “Outside Date“); provided, that this right of termination will not be available to any Party whose failure to comply with its
obligations under this Agreement has been the primary cause of, or has primarily resulted in, the failure of any such conditions to be satisfied before such date; and, provided, further, that Buyer will have no right to terminate this Agreement
pursuant to this Section 11.1(c) during the pendency of a legal proceeding by Seller for specific performance pursuant to Section 13.13. 

(d)    by Buyer upon written notice to Seller, in the event of a breach of any representation, warranty,
covenant or agreement on the part of Seller, such that the conditions specified in Section 8.1 would not be satisfied at the Closing, and which, (i) with respect to any such breach that is capable of being cured, is
not cured by Seller within [***] days after receipt of written notice thereof, or (ii) is incapable of being cured prior to the applicable Outside Date; provided, that Buyer will not have the right to terminate this Agreement pursuant to this
Section 11.1(d) if it is then in material breach of any of its representations, warranties, covenants or agreements set forth in this Agreement; 

  
 -36- 

 (e)    by Seller upon written notice to Buyer, in the
event of a breach of any representation, warranty, covenant or agreement contained in this Agreement on the part of Buyer, such that the conditions specified in Section 8.2 would not be satisfied at the Closing, and which,
(i) with respect to any such breach that is capable of being cured, is not cured by Buyer within [***] days after receipt of written notice thereof, or (ii) is incapable of being cured prior to the applicable Outside Date; provided, that
Seller will not have the right to terminate this Agreement pursuant to this Section 11.1(e) if Seller is then in material breach of any of its representations, warranties, covenants or agreements set forth in this
Agreement; or 
 (f)    by Seller or Buyer if the PCA is terminated in accordance with its terms. 

Section 11.2    Procedure upon Termination. In the event that this Agreement is terminated by Buyer or Seller
pursuant to Section 11.1, written notice thereof will forthwith be given to the other Party in accordance with Section 11.1 and Section 13.6, and this Agreement will
terminate, and the transactions contemplated hereby will be abandoned, without further action by Seller or Buyer. 

Section 11.3    Effect of Termination. Except as otherwise set forth in this Section 11.3,
in the event of the termination of this Agreement pursuant to Section 11.1, this Agreement will forthwith become void and have no further force or effect, without any liability on the part of any Party hereto or its
Affiliates, officers, directors or stockholders, other than liability of Seller or Buyer, as the case may be, for any willful breach of this Agreement occurring prior to such termination; provided, however, that, (a) any failure of Seller to
consummate the transactions contemplated hereby in breach of this Agreement will be deemed to be willful and (b) any failure of Buyer to consummate the transactions contemplated hereby in breach of this Agreement will be deemed to be willful
(whether or not Buyer had sufficient funds available to consummate the transactions contemplated hereby). Notwithstanding the foregoing, the provisions of the last sentence of Section 6.2,
Section 6.4, Section 6.6, Section 6.10, this Article XI, Article XII, Article XIII and the Confidentiality Agreement will survive any termination of
this Agreement pursuant to Section 11.1 and remain valid and binding obligations of the Parties. 
 ARTICLE XII

 CERTAIN DEFINITIONS 

Section 12.1    Certain Definitions. The following terms, as used in this Agreement, have the following
meanings: 
 “Action” means any action, claim, suit, arbitration, investigation or proceeding, in each case, by or before
any Governmental Authority. 
 “Actually Realized” means, with respect to any Tax Benefit, the time that

  
 -37- 

 
any refund of Taxes is actually received or applied against other Taxes due, or at the time of the filing of a Tax Return on which a loss, deduction, credit or an increase in basis is applied to
reduce the amount of Taxes that would otherwise be payable. 
 “Affiliate” of any Person means another Person that directly
or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person. The term “control” means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and the terms “controlled by” and “under common control with” have meanings
correlative thereto. 
 “Ancillary Agreements” means the IP Assignment Agreement and the License Agreement. 

“Assets” means assets, properties and rights, wherever located (including in the possession of vendors or other third-parties
or elsewhere), whether real, personal or mixed, tangible, intangible or contingent, in each case whether or not recorded or reflected or required to be recorded or reflected on the books and records or financial statements of any Person. 

“Business” means the business of selling and performing the Test for the risk stratification of indeterminate pulmonary
nodules in patients in the United States currently operated by Oncimmune USA. 
 “Business Contract” means any Contract to
which a member of the Seller Group is party and of the type described in Section 1.1(g). 
 “Business
Days” means a day other than Saturday, Sunday or other day on which commercial banks in New York, New York are required to or may be closed. 

“Business Employee” means each individual whose employment duties are primarily connected to performance of services for the
Business, including all such employees absent due to vacation, holiday, sickness, short term disability or approved leave of absence. 

“Business IP” means any Intellectual Property that is included in the Acquired Assets or the License Agreement and any
licenses to use Intellectual Property that are included in the Acquired Assets or the License Agreement. 
 “Closing Date”
means October 31, 2019. 
 “Code” means the Internal Revenue Code of 1986. 

“Contract” means any contract, agreement, license, lease, guaranty, indenture, sales or purchase order or other legally
binding commitment in the nature of a contract, whether written or oral. 

  
 -38- 

 “Damages” means all damages, losses, fines, penalties, costs and expenses,
including reasonable attorneys’ fees and expenses incurred in investigating or defending a claim. 
 “Development
Agreement” means the development agreement between the Parties contemplated by the PCA. 
 “Effect” has the
meaning set forth in the definition of “Material Adverse Effect.” 
 “Employee Benefit Plan” means (a) an
employee benefit plan (as such term is defined in Section 3(3) of ERISA), other than a Multiemployer Plan, (b) other plans or arrangements providing welfare (including health, dental, vision, life and disability), pension, retirement
benefits or vacation benefits, and (c) profit-sharing, bonus, stock option or stock appreciation plans or arrangements or similar forms of incentive compensation, in each case maintained by Seller or a Subsidiary of Seller for Transferred
Employees. Notwithstanding the foregoing, “Employee Benefit Plan” will not include any statutory plan or similar employee benefits required by Law. 

“Encumbrances” means options, pledges, security interests, liens, mortgages, charges, claims or other encumbrances or
restrictions. 
 “ERISA” means the Employee Retirement Income Security Act of 1974. 

“Fraud” means (a) with respect to Seller, that (i) a representation and warranty made by Seller was false when
made, (ii) to the knowledge of Seller, such representation and warranty was false when made, (iii) Seller had an intent to induce Buyer to act or refrain from acting in such context and (iv) Buyer acted in justifiable reliance on such
representation and warranty, and (b) with respect to Buyer, that (i) a representation and warranty made by Buyer was false when made, (ii) to the knowledge of Buyer, such representation and warranty was false when made,
(iii) Buyer had an intent to induce Seller to act or refrain from acting in such context and (iv) Seller acted in justifiable reliance on such representation and warranty. 

“Fundamental Representations” means the representations and warranties of Seller contained in Sections 4.1
(Organization, Existence and Good Standing), 4.2 (Authorization, Validity and Execution), 4.10(a) (Title to Assets) and 4.20 (Brokers). 

“GAAP” means United States generally accepted accounting principles. 

“Governmental Authority” means (a) any national, federal, state, county, municipal or foreign or supranational
government, or other political subdivision thereof, (b) any entity exercising executive, legislative, judicial, regulatory, tribunal, taxing or administrative functions of or pertaining to government, and (c) any arbitrator or arbitral body or
panel, department, ministry, instrumentality, agency, court, commission or body of competent jurisdiction. 

  
 -39- 

 “HCP” means any Person performing any professional medical, laboratory or
research services, nursing services, behavioral health, or other clinical services, including any research investigator, physician, pharmacist, registered nurse, licensed practical nurse, advanced practice nurse, nurse practitioner, certified
registered nurse practitioner, physician assistant, healthcare provider, therapist, mental health coach or other similar practitioner that is classified as a health care professional under applicable Law. 

“Healthcare Laws” means all applicable Laws regulating health services or payment, including, but not limited to, the federal
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the Stark Law (42 U.S.C. § 1395nn), the civil False Claims Act (31 U.S.C. § 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the exclusion laws (42 U.S.C. § 1320a-7), the civil monetary penalty laws (42 U.S.C. § 1320a-7a), the
administrative simplification provisions of HIPAA, the Medicare Prescription Drug, Improvement and Modernization Act of 2003, Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), the Food, Drug and
Cosmetic Act (21 C.F.R. §§ 301 et seq.), the Prescription Drug Marketing Act of 1987, the Deficit Reduction Act of 2005, HIPAA, HITECH, the Patient Protection and Affordable Care Act of 2010, any amendments thereto, the regulations
promulgated pursuant to such Laws, and any state analogs to any of the foregoing Laws. 
 “HIPAA” means the Health
Insurance Portability and Accountability Act of 1996 and the rules and regulations promulgated thereunder, including the privacy rule at 45 C.F.R. Part 160 and Part 164, Subparts A and E, the security rule at 45 C.F.R. 164, Subpart C, and the data
breach notification rule at 45 C.F.R. Subpart D, as each be amended from time to time. 
 “Income Taxes” means U.S.
federal, state or local or foreign net income or capital gain Taxes (but not any gross income Taxes and not any withholding Taxes or payroll, employment or employee Taxes), together with any interest or penalties imposed with respect thereto. 

“Intellectual Property” means any (a) utility and design patents, (b) trademarks, service marks, trade names, brand
names, trade dress, slogans, logos and internet domain names, (c) inventions, discoveries, ideas, processes, formulae, designs, models, industrial designs, know-how, proprietary information, trade
secrets, and confidential information, whether or not patented or patentable, (d) copyrights, writings and other copyrightable works and works in progress, databases and software, (e) all other intellectual property rights and foreign
equivalent or counterpart rights and forms of protection of a similar or analogous nature or having similar effect in any jurisdiction throughout the world, (f) all registrations and applications for registration of any of the foregoing, and
(g) any renewals, extensions, continuations, divisionals, reexaminations or reissues or equivalent or counterpart of any of the foregoing in any jurisdiction throughout the world. 

“Kansas Lab” means the CLIA-licensed laboratory at 8960 Commerce Drive, Building #6, De Soto, Kansas 66018, USA leased by
Oncimmune USA pursuant to the Lease. 

  
 -40- 

 “Law” means any statute, law (including common law), ordinance, rule,
regulation, order or decree promulgated by any Governmental Authority. 
 “Lease” means that certain Commercial and
Industrial Lease Agreement, between Fish Development, LLC and Oncimmune (USA) LLC, dated November 29, 2007, as amended by the First Amendment to Lease, by Great Southern Bank, successor in interest to Fish Development, LLC and Oncimmune (USA)
LLC, dated October 29, 2012 and the Second Amendment to Lease, by Desoto Investments, L.L.C., successor in interest to Great Southern Bank, and Oncimmune (USA) LLC, dated July 26, 2017. 

“Liability” means all debts, claims, liabilities, obligations, damages, fines, penalties, costs and expenses (whether known
or unknown, vested or unvested, asserted or unasserted, absolute or contingent, accrued or unaccrued, assessed or unassessed, liquidated or unliquidated, actual or potential, and due or to become due). 

“Material Adverse Effect” means any change, effect or event (each, an “Effect”) that is materially adverse
to the financial condition or results of operations of the Business, taken as a whole; provided, however, that no Effect will be considered when determining whether a Material Adverse Effect has occurred to the extent such Effect resulted or arose
from any of the following: (a) the negotiation, execution, announcement or pendency of the transactions contemplated by this Agreement, including any impact thereof on relationships, contractual or otherwise, with any customers, suppliers,
distributors, partners or employees; (b) conditions affecting the industry in which the Business participates, the U.S. economy as a whole or the capital markets in general or the markets in which the Business operates; (c) compliance with
the terms of, or the taking of any action required by, this Agreement, the Ancillary Documents or the other agreements and transactions contemplated hereby; (d) any change in applicable Laws or the interpretation thereof; (e) actions
required to be taken under applicable Laws; (f) any change in GAAP or other accounting requirements or principles or any change in related Laws or the interpretation thereof; (g) any national or international political or social
conditions, including an outbreak or escalation of hostilities, acts of terrorism, military acts, political instability or other national or international calamity, crisis or emergency, or any governmental or other response to the foregoing, in each
case whether or not involving the United States; (h) any change in conditions in the United States, foreign or global financial, banking or securities markets generally (including any disruption thereof and any decline in the price of any
security or any market index or any change in interest or exchange rates); (i) any hurricane, earthquake, flood or other natural disasters; (j) any failure by the Business to meet any internal or published projections, forecasts or revenue or
earnings predictions for any period ending (or for which revenues or earnings are released) on or after the date of this Agreement (provided that this clause (j) will not prevent a determination that any Effect underlying such failure has
resulted in a Material Adverse Effect); or (k) any action taken with the consent or upon the request of Buyer, but in the case of clause (b), only to the extent any such Effects do not have a materially disproportionate adverse impact on the
Business relative to other Persons in the industries in which the Business operates. 

  
 -41- 

 “Permit” means any approval, permit, license, certificate, franchise,
permission, clearance, registration, qualification or other authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority. 

“Permitted Encumbrances” means (a) (i) Encumbrances for Taxes, assessments or governmental charges or levies on property
not yet delinquent or the validity of which are being contested in good faith by appropriate proceedings, (ii) mechanics’, carriers’, workmen’s, repairmen’s and other like Encumbrances arising or incurred in the ordinary
course of business and (iii) Encumbrances arising under equipment leases with third parties entered into in the ordinary course of business; (b) the terms of the Lease; (c) Encumbrances consisting of zoning or planning restrictions,
Permits and other governmental or non-governmental restrictions or limitations on the use of real property or irregularities in title thereto which do not materially impair the use of such real property in the
operation of the Business as currently conducted; (d) covenants, conditions and restrictions of record; (e) private and public easements, rights of way and utility agreements, and roads or highways, if any; (f) all covenants,
conditions, restrictions, easements, rights of way, encumbrances, defects, imperfections, irregularities of title or other Encumbrances that would be readily apparent upon physical inspection of the Leased Real Property or review of an accurate
survey covering the Leased Real Property; (g) with respect to any Leased Real Property, (i) the interests and rights of the respective lessors with respect thereto, including any statutory landlord liens and any Encumbrance thereon, and
(ii) any Encumbrance permitted under the applicable lease agreement and any ancillary documents thereto; (h) Encumbrances created by Buyer or its successors and assigns; (i) Encumbrances disclosed in the Seller Disclosure Letter;
(j) Encumbrances (other than monetary encumbrances) incurred in the ordinary course of business since December 31, 2018; and (k) licenses to Intellectual Property granted in the ordinary course of business. 

“Person” means any individual, corporation (including
not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, Governmental Authority or other
entity of any kind or nature. 
 “Personal Information” means, in addition to any definition for any similar term (e.g.,
“personally identifiable information” or “PII”) provided by applicable Law, or by the Business in any of its privacy policies, notices or contracts, all information that alone or in combination with other information identifies,
or that could be used to identify an individual person or a device belonging to an individual person, including name, physical address, telephone number, email address, financial information, financial account number or government-issued identifier.

 “PHI” means “protected health information” as defined under HIPAA. 

  
 -42- 

 “Privacy Laws” means any and all applicable Laws relating to the receipt,
collection, compilation, use, storage, processing, sharing, safeguarding, security (both technical and physical), disposal, destruction, disclosure or transfer (including cross- border) of Personal Information, including the Federal Trade Commission
Act and any and all applicable Laws relating to breach notification in connection with Personal Information. 

“Representatives” means a Party’s accountants, counsel, consultants, advisors and agents. 

“Seller Disclosure Letter” means the disclosure letter delivered by Seller to Buyer immediately prior to the execution of
this Agreement, as the same may be updated in accordance herewith. 
 “Seller Group” means Seller and Oncimmune USA. 

“Seller Guaranty” will mean any guaranty, letter of credit, indemnity or contribution agreement or other similar agreement
entered into by any member of the Seller Group in favor of any third party guaranteeing or assuring such third party of the payment of any actual or potential liability or obligation of the Business to such third party. 

“Shared Business Contracts” means the Contracts between Seller or an Affiliate, on the one hand, and unrelated third parties,
on the other hand, that are related to the Business but are not Business Contracts. 
 “Subsidiary” means, with respect to
any Person: (a) any other Person of which such Person beneficially owns, either directly or indirectly, more than fifty percent (50%) of (i) the total combined voting power of all classes of voting securities of such other Person,
(ii) the total combined equity interests of such other Person, or (iii) the capital or profit interests of such other Person; or (b) any other Person of which such Person has the power to vote, either directly or indirectly,
sufficient securities to elect a majority of the board of directors or similar governing body of such other Person. 

“Tax” or “Taxes” means any income, alternative or add-on minimum,
gross income or receipts, sales, use, value added, consumption, transfer, gains, ad valorem, franchise, profits, license, withholding, payroll, direct placement, employment, excise, severance, stamp, procurement, occupation, premium,
property, escheat, environmental or windfall profit tax, custom, duty or other tax, together with any interest, additions or penalties with respect thereto. 

“Tax Benefit” means any refund of Taxes paid or any reduction in the amount of Taxes which otherwise would have been paid,
calculated on a with and without basis. 
 “Tax Return” means any return, declaration, report, claim for refund,
information return or similar statement filed or required to be filed with respect to any Taxes, including any schedule or attachment thereto, and including any amendment thereof. 

  
 -43- 

 “Test” means the EarlyCDT-Lung blood test detecting a panel of seven lung
cancer autoantibodies (p53, CAGE, GBU4-5, NY-ESO-1, MAGE A4, HuD and SOX2) in blood or serum collected by venipuncture or finger
stick, the first intended use of which is a rule-in test for use by physicians to further assess lung cancer risk in patients previously identified by CT scan to have IPNs of intermediate risk (10-65%) and the second intended use of which is a targeted screen for use by health care providers (HCPs) to triage patients at risk of lung cancer to CT scan. For clarity, “Test” includes any Successor
Iteration (as defined in the PCA) developed by or on behalf of Oncimmune or its Affiliates or their respective licensees. 

“Transferred Employee” means each employee set forth on Exhibit 12.1, which Exhibit may be updated prior to the
Closing by mutual agreement of the Parties. 
 “Treasury Regulations” means final and temporary income tax regulations
proposed by the U.S. Department of Treasury existing as of the Closing Date. 
 Section 12.2    Cross
References. Each of the following terms is defined in the Section set forth opposite such term: 
  

					
	 Acquired Assets
	  	 	Section 1.1	 
	 Acquired IT Assets
	  	 	Section 1.1(i)	 
	 Agreement
	  	 	Introductory Paragraph	 
	 Assigned Intellectual Property
	  	 	Section 1.1(e)	 
	 Assumed Liabilites
	  	 	Section 1.3	 
	 Balance Sheet
	  	 	Section 4.5(a)	 
	 Bankruptcy and Equity Exception
	  	 	Section 4.2	 
	 Basket
	  	 	Section 9.4(a)	 
	 Buyer
	  	 	Introductory Paragraph	 
	 Buyer Indemnitees
	  	 	Section 9.2(a)	 
	 Cap
	  	 	Section 9.4(b)	 
	 Claim Notice
	  	 	Section 9.3(a)	 
	 Closing
	  	 	Section 3.1	 
	 COBRA
	  	 	Section 7.4	 
	 Confidentiality Agreement
	  	 	Section 6.4	 
	 Convey
	  	 	Section 1.1	 
	 Equipment
	  	 	Section 1.1(b)	 
	 Equitable Manner
	  	 	Section 10.2	 
	 Excluded Assets
	  	 	Section 1.2	 
	 Excluded Liabilities
	  	 	Section 1.4	 
	 Execution Date
	  	 	Introductory Paragraph	 
	 Final Allocation
	  	 	Section 2.3	 
	 Financial Statements
	  	 	Section 4.5(a)	 
	 Indemnified Party
	  	 	Section 9.3(a)	 
	 Indemnifying Party
	  	 	Section 9.3(a)	 

  
 -44- 

					
	 Inventory
	  	 	Section 1.1(a)	 
	 IP Assignment Agreement
	  	 	Section 3.2(a)(ii)	 
	 Knowledge
	  	 	Section 13.7(b)	 
	 Leased Real Property
	  	 	Section 4.7(b)	 
	 Legal Requirement
	  	 	Section 4.12	 
	 License Agreement
	  	 	Section 3.2(a)(iii)	 
	 Material Contract
	  	 	Section 4.9(b)	 
	 Material Relationships
	  	 	Section 4.17	 
	 Multiemployer Plan
	  	 	Section 4.14(b)	 
	 Oncimmune USA
	  	 	Recitals	 
	 Outside Date
	  	 	Section 11.1(c)	 
	 Parties
	  	 	Introductory Paragraph	 
	 Party
	  	 	Introductory Paragraph	 
	 PCA
	  	 	Recitals	 
	 Potential Contributor
	  	 	Section 9.5	 
	 Purchase Price
	  	 	Section 2.1(a)	 
	 Quarterly Amount
	  	 	Section 2.1(a)	 
	 Seller
	  	 	Introductory Paragraph	 
	 Seller Indemnitees
	  	 	Section 9.2(b)	 
	 Sharing Arrangements
	  	 	Section 6.11(b)(i)	 
	 Supply Agreement
	  	 	Section 1.2(e)	 
	 Third Party Claim
	  	 	Section 9.3(a)	 
	 Transfer Documents
	  	 	Section 3.3	 
	 Welfare Plans
	  	 	Section 7.4	 

 ARTICLE XIII 

GENERAL PROVISIONS 

Section 13.1    Seller Disclosure Letter. Any disclosure in any section of the Seller Disclosure Letter of any
Contract, Liability, default, breach, violation, limitation, impediment or other matter, although the provision for such disclosure may require such disclosure only if such Contract, Liability, default, breach, violation, limitation, impediment or
other matter be “material,” will not be construed against Seller, as an assertion by Seller, that any such Contract, Liability, default, breach, violation, limitation, impediment or other matter is, in fact, material. No reference to or
disclosure of any item or other matter in the Seller Disclosure Letter will be construed as an admission or indication that such item or other matter is material or that such item or other matter is required to be referred to or disclosed in the
Seller Disclosure Letter. Any disclosure in any section of the Seller Disclosure Letter will be deemed to be fully disclosed regardless of whether it could have been listed in another section of the Seller Disclosure Letter. Any disclosure by Seller
in any section of the Seller Disclosure Letter will be deemed to be fully disclosed with respect to all other sections of the Seller Disclosure Letter, to the extent that the relevance to the disclosure required by or provided in another section of
the Seller Disclosure Letter is reasonably apparent. The Seller Disclosure Letter is qualified in its entirety by reference to specific provisions of this Agreement and is not intended to constitute, and will not be construed as

  
 -45- 

 constituting, any representations or warranties of Seller except as and to the extent provided in this
Agreement, subject to the limitations and conditions provided for in this Agreement. The Seller Disclosure Letter may include items or information which Seller is not required to disclose under this Agreement; disclosure of such items or information
will not affect (directly or indirectly) the interpretation of this Agreement or the scope of any disclosure obligation under this Agreement. The attachments to the Seller Disclosure Letter form an integral part of the Seller Disclosure Letter and
are incorporated by reference for all purposes as if set forth fully therein. The headings contained in the Seller Disclosure Letter are for convenience of reference purposes only and will not affect in any way the meaning or interpretation of this
Agreement or the Seller Disclosure Letter. No disclosure in the Seller Disclosure Letter relating to any possible breach or violation of any Contract or applicable Law will be construed as an admission or indication that any such breach or violation
exists or has actually occurred. The exceptions, modifications, descriptions and disclosures in any section of the Seller Disclosure Letter are made for all relevant purposes of this Agreement and are exceptions by members of the Seller Group to all
representations and warranties set forth in this Agreement or in any instrument delivered pursuant to this Agreement to the extent applicable thereto. From time to time prior to the Closing, Seller shall have the right (but not the obligation) to
supplement or amend the Seller Disclosure Letter with respect to any matter hereafter arising, which, if existing or occurring at the date of this Agreement, would have been required to be set forth or described in the Seller Disclosure Letter. Any
such supplement shall be deemed to have cured any inaccuracy in or breach of any representation or warranty contained in this Agreement for purposes of satisfying the Closing conditions set forth in Section 8.1(a) and for
purposes of ARTICLE XI, but shall otherwise not be deemed to have cured any inaccuracy in or breach of any representation or warranty contained in this Agreement for purposes of the indemnification rights contained in this Agreement. 

Section 13.2    Assignment. This Agreement may not be assigned by Buyer or Seller without the prior written
consent of the other Party. Notwithstanding anything to the contrary, either party shall be permitted to assign or otherwise transfer (by operation of law or otherwise) this Agreement in connection with the sale of such party or all or substantially
all of its assets, provided that such party obtains prior written consent of the other Party, which consent shall not be unreasonably withheld. 

Section 13.3    No Third-Party Beneficiaries. Except for the Persons entitled to indemnification under
Article IX, this Agreement is for the sole benefit of the parties to this Agreement and does benefit or create any right or cause of action for any other Persons. 

  
 -46- 

 Section 13.4    Entire Agreement; Amendments. This
Agreement, including any Exhibits, Schedule, the Seller Disclosure Letter, the PCA, the Supply Agreement, the Development Agreement and the Ancillary Agreements contain the complete and entire understanding of the parties with respect to their
subject matter. This Agreement supersedes all prior written or oral statements representations, warranties, promises, assurances, agreements and understandings between the Parties relating to or in connection with the subject matter of this
Agreement. For clarity, this Agreement does not supersede any other related agreements executed by the Parties in connection with or relating to the subject matter of this Agreement. Each Party to this Agreement hereby acknowledges that they have
not relied on any promise, representation or warranty that is not set forth in this Agreement. This Agreement may not be amended except in writing signed by each Party. 

Section 13.5    Waiver. At any time at or prior to the Closing, Seller may agree to (a) extend the time for
the performance of any of the obligations or other acts of Buyer contained herein, (b) waive any inaccuracies in the representations and warranties of Buyer contained herein or in any document, certificate or writing delivered by Buyer pursuant
hereto or (c) waive compliance by Buyer with any of the agreements or conditions contained herein. At any time at or prior to the Closing, Buyer may (i) extend the time for the performance of any of the obligations or other acts of Seller
contained herein, (ii) waive any inaccuracies in the representations and warranties of Seller contained herein or in any document, certificate or writing delivered by Seller pursuant hereto or (iii) waive compliance by Seller with any of
the agreements or conditions contained herein. Any agreement on the part of any Party to any such extension or waiver will be valid only if set forth in a written instrument signed on behalf of such Party. The failure of any Party to assert any of
its rights hereunder will not constitute a waiver of such rights. 
 Section 13.6    Notices. All notices,
requests, demands and other communications (including, for the avoidance of doubt, any notice or document sent by any Party) under this Agreement will be in writing and will be deemed to have been duly given (i) on the date of service if served
personally on the Party to whom notice is to be given; (ii) on the day of transmission if sent by e-mail to the e-mail address given below (provided no delivery
failure message is received by the sender); (iii) on the Business Day after delivery to Federal Express or similar overnight courier or the Express Mail service maintained by the United States Postal Service; or (iv) on the fifth day after
mailing, if mailed to the Party to whom notice is to be given, by first class mail, registered or certified, postage prepaid and properly addressed, to the Party as follows: 
  

	 	(a)	 If to Buyer: 

Biodesix, Inc. 
 2970 Wilderness
Place, Suite 100 
 Boulder, Colorado 80301 

Attn: Legal Affairs 
 Email:
legalaffairs@biodesix.com 

  
 -47- 

 with a copy to: 

Cooley Godward 
 380 Interlocken
Crescent #900 
 Broomfield, Colorado 80021 

Attn: Brent Fassett 
 Email:
fassettbd@cooley.com 
  

	 	(b)	 If to Seller: 

Oncimmune Limited 
 51 Eastcheap

 London EC3M 1JP 
 United
Kingdom 
 Email: [***] 
 with
a copy to: 
 Jones Day 
 1420
Peachtree St., NE 
 Atlanta, Georgia 30309 

Attn: R. Kenneth Boehner 

Email: kboehner@jonesday.com 
 or such other
addresses or numbers and/or addressee as are furnished in writing by either Party. 

Section 13.7    Interpretation. 

(a)    The words “hereof” “herein” and “herewith” and
words of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement, and Article, Section, Exhibits and Schedule references are to the Articles, Sections,
Exhibits and Schedule of this Agreement unless otherwise specified. Whenever the words “include,” “includes” “including” or similar expressions are used in this Agreement, they will be understood be
followed by the words “without limitation.” The words describing the singular number will include the plural and vice versa, and words denoting any gender will include all genders and words denoting natural persons will include
corporations and partnerships and vice versa. The phrase “made available” in this Agreement will mean that the information referred to has been made available if requested by the Party to whom such information is to be made
available. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event of an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties
and no presumption or burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this 

  
 -48- 

 Agreement. All references to “$” or “dollars” are to U.S. dollars, and
all amounts to be calculated or paid under this Agreement will be in U.S. dollars. References to statutes include all regulations promulgated thereunder and reference to statutes or regulations will be construed as including all statutory and
regulatory provisions consolidating, amending or replacing the statute or regulation. 
 (b)    For all
purposes of this Agreement, the phrase “to the Knowledge of Seller” and any derivations thereof will mean, as of the applicable date, the actual knowledge of Adam Hill, Matthew Hall, Andrew Stewart, Marco Casarin and Laura Peek, who will
not have any personal liability or obligations regarding such knowledge or any duty of inquiry or investigation with respect thereto. 

Section 13.8    Counterparts. This Agreement may be executed in multiple original, PDF or facsimile
counterparts, each of which will be deemed an original, and all of which taken together will be considered one and the same agreement. In the event that any signature to this Agreement or any agreement or certificate delivered pursuant hereto, or
any amendment thereof, is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature will create a valid and binding obligation of the Party executing (or
on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. No Party will raise the use of a facsimile machine or
e-mail delivery of a “.pdf” format data file to deliver any such signature page or the fact that such signature was transmitted or communicated through the use of a facsimile machine or e-mail delivery of a “.pdf” format data file as a defense to the formation or enforceability of a contract and each Party forever waives any such defense. 

Section 13.9    Severability. If any provision of this Agreement or the application of any such provision to
any Person or circumstance is held invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision of this Agreement. 

Section 13.10    Governing Law; Consent to Exclusive Jurisdiction. 

(a)    The interpretation and construction of this Agreement, and all matters relating to this Agreement,
will be governed by the laws of the State of Delaware applicable to contracts made and to be performed entirely within the State of Delaware without giving effect to any conflict of law provisions thereof. 

(b)    Each of the parties agrees that any legal action or proceeding with respect to this Agreement may be
brought in the federal and state courts located in the State of Delaware, and, by execution and delivery of this Agreement, each Party to this Agreement irrevocably submits itself in respect of its property, generally and unconditionally, to the
exclusive jurisdiction of the aforesaid courts in any legal action or proceeding arising out of this Agreement. Each of the parties irrevocably waives any objection which it may now or hereafter have to the laying of venue of any of the aforesaid
actions or proceedings arising out of or in connection with this Agreement brought in the courts referred to in the 

  
 -49- 

 preceding sentence. Each Party consents to process being served in any such action or
proceeding by the mailing of a copy thereof to the address (set forth in Section 13.6) below its name and agrees that such service upon receipt will constitute good and sufficient service of process or notice thereof.
Nothing in this paragraph will affect or eliminate any right to serve process in any other manner permitted by law. 

Section 13.11    WAIVER OF JURY TRIAL. THE PARTIES TO THIS AGREEMENT IRREVOCABLY WAIVE THEIR RESPECTIVE RIGHTS
TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, COUNTERCLAIM OR CROSS- COMPLAINT IN ANY ACTION OR OTHER PROCEEDING BROUGHT BY ANY PARTY TO THIS AGREEMENT AGAINST ANY OTHER PARTY OR PARTIES TO THIS AGREEMENT WITH RESPECT TO ANY MATTER ARISING OUT OF,
OR IN ANY WAY CONNECTED WITH OR RELATED TO THIS AGREEMENT OR ANY PORTION OF THIS AGREEMENT, WHETHER BASED UPON CONTRACTUAL, STATUTORY, TORTUOUS OR OTHER THEORIES OF LIABILITY. EACH PARTY REPRESENTS THAT IT HAS CONSULTED WITH COUNSEL REGARDING THE
MEANING AND EFFECT OF THE FOREGOING WAIVER OF ITS RIGHT TO A JURY TRIAL. 
 Section 13.12    Recovery of Fees by
Prevailing Party. In any action at law or in equity to enforce any of the provisions or rights under this Agreement, the Party which does not prevail in such litigation, as determined by the court in a final judgment or decree, will pay to the
prevailing Party all costs, expenses and attorneys’ fees incurred by the prevailing Party, including such costs, expenses and fees of any appeals. If the prevailing Party will recover judgment in any action or proceeding, its costs, expenses
and attorneys’ fees will be included as part of such judgment. 
 Section 13.13    Specific
Performance. Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or conferred by Law or equity, upon such Party, and the
exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the
parties do not perform their respective obligations under the provisions of this Agreement in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed that, prior to the valid termination of this Agreement
pursuant to Article XI, the parties will be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this
Agreement, this being in addition to any other remedy to which they are entitled at Law or in equity. Each of the parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief when expressly
available pursuant to the terms of this Agreement, and hereby waives (a) any defenses in any action for an injunction, specific performance or other equitable relief, including the defense that the other parties have an adequate remedy at Law
or an award of specific performance is not an appropriate remedy for any reason at Law or equity, and (b) any requirement under Law to post a bond, undertaking or other security as a prerequisite to obtaining equitable 

  
 -50- 

 
relief. To the extent any Party hereto brings an action, suit or proceeding to enforce specifically the performance of the terms and provisions of this Agreement (other than an action to enforce
specifically any provision that expressly survives termination of this Agreement), the Outside Date will automatically be extended to (i) the [***] Business Day following the resolution of such action, suit or proceeding or (ii) such other
time period established by the court presiding over such action, suit or proceeding. 
 [Remainder of this Page Intentionally Left Blank;
Signature Page Follows] 

  
 -51- 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed as of the
date first written above. 
  

			
	ONCIMMUNE LIMITED
		
	By:	 	 /s/Adam M. Hill

	Name:	 	Adam M. Hill
	Title:	 	Chief Executive Officer
	
	BIODESIX, INC.
		
	By:	 	 /s/ David Brunel

	Name:	 	David Brunel
	Title:	 	CEO

 [SIGNATURE PAGE TO ASSET PURCHASE AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]